WO2018212588A1 - Composition containing camellia sinensis extract - Google Patents

Composition containing camellia sinensis extract Download PDF

Info

Publication number
WO2018212588A1
WO2018212588A1 PCT/KR2018/005605 KR2018005605W WO2018212588A1 WO 2018212588 A1 WO2018212588 A1 WO 2018212588A1 KR 2018005605 W KR2018005605 W KR 2018005605W WO 2018212588 A1 WO2018212588 A1 WO 2018212588A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
gallate
composition
methyl
epigallocatechin
Prior art date
Application number
PCT/KR2018/005605
Other languages
French (fr)
Korean (ko)
Inventor
황경환
박준성
박녹현
이민석
유주
Original Assignee
주식회사 아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아모레퍼시픽 filed Critical 주식회사 아모레퍼시픽
Priority to CN201880032982.9A priority Critical patent/CN111050783A/en
Priority to MYPI2019006749A priority patent/MY197901A/en
Publication of WO2018212588A1 publication Critical patent/WO2018212588A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
    • C09K15/06—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/34—Anti-oxidant compositions; Compositions inhibiting chemical change containing plant or animal materials of unknown composition
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Definitions

  • the present invention is a composition containing an extract of a tea tree, preferably an extract of a new type of tea tree (Jangwon No. 3), more specifically epigallocatechin-3- O- (3- O -methyl) gallate (epigallocatechin-
  • the present invention relates to a composition containing an extract of Camellia sinensis , which contains a high content of 3-O- (3-O-methyl) gallate; EGCG3 ”Me; 3” -O- Me-EGCG) as an active ingredient.
  • Human skin is changed by a number of internal and external factors as it ages. That is, internally, the secretion of various hormones that regulate metabolism decreases, and the function of immune cells and the activity of cells decreases, thereby reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms. Due to the increase in the amount of ultraviolet rays that reach the surface of the sun's rays and intensifying environmental pollution, free radicals and active oxygen radicals increase, thereby reducing the thickness of the skin, increasing wrinkles, and reducing elasticity. The color of the skin becomes dull, skin problems frequently occur, and there are various changes such as blemishes, freckles, and black mushrooms.
  • cyclooxygenase-2 (Cox-2, cyclooxygenase), an enzyme that produces proinflammatory cytokine, which is known to cause inflammation in most cells constituting the skin, due to aging or ultraviolet rays.
  • MMP matrix metalloproteinase
  • iNOS inducible nitric oxide synthase
  • the biosynthesis of the substrate material is reduced due to the decrease of cellular activity and micro-inflammatory due to the naturally occurring endogenous aging, the external factors such as the increase of stress caused by various harmful environments and the increase of free radical species by the sun's rays. Degradation and degeneration are accelerated by this, resulting in the destruction and thinning of the skin matrix, resulting in various symptoms of skin aging. Therefore, a lot of research is being conducted on the active ingredient that can prevent and improve the phenomenon of aging.
  • SOD superoxide dismutase
  • Free radicals such as superoxide, are produced in the body by external stress, ultraviolet rays, smoking, drugs, free radicals, etc., and have non-selective and irreversible destruction against cellular components such as lipids, proteins, sugars, and nucleic acids (eg, DNA). By doing so, it is known to cause various diseases such as cancer, stroke, Parkinson's disease, heart disease, ischemia, arteriosclerosis, skin disease, digestive disease, inflammation, rheumatism, autoimmune disease, as well as aging. In this way, free radicals cause various functional disorders due to oxidative destruction of cells, thereby causing aging and disease.
  • diseases such as cancer, stroke, Parkinson's disease, heart disease, ischemia, arteriosclerosis, skin disease, digestive disease, inflammation, rheumatism, autoimmune disease, as well as aging.
  • free radicals cause various functional disorders due to oxidative destruction of cells, thereby causing aging and disease.
  • the tea tree is an evergreen belonging to the family Camellia (Family: Theaceae ), and the scientific name is Camellia sinensis .
  • the cultivated tea tree can be divided into varieties ( var. Assamica ) and Chinese varieties ( var.sinesis ), which have broad leaf characteristics and are distributed in tropical and subtropical areas such as India and Sri Lanka. It is widely used as a dragon, and Chinese species have lobular characteristics, and are distributed in temperate regions such as Korea, China, and Japan, and have strong cold resistance.
  • Korean native tea trees are mainly classified as Chinese species.
  • the tea tree is a subtropical crop with an average annual temperature of 14 ⁇ 16 °C.
  • Low temperature is a limiting factor for the growth of tea trees, and even after a one-hour pass at -15 °C, the leaves will die, and if it exceeds 40 °C, a high temperature disorder occurs.
  • the minimum amount of precipitation required to grow the tea tree is at least 1,300 mm, but for optimal tea cultivation requires more than 1,500 mm of precipitation per year.
  • the tea tree is reported to have been planted around China in Jirisan during the late Silla 828.
  • Native plants are grown in the southern part of Korea, which is below the cultivation limit of 13 °C, and are grown in Jeonbuk, Jeonnam, Gyeongnam, and Jeju.
  • Tea is characterized by a higher content of nitrogen compounds, polyphenols, sugars, organic acids, vitamins and minerals than other beverages.Amino acids are closely related to the taste of tea and certain amino acids such as deanine affect the quality. It is also known that the components of these amino acids correlate with the price of the product. The total nitrogen content of tea leaves is traditionally an important factor in determining the quality of tea along with amino acids.
  • Tea protein is hardly eluted due to coagulation with tannin or coagulation by heating in the manufacturing process, but amino acids and amides are water soluble and are eluted to greatly influence the taste of tea.
  • Tea has been used since ancient times as well as various pharmacological action. In recent years, research on this has been actively conducted, focusing on the functionality of the car. Tea is particularly rich in polyphenols, and most of the polyphenols in tea are flavonoids known as catechin compounds.
  • Deanine is a high component of about 40 to 60% by weight of the total free amino acids of green tea, which is rarely found in other crops and is contained only in the leaves of tea trees. Deanin has a great influence on the taste of tea, and it is correlated with the quality of tea along with total free amino acids and total nitrogen, and is used as an important indicator for quality evaluation along with sensory evaluation. It is evaluated as a factor.
  • the tea tree is a corrosive crop in which the pollination is made between individuals with different genotypes, and the variation between individuals is severe. Therefore, conventionally grown cultivated tea is not a single cultivar, but a hybrid that has been descended for a long time by sexual reproduction, and the genetic characteristics of each tea tree are all different. Harvesting time, growth rate, leaf shape and color, composition, disease resistance, and cold resistance And many other characteristics. These conventional species have high genetic value for breeding, but it is urgent to develop tea varieties that can maintain a uniform quality while showing excellent functionality even after multiple breeding.
  • the breeding method of the new tea tree varieties (named “Changwon No. 2”) having a high amino acid and deanin content has been developed. All of these breeding methods are characterized by selecting tea trees having the desired characteristics among conventional tea trees, and abundantly breeding by cutting to reproduce excellent genetic traits without mutation.
  • tea tree varieties are difficult to improve because they are genetically very sparse because they have a long breeding period like other young plants.
  • efficacy of the tea leaf extract obtained from these tea trees has not been specifically identified.
  • the present inventors analyzed the components of the extract obtained from the tea leaves of the new tea tree varieties (Changwon No. 3) produced through the breeding method and the cultivation method of the new tea tree and its efficacy and applied to pharmaceuticals, cosmetics, food, etc. , a tea extract, preferably a new variety of tea (manor third) extract of 3-epi catechins in particular go O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl ) gallate; EGCG3 ”Me; 3” -O- Me-EGCG), and found to be excellent in antioxidant, anti-inflammatory, anti-aging and anti-cancer effects, and completed the present invention.
  • a tea extract preferably a new variety of tea (manor third) extract of 3-epi catechins in particular go O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl ) gallate; EGCG3 ”Me; 3
  • An object of the present invention the epi catechins to go in accordance with the present invention -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" It is to provide a composition containing an extract of a tea tree containing a high content of O -Me-EGCG, preferably an extract of a new tea tree (Changwon No. 3) as an active ingredient.
  • the extract of the tea tree containing a high content of epigallocatechin-3- O- (3- O -methyl) gallate according to the present invention preferably of a new type of tea tree (Changwon No. 3)
  • the present invention provides a pharmaceutical composition, a cosmetic composition or a nutraceutical composition containing the extract as an active ingredient and having antioxidant, anti-inflammatory, anti-aging and anticancer uses.
  • the present invention is a composition containing an extract of tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new type of tea tree (Jangwon No. 3) as an active ingredient. To provide.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an antioxidant pharmaceutical composition, cosmetic composition or health functional food composition preferably an extract of a tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient.
  • an anticancer pharmaceutical composition, cosmetic composition or health functional food composition preferably an extract of a tea tree species (Changwon No. 3) as an active ingredient.
  • the present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an antioxidant pharmaceutical composition or medicament.
  • an extract of (Changwon 3) as an antioxidant is provided.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the production of an antioxidant cosmetic composition, preferably a new kind of tea tree (Changwon 3 The use of the extract of the present invention) as an antioxidant.
  • the present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an antioxidant functional food composition.
  • the present invention also provides an extract of a tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a pharmaceutical composition or medicament for anti-inflammatory or anti-inflammatory, preferably Provides the use of an extract of tea tree new varieties (Jangwon 3) as an anti-inflammatory or anti-inflammatory agent.
  • the present invention is also an extract of a tea tree, preferably a new kind of tea tree, which comprises a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the preparation of an anti-inflammatory or anti-inflammatory cosmetic composition.
  • the use of the extract of (Changwon 3) as an anti-inflammatory or anti-inflammatory agent is provided.
  • the present invention also provides an extract of a tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate, in the preparation of an anti-inflammatory or anti-inflammatory health food composition.
  • an anti-inflammatory or anti-inflammatory agent of an extract of a new tea tree species (Changwon No. 3).
  • the present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anti-aging pharmaceutical composition or medicament.
  • the use of the extract of (Changwon 3) as an anti-aging agent is provided.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the preparation of an anti-aging cosmetic composition, preferably a new kind of tea tree (Jangwon 3 The use of the extract of the present invention) as an anti-aging agent.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anti-aging dietary supplement composition, preferably a new kind of tea tree ( The use of the extract of Jangwon 3) as an anti-aging agent.
  • the present invention is also an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a pharmaceutical composition or medicine for anticancer
  • the use of the extract of (Changwon 3) as an anticancer agent is provided.
  • the present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anticancer cosmetic composition, preferably a new kind of tea tree (Changwon 3
  • An anticancer agent is provided as an anticancer agent.
  • the present invention is also an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a dietary supplement composition for anticancer, preferably a new kind of tea tree ( The use of the extract of Jangwon 3) as an anticancer agent.
  • composition containing the extract of the tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in high content according to the present invention as an active ingredient has an antioxidant effect and cola due to free radical scavenging and inhibition. It has an excellent inhibitory ability to generate geneases to prevent skin aging, and it has anti-inflammatory effect by inhibiting the expression and secretion of inflammatory factors such as prostaglandin and IL-8 in skin cells, and anti-cancer effect against cancer cell lines derived from various tissues. great.
  • Figure 1 shows the elite line selection of the collected green tea tree germplasm (germplasm).
  • Figure 2 shows the single cutting propagation of a single tea tree of the selected green tea tree.
  • Figure 3 shows a new varieties of tea tree (Mountain 3).
  • Figure 4 shows the superoxide anion scavenging activity of the new tea extract (Changwon No. 3).
  • Figure 5 shows the hydroxyl radical (hydroxyl radical) scavenging activity of a new tea (Jangwon No. 3) extract.
  • the new tea varieties (New Cultivar of Camellia sinensis) is a new tea varieties (Changwon No. 3) (seed accession number: KCTC (Korean Collection for Type Cultures) 12213BP (2012.5.14); No.] of the tea leaf extract, after analyzing the components of the extract, the total content of the catechin is 41.1% by weight of the extract of the new tea (Changwon No. 3) tea leaves, Yabugi is a general tea tree introduced varieties Leaf extract (28.1% by weight), kanayamidori leaf extract (26.7% by weight), utagamidori leaf extract (26.4% by weight) was higher than the extract.
  • new varieties of tea (manor third) extract of catechin to go epi -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG
  • EGCG3 "Me; 3 ” -O- Me-EGCG was contained in an amount of 2.5% by weight, and was found to contain 10 times or more higher than the general tea tree introduced varieties (see Example 1 and Test Example 1, Table 6).
  • the extract of the new tea tree (Changwon No. 3) leaf was Yabu
  • the total content of catechin was higher than the extract.
  • the content of 3 ” -O- Me-EGCG) in the extracts of the leaves of the new tea tree (Changwon No. 3) was 4.7 mg ⁇ g -1 , 3.6 in green tea, oolong tea (semi-fermented tea) and black tea (fermented tea), respectively. mg.g -1 and 1.94 mg.g -1 .
  • the antioxidant effect of the extract of tea tree new varieties (Jangwon No. 3) according to the present invention was confirmed.
  • Table 8 (i) new tea tree varieties (Changwon 3) in the DPPH (1,1-diphenyl-2-picrylhydrazyl; 1,1-diphenyl-2-picryl hydrazyl) test Extract (Example 1) showed a similar antioxidant effect compared to the ascorbic acid (vitamin C), an antioxidant used as a positive control, and extracts Yabugida, Kanayamidori and Yutagami-dori extracts of general tea trees of Comparative Examples 1 to 3 Compared with, it showed significantly higher antioxidant efficacy, and (ii) In the superoxide anion scavenging activity test, the new tea extract (Changwon No.
  • the anti-aging effect of the extract of the new tea varieties (Changwon No. 3) according to the present invention was confirmed through the ability to inhibit the production of collagenase.
  • Table 9 the lower the expression level of collagenase, the higher the expression inhibiting ability of collagenase, less degradation of collagen in the skin, inhibiting the decrease in skin elasticity, and the amount of wrinkles produced decreased.
  • the extract of the new tea tree (Changwon No. 3) according to the present invention (Example 1) effectively inhibited the expression of collagenase in vitro , and inhibited the expression of collagenase than tocopherol used as a positive control. This excellence could be confirmed.
  • the extract of Tea tree new varieties (Changwon No. 3) according to the present invention is more to the expression of collagenase than the general tea tree introduced varieties Yabugida, Kanayami-dori and Yutagami-dori extracts of Comparative Examples 1 to 3 It was confirmed that the effect of inhibiting collagen breakdown in the skin by effectively inhibiting the skin elasticity enhancing effect and wrinkle reduction effect is excellent (see Test Example 3).
  • the anti-inflammatory effect of the extract of the new tea tree (Changwon No. 3) according to the present invention is confirmed through the inhibitory effect of the production of prostaglandins and the inhibitory effect of the production of Interleukin-8 (IL-8) It was.
  • the extract (Example 1) of the new tea tree (Changwon No. 3) according to the present invention was found to have a very high inhibitory effect of the production of prostaglandins, as in the control group treated with aspirin, compared to It was found that the effect of inhibiting prostaglandin production was significantly higher than that of Yabugida, Kanayami-dori, or Yutagami-dori extracts.
  • the extract (Example 1) of the new tea tree varieties (Changwon No. 3) according to the present invention has a very high inhibitory effect on the secretion of IL-8 increased by PGSA, an inflammation-inducing stimulant. It was found that the secretion of IL-8 was significantly reduced and suppressed compared to the general tea tree-introduced varieties Yabugida, Kanayami-dori or Yutagami-dori extracts of Comparative Examples 1 to 3 (see Test Example 4).
  • the anticancer effect of the extract of the new tea tree varieties (Changwon No. 3) according to the present invention was confirmed through the cancer cell proliferation inhibitory effect.
  • Table 12 when (i) a new tea tree (Changwon No. 3) extract was treated to each cancer cell line at a concentration of 100 ⁇ g ⁇ mL ⁇ 1 , the cancer cell proliferation rate was 50% or less in all cancer cell lines. (Survival rate); When a new tea tree (Changwon No.
  • Lung cancer cell line (A549) showed cancer cell proliferation rate when 3 ” -O- Me-EGCG was treated at concentrations of 50 ⁇ g mL- 1 , 100 ⁇ g mL- 1 and 200 ⁇ g mL- 1 . 41.0%, 20.0%, and 16.0%, respectively, and lung cancer cell line (A549) inhibited cancer cell proliferation higher than prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7). It exhibited the features (see Test Example 5).
  • the sensory evaluation of the polysaccharide containing the extract of a new type of tea tree (Changwon No. 3) according to the present invention was performed.
  • the new variety of tea tree (Changwon No. 3) had higher palatability in both semi-fermented tea, fermented tea, and post-fermented tea than Yabugida and Okumi-dori. Was evaluated (see Test Example 6).
  • the invention in one aspect, to go epi catechins -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - It relates to a composition containing as an active ingredient the extract of Camellia sinensis containing a high content of O- Me-EGCG).
  • the extract of the tea tree may be characterized in that the extract of the tea tree new varieties (Changwon No. 3), but is not limited thereto.
  • the composition may be an antioxidant, anti-inflammatory, anti-aging and anticancer pharmaceutical composition, cosmetic composition or health functional food composition, but is not limited thereto.
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the invention from another point of view, as the epi catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O -
  • pharmaceutical composition, cosmetic composition or health functional food composition for antioxidant containing as an active ingredient the extract of the tea tree ( Camellia sinensis ) containing a high content of Me-EGCG),
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the epi-catechins to go -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the epi-catechins to go -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O
  • cosmetic composition or health functional food composition containing the extract of the tea tree ( Camellia sinensis ) containing a high content of -Me-EGCG as an active ingredient,
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • the epi-catechins to go -3- O - (3- O - methyl) gallate epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O
  • anti-cancer pharmaceutical composition, cosmetic composition or health functional food composition containing as an active ingredient an extract of tea tree containing Camellia sinensis with a high content of -Me-EGCG
  • the content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
  • Tea tree new varieties (Jangwon No. 3) (seed accession number: KCTC (Korean Collection for Type Cultures) 12213BP (2012.5.14)) according to the present invention is supplied from Jangwon.
  • a new type of tea tree (Changwon No. 3) is obtained for the purpose of developing varieties of functional tea trees containing a large amount of catechins, which are excellent in antioxidant, anti-aging, skin whitening, anti-cancer and anti-allergic effects.
  • As a cultivar we conducted a separate breeding method on tea tree genes of Andeok-myeon, Andeok-myeon, Seogwipo-si, collected in 2006, and selected a small number of tea trees with high catechins by evaluation of growth characteristics and component contents.
  • the mating and breeding system was conducted in consideration of quality and quantity.
  • the seedlings were sown in breeding houses for mating livestock, and after the formalization of this pavement, the second selection was carried out in 2010 through component analysis and plant characteristics evaluation. Crop characteristics were measured according to the International Union for the Protection of New Varieties of Plants (UPOV) of the Korean National Species (see Preparation Example below).
  • the extract of the tea tree may be at least one extract selected from the group consisting of flowers, leaves, fruits, stems and roots of the tea tree, but is not limited thereto, preferably the extract of the tea tree leaves to be.
  • the tea tree according to the present invention in particular, has a high catechin content in its leaves, epigallocatechin-3- O ⁇ among the catechins contained in the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3).
  • the content of (3- O -methyl) gallate is at least 1.25% by weight, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight, most preferably 2.25 to 6.00% by weight.
  • the extract of the tea tree is epigallo contained in the tea tree's flowers, leaves, berries, stems or roots depending on the harvest time (harvest season), or the harvesting time (harvest season) of the flower, leaf, fruit, stem or root of the tea tree.
  • the content of catechin-3- O- (3- O -methyl) gallate may vary. For example, 2.50% by weight of the new cultivated tea tree (Changwon No. 3) in May, 4.16% in August, or 5.36% in November by epigallocatechin-3- O- (3- O -methyl ) Tea leaf extract containing gallate can be obtained.
  • epi catechins go -3- O - (3- O - methyl) acrylate go are O - as EGCG with a methylated form , 3 ” -O- Me-EGCG or EGCG3” Me.
  • the tea tree according to the present invention has a high catechin content in its leaves, the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3) is gallocatechin (gallocatechin (GC), epigallocatechin ( epigallocatechin (EGC), catechin (C), epicatechin (EC), epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), epicatechin gallate (Epicatechin gallate) Eight catechins of ECG) and catechin gallate (CG) are contained in an amount of 20.55 to 82.2 wt%, preferably 30.8 to 61.65 wt%, more preferably 37 to 51.38 wt%.
  • the extract of the tea tree preferably the extract of the new tea tree (Changwon No. 3) may be characterized by containing 0.01 to 20% by weight relative to the total weight of the composition.
  • the extract of the tea tree preferably the extract of the new type of tea tree (Changwon No. 3) is contained less than 0.01% by weight, anti-oxidant effect, anti-inflammatory effect, anti-aging effect, and anti-cancer effect can not be expected
  • extract of tea tree preferably When the content of the extract of tea tree new varieties (Changwon No. 3) exceeds 20% by weight, skin irritation due to cytotoxicity may be concerned.
  • Tea tree new varieties (Jangwon No. 3) according to the present invention, the step of selecting a tea tree having the characteristics of the following (1) to (5) in the conventional tea tree; Harvesting the selected tea tree when the base of the stem which has not harvested the first tea begins to harden; It is obtained by the breeding method of a new type of tea tree, including the step of inserting into 1 section and 2 sections 2 leaves 1 and obtaining a new tea tree breeding by the asexual propagation method by cutting.
  • the selected tea tree is characterized by having the following characteristics (1) to (5):
  • 1 of the tea extract (e.g., the extract of the tea leaves) to epi go of the catechins contained in the catechin -3- O - (3- O - methyl) gallate is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight, most preferably 2.25 to 6.00% by weight ;
  • leaf width is 37-47 mm, preferably 39-46 mm, more preferably 43-45 mm, most preferably 44.1 mm
  • the leaf length is 85-95 mm, preferably 87-95 mm, more preferably 94 ⁇ 95mm, most preferably be 94.2mm
  • leaf area is 2200 ⁇ 3200mm 2 or 4000 ⁇ 4500mm 2, preferably 2500 ⁇ 2800mm 2 or 4100 ⁇ 4300mm 2, more preferably 4150 ⁇ 4200mm 2, and most preferably from 4154.2 mm 2 ;
  • the lobe is long oval, the mother's hair is medium, and the lobe is green;
  • the new chickpea is 145.0-165.0 mm, preferably 150.0-165.0 mm, more preferably 162.0-164.0 mm, most preferably 163.5 mm, and among white eggs 123.0-143.0 g / 100bud, preferably 128.0- 139.0 g / 100bud, more preferably 136.0-139.0 g / 100bud, most preferably 138.3 g / 100bud; And
  • the selected tea tree may be a tea tree additionally having the following properties (6) to (17).
  • chlorophyll content (soil & plant analyzer development, SPAD) is 58-62;
  • the total amino acid (TFAA) content is at least 3.50 wt%
  • the deanine content is at least 2.20% by weight
  • the total nitrogen content is at least 6.00% by weight
  • the caffeine content is 23.5 mg / g or less
  • the water washing of the eggplant is medium, and the eggplant thickness and eggplant density are medium;
  • the extract of the tea tree is 6.35 to 25.4% by weight, preferably 9.53 to 19.05% by weight, more preferably 11.4 to 15.9% by weight epigallocatechin (EGC), 9.4 to 37.6% by weight, preferably 14.1-28.2 wt%, more preferably 16.9-23.5 wt% epigallocatechin gallate (EGCG) and 2.65-10.6 wt%, preferably 3.98-7.95 wt%, more preferably 4.77-66.63 Weight percent epicatechin gallate (ECG); And
  • the breeding method may further comprise the step of immersing in water for 1 to 2 hours by cutting the lower part of the cut branch obliquely left 2 ⁇ 3 cm from the lowermost leaf after the insertion. .
  • the general cultivation conditions of the conventional tea plant is applied, for example, it can be carried out as follows. Sunscreening should be done immediately after cutting and the transmittance should be around 30 ⁇ 45%. Until the roots are inserted, they are usually absorbed from the lower cut mortar, such as cut flowers, and survive. Approximately 1 month after cutting, root cuttings are excised slightly. After rooting, 50 to 60% of the maximum water is appropriate. Fertilization starts after August and may start from September. Weeding and pest control in seedlings should be carried out with care and sufficient debris after rooting and growth.
  • the tea tree was grown using the cultivation method of the new Camellia sinensis species, characterized by growing the tea tree under the conditions of (1) to (5):
  • the cultivated tea tree is not particularly limited, but is preferably a new tea tree species according to the present invention having the following characteristics (1) to (16):
  • extract of the tea plant new varieties e.g., the extract of the tea leaves
  • epi catechins go of the catechins contained in the -3- O - (3- O - methyl) acrylate
  • EGCG3 Me
  • 3 -O- Me-EGCG
  • EGCG3 Me
  • 3 -O- Me-EGCG
  • chlorophyll content (soil & plant analyzer development, SPAD) is 58-62;
  • the deanine content is at least 2.20% by weight
  • the total nitrogen content is at least 6.00% by weight
  • the caffeine content is 23.5 mg / g or less
  • the leaf width is 37 to 47 mm, preferably 39 to 46 mm, more preferably 43 to 45 mm, most preferably 44.1 mm
  • the leaf length is 85 to 95 mm, preferably 87 to 95 mm, more preferably 94 ⁇ 95mm, most preferably be 94.2mm
  • leaf area is 2200 ⁇ 3200mm 2 or 4000 ⁇ 4500mm 2, preferably 2500 ⁇ 2800mm 2 or 4100 ⁇ 4300mm 2, more preferably 4150 ⁇ 4200mm 2, and most preferably from 4154.2 mm 2 ;
  • the lobes are long oval, the hairs medium and the lobes are green;
  • the new chickpea is 145.0-165.0 mm, preferably 150.0-165.0 mm, more preferably 162.0-164.0 mm, most preferably 163.5 mm, and among white eggs 123.0-143.0 g / 100bud, preferably 128.0- 139.0 g / 100bud, more preferably 136.0-139.0 g / 100bud, most preferably 138.3 g / 100bud;
  • the extract of the new varieties of tea tree is 6.35 to 25.4% by weight, preferably 9.53 to 19.05% by weight, more preferably 11.4 to 15.9% by weight epigallocatechin (EGC), 9.4 to 37.6% by weight, preferably 14.1-28.2% by weight, more preferably 16.9-23.5% by weight epigallocatechin gallate (EGCG) and 2.65-10.6% by weight, preferably 3.98-7.95% by weight, more preferably 4.77- 6.63 wt% epicatechin gallate (ECG); And
  • the total content of catechins of gallate, EGCG), gallocatechin gallate (GCG), epicatechin gallate (ECG) and catechin gallate (CG) is preferably 20.55 to 82.2% by weight, preferably 30.8-61.65 weight%, More preferably, 37-51.38 weight%.
  • the pharmaceutical composition containing the extract of the tea tree is a pharmaceutical, such as preservatives, stabilizers, wetting or emulsifiers, salts and / or buffers for the control of osmotic pressure
  • Adjuvants and other therapeutically valuable substances may further be contained and may be formulated in various oral or parenteral dosage forms in accordance with conventional methods.
  • carrier is defined as a compound that facilitates the addition of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • carrier facilitates the incorporation of many organic compounds into cells or tissues of an organism.
  • excipient is a substance that is added to make it easier to take medicine or to have a certain color and form when the amount of the main medicine is small in the process of preparation of tablets or pills, such as lactose or starch. do.
  • diot is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
  • a composition containing an extract of a tea tree preferably an extract of a new tea tree (Changwon No. 3)
  • As a composition it may be administered.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the oral dosage form may include powders, granules, tablets, capsules, syrups, etc.
  • the parenteral dosage forms may include, for example, injections, drops, ointments, lotions, gels, creams, sprays, suspensions, Formulations such as emulsions, suppositories, and patches may be used, but are not limited thereto.
  • compositions according to an embodiment of the present invention may be administered parenterally, rectally, topically, or transdermally.
  • Pharmaceutical compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
  • the pharmaceutically acceptable dose, ie dosage, of the active ingredient depends on the age, sex, and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Will be different. Dosage determination based on these factors is within the level of skill in the art.
  • the dosage is, for example, 1 to several times so as to be administered in an amount of 0.01 to 5000 mg, preferably 0.1 to 2000 mg, more preferably 0.5 to 500 mg, and most preferably 1 to 100 mg per kg of body weight per day. It can be administered in divided, but the dosage is not intended to limit the scope of the invention in any way.
  • compositions suitable for use in the present invention include compositions in which the active ingredients, including extracts of tea tree, preferably extracts of the new tea tree species (Changwon No. 3), are contained in an amount effective to achieve their intended purpose. do. More specifically, a therapeutically effective amount means an amount of a compound effective to prolong the survival of the subject to be treated or to prevent, alleviate or alleviate the symptoms of a disease. Determination of a therapeutically effective amount is within the capabilities of those skilled in the art, in particular in terms of the detailed disclosure provided herein.
  • a therapeutically effective amount for an extract of tea tree, preferably an extract of a new tea tree (Changwon No. 3), and a composition (compounds) containing the same as an active ingredient used in the methods of the present invention is determined initially from cell culture assays.
  • dose can be calculated in an animal model to obtain a range of circulating concentrations that includes an IC 50 (half maximal inhibitory concentration) or EC 50 (half maximal effective concentration) determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficiency of the extracts of the tea tree described herein, preferably the extract of the new tea tree (Changwon No. 3), or compositions (compounds) containing the same as active ingredients, are described, for example, in LD 50 ( To determine lethal dose for 50%), ED 50 (dose with therapeutic effect for 50% of the population), IC 50 (dose with therapeutic inhibitory effect for 50% of the population), in cell culture or laboratory animals. It can be estimated by the table of constraint constraints of. The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 50 (or IC 50 ). Compounds showing high therapeutic indices are preferred. The data obtained from these cell culture assays can be used to estimate the range of doses used in humans. The dosage or dosage of such compounds is preferably in the range of circulating concentrations including ED 50 (or IC 50 ) in the absence or little toxicity.
  • the formulation of the pharmaceutical composition is preferably any one selected from the group consisting of ointments, lotions, gels, creams, sprays, suspensions, emulsions, and patches.
  • the composition according to the present invention is applied to a pharmaceutical composition, the composition may be formulated in a solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier using the composition as an active ingredient.
  • the active ingredient of the present invention can be easily formulated, and it can be easily formulated with surfactants, excipients, colorants, spices, stabilizers, preservatives, preservatives, wetting agents, emulsifiers, suspending agents, salts for controlling osmotic pressure and / or Buffers and other commercial auxiliaries can be used as appropriate.
  • the pharmaceutical composition may be a pharmaceutical composition that is effective in treating cancer or a tumor.
  • cancer typically refers to or describes the physiological state of a mammal characterized by unregulated cell growth / proliferation.
  • cancer include, but are not limited to, carcinoma, lymphoma (eg, Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia.
  • cancers include squamous cell cancer, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, Bladder cancer, hepatocellular cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver carcinoma, leukemia and other lymphocytic disorders, and various types of two Contains cervical cancer.
  • the cancer is preferably prostate cancer, lung cancer or breast cancer.
  • the cosmetic composition containing the extract of the tea tree preferably the extract of the new tea tree (Changwon No. 3) is a skin external composition, supple cosmetics, astringent cosmetics, nourishing cosmetics, lotions, eye creams, nutrition creams, massage It may be characterized in that it is formulated into any one selected from the group consisting of cream, cleansing cream, cleansing foam, cleansing water, powder, essence, and pack.
  • composition according to the present invention can be used for fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non- With ionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in cosmetics. It may contain adjuvants commonly used in the same cosmetic or dermatology field. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts.
  • the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
  • carriers useful in cosmetic compositions include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate or mineral oil.
  • the carrier may be a solution, a colloidal dispersant, an emulsion (oil-in-water or water-in-oil), a suspension, a cream, a lotion, a gel, a foam, a mousse, a spray, and the like.
  • Other ingredients may also be included that may be selected depending on the intended use of the carrier and / or combination.
  • Additional ingredients include water-soluble colorants (such as FD & C Blue # 1); Oil-soluble colorants (such as D & C Green # 6); Water-soluble sunscreens (such as Eusolex 232); Oil-soluble sunscreens (such as octyl methoxycinnamate); Particulate sunscreens (such as zinc oxide); Antioxidants (such as BHT); Chelating agents (such as disodium EDTA); Emulsion stabilizers (such as carbomers); Preservatives (such as methyl parabens); Flavoring (such as pinene); Flavorings (such as sorbitol); Humectant (such as glycerin); Waterproofing agents (such as PVP / eicosene copolymers); Water-soluble film forming agents (such as hydroxypropyl methylcellulose); Oil-soluble film-forming agents (such as hydrogenated C-9 resins); Cationic acid polymers (such as polyquaternium 10); Anionic polymers (such as xanthan
  • 'Functional food' or 'functional food' in the present invention means a food that improves the functionality of the general food by adding the extract of the tea tree according to the present invention, preferably the extract of the new tea tree (Changwon No. 3) to the general food do.
  • Functionality can be roughly divided into physical properties and physiological functions.
  • the physical properties and physiological functions of general foods will be improved, and the present invention provides a food product of such an improved function as a comprehensive 'functional food.
  • Health functional food "or" functional food (health functional food) ".
  • health functional food refers to a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Health Functional Food Act No. 10213, and nutrients for the structure and function of the human body. It is meant to be consumed for the purpose of regulating or obtaining a useful effect for health use such as physiological action.
  • the health functional food containing the extract of the tea tree according to the present invention preferably the extract of the new tea tree (Changwon No. 3), will give a synergistic effect to the main effect within the scope of not impairing the main effect of the present invention.
  • other ingredients that may be present.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
  • compositions of the present invention can be used in the form of additives for other foods.
  • the formulation of the functional food containing the extract of the tea tree, preferably the extract of tea tree (Changwon No. 3) according to the present invention is not particularly limited, for example, tablets, granules, drinks, beverages, solutions, emulsions, It may be formulated in various forms, such as viscous mixtures, tablets, powders, liquids, teas, and the like, and is preferably a functional tea composition.
  • the health functional food administration may be administered by a variety of methods, such as simple drinking, injection, spray or squeeze method.
  • the cropping method and cultivation management were performed according to the Rural Development Administration Standard Agricultural Exchange Number.
  • the hybrid breeding is first selected from the gene source containing a high content of 3 " -O- Me-EGCG, a specific functional ingredient among domestic native tea tree gene sources, the gene After mating the originals to obtain lively progeny, they were grown, but elites containing high content of 3 " -O- Me-EGCG were grown.
  • sprouting time and leaf properties (leaf shape, parenting, leaf color, leaf width, leaf length, leaf area, chlorophyll content, etc.);
  • eggplant characteristics soot, water washing, eggplant thickness and eggplant density
  • the growth characteristics test more specifically, in the first tea period (April 24 to May 5) at the time of opening 70% of the infants, a grid of 20 cm horizontal and vertical on the tea tree and 1 in the lattice All shoots were harvested up to 3 cores of the core, and the mean values of the growth indicators, including fertility, leaf length, leaf width, renal intestine and renal middle weight, were measured according to the International Plant Genetic Standards of Korea's National Species. Fertility was compared by examining the germination of the germination which is 70% of the total sprouts. Kidneys measured the stem length from the base of the shoot to the uppermost lobe. The infant weight was evaluated as the weight of 100 buds. Leaf area, leaf width, and leaf area were irradiated to the third leaf from the collected kidney, and leaf area was measured using a leaf area meter (LI-3100 Area Meter, LI-COR. Inc., Japan).
  • Table 1 below shows the cropping characteristics, which are the selection criteria for new varieties of tea tree.
  • Table 2 shows the chemical component characteristics for the evaluation of chemical components, which is a selection criteria of new tea varieties.
  • Component Content Characteristics Content range 3 -O- Me-EGCG (mg / g) 4.00 or more Total amount of amino acid (TFAA) (% by weight) 3.50 or more Deanine content (% by weight) 2.20 or more Nitrogen content (% by weight) 6.00 or more Caffeine Content (mg / g) 23.5 or less Total catechin (mg / g) 100.0 or less
  • the "SPAD” value described herein is a value measured by a non-destructive method of predicting chlorophyll content or nitrogen content of a leaf by measuring the greenness of the leaf using a chlorophyll meter (SPAD-502, Minolta, Japan). Means.
  • “SPAD (Soil & Plant analyzer development)” is a measuring instrument developed by the Soil & Plant Analyzer Development Project (SPAD) in the Ministry of Agriculture, Forestry and Fisheries. The principle of this instrument is to generate light in the chlorophyll-sensitive wavelength band of 650nm and insensitive wavelength band of 940nm using light emitting diodes, and then pass the light through a 2 * 3mm window and measure 1.2mm in thickness. The intensity of light passing through the leaves of plants within is measured with a silicon photodiode and the chlorophyll content is expressed as a value between -9.9 and 99.9 using the difference between the two wavelength bands.
  • the NIR analyzer (NIRs-XDS, Foss) was used to measure the near-infrared absorption spectra (400-2500nm) for each sample, and the individual contents were calculated.
  • Table 3 below shows the growth characteristics that are the selection criteria of new varieties of tea tree.
  • Jangwon No. 3 a new type of tea tree selected by the above breeding method, was collected from the first to third leaves of the new shoots based on the 70% of the first five-leaf openings during the first water vehicle (early May). Steam was passed for 40 seconds in the hot air, dried in an 80 °C dryer, powdered by a grinder, and then separated into a 60 mesh sieve and powdered. 100 g of a new cultivated tea tree (Changwon No. 3) was refluxed by adding 1 L of 70% (v / v) aqueous solution of ethanol (v / v) + 30% (v / v) of distilled water). Extraction, filtration and concentration under reduced pressure at 40 ⁇ 45 °C finally secured 19.2g of the dried extract (Example 1) of the tea varieties (Changwon No. 3) leaves.
  • Example 1 Except for using a new tea tree varieties Yabugida in Example 1 instead of Yabugida varieties introduced in Example 1, was prepared in the same manner as in Example 1 to finally secure 17.5g of the dried extract of Yabugida leaves.
  • Example 1 Except for using a new tea varieties Kanayamidori instead of a new tea tree (Changwon No. 3) in Example 1 was prepared in the same manner as in Example 1 to finally secure 17.1g of the dried extract of Kanayamidori leaves.
  • Example 3 Except for using a new tea tree (Changwon No. 3) in Example 1, except that the general tea tree introduced varieties Yutagami-dori, prepared in the same manner as in Example 1 finally secured 18.3g of the dried extract of the leaves of Yutagami-dori It was.
  • Example 10 Except for fermented tea, oolong tea (semi-fermented tea), and black tea (fermented tea) in the same manner as in Example 2, except that Yabugida, a general tea tree introduced variety, was used in place of the new tea tree varieties (Changwon No. 3). And post-fermented tea was prepared (see Formulation Example 10 below).
  • Example 10 Except for fermented tea, oolong tea (semi-fermented tea), and black tea (fermented tea) in the same manner as in Example 2, except that Okumidori, a general tea tree introduced variety, was used in place of the new tea tree varieties (Changwon No. 3). ) And post-fermented tea were prepared (see Formulation Example 10 below).
  • Extract of the new tea varieties (Changwon No. 3) leaf prepared in Example 1, the extract of Yabugida leaf prepared in Comparative Example 1, the extract of the Kanayami-dori leaf prepared in Comparative Example 2, the yutagami-dori prepared in Comparative Example 3
  • the catechin and caffeine components of the extracts of the leaves were analyzed.
  • each of the extracts were dissolved in 50% methanol to make a 10,000 ppm solution, followed by component analysis using High-Performance Liquid Chromatography (HPLC) (Waters). Waters, 2996 PDA detector).
  • HPLC High-Performance Liquid Chromatography
  • the stationary phase was Mightysil RP-18 GP 250 * 4.6 (5 ⁇ m) column of Kanto Chemical, and the mobile phase was used in the composition ratio shown in Table 5. If necessary, catechin and caffeine component analysis can be performed by near infrared spectroscopy.
  • the total content of catechin was 41.1% by weight in the extract of the new type of tea tree (Changwon No. 3) leaves, extract of Yabugida leaf (28.1% by weight), Ghana, the general tea tree introduced varieties It was higher than the extract of Yami-dori leaves (26.7 wt%) and the extract of Yutagami-dori leaves (26.4 wt%).
  • tea tree new varieties (manor third) of the leaf extract is a catechin epi go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) was found to be present in an amount of 2.5% by weight, which is more than 10 times higher than that of general tea plants.
  • the extracts derived from the new tea tree are more antioxidant and It can be expected that the aging and anti-inflammatory effects will be better.
  • the extract of the new tea tree (Changwon No. 3) leaf of Example 2 showed a higher total content of catechin than Yabugida extract of 4.
  • the total content of the catechin is gallic acid (GA), gallocatechin (gallocatechin, GC), epigallocatechin (epigallocatechin, EGC), catechin (catechin, C), epigallocatechin gallate (epigallocatechin gallate) , EGCG), epicatechin (epicatechin, EC), Gallo catechin gallate (gallocatechin gallate, GCG), to epi-catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" -O- Me-EGCG) and epicatechin gallate (ECG).
  • the content of 3 ” -O- Me-EGCG) of the extracts of the tea varieties (Changwon No. 3) leaves of Example 2 was 4.7 mg ⁇ g in green tea, oolong tea (semi-fermented tea) and black tea (fermented tea), respectively. 1, it is shown with 3.6mg ⁇ g -1, 1.94mg ⁇ g -1. That is, 3 ” -O- Me-EGCG contained in the leaves of the new tea tree (Changwon No. 3) is transformed into components such as deoflavin and deorubidine, which are catechin polymers by oxidation during processing like other catechin compounds. It was confirmed that the content of 3 ” -O- Me-EGCG contained in the tea stream was reduced.
  • Test substance IC 50 (ppm) AsA (Vitamin C) 7.1 Tea tree new varieties (Jangwon No. 3) extract (Example 1) 10.2 Yabugida Extract (Comparative Example 1) 35.1 Kanaya Midori Extract (Comparative Example 2) 31.5 Yutagami-dori Extract (Comparative Example 3) 37.7
  • the extract (Example 1) of a new type of tea tree (Changwon No. 3) showed a similar antioxidant effect as compared to the ascorbic acid, an antioxidant used as a positive control. Compared to Gan, Kanaya Midori and Yutagamidori extracts, it showed significantly higher antioxidant efficacy.
  • the new tea tree (Changwon 3) In order to confirm the superoxide anion scavenging activity of the new extract of Tea tree (Changwon 3) and the Yabugida extract (Comparative Example 1), the new tea tree (Changwon 3) at concentrations of 10 ⁇ M and 20 ⁇ M Superoxide anion scavenging activity of the extract, Yabugida extract and ascorbic acid (Ascorbic acid, AsA, Vitamin C) as a positive control was measured by ESR spectrophotometer.
  • the DMPO-OOH signal generated without the treatment of antioxidants can be strongly erased, and when calculated by the number of mol, the extract of new tea tree (Changwon No. 3) than the rate of DMPO reacting with superoxide anion (or 3 " O- Me-EGCG) reacted with superoxide anion about 10,000 times higher.
  • the superoxide anion scavenging activity of the extract of new tea tree was higher than that of AsA, which is the major functional ingredient of EGCG (epigallocatechin gallate) and 3 " -O -Me This may be due to ortho-trihydroxy in the gallate group and the B ring.
  • the new extract of tea tree (Changwon No. 3) showed higher superoxide anion scavenging activity than Yabugida extract, not only by the catechin component but also by the catechin component 3 " -O- Me-EGCG. We believe this is due to a synergistic effect.
  • the new extract of tea tree (Changwon No. 3) was higher in scavenging activity at a concentration of 10 ⁇ M or 25 ⁇ M than Yabugida extract.
  • the scavenging activity between the two extracts was not significantly different, but the new extract of tea tree (Changwon No. 3) showed about 5 times higher hydroxyl radical scavenging activity than AsA.
  • the collagenase production inhibitory ability of each extract prepared in Example 1 and Comparative Examples 1 to 3 was measured by comparing with Tocopherol.
  • Tocopherol is a representative antioxidant that is known to have a function of preventing skin aging by regenerating epidermal cells of the skin.
  • the test was performed by placing human fibroblasts at 5,000 cells / well in a 96-well microtiter plate containing Dulbecco's Modified Eagle's Media (DMEM) medium containing 2.5% fetal calf serum. Incubate until growth. After culturing in serum-free DMEM medium for 24 hours, the extracts of Preparation Example 1 and Comparative Examples 1 to 3 dissolved in serum-free DMEM medium were treated at 50 ppm concentration and tocopherol at 1x10 -4 molar concentration for 24 hours. Cell culture was collected.
  • DMEM Dulbecco's Modified Eagle's Media
  • the collected cell culture solution was measured for the degree of collagenase production using a commercially available collagenase measuring instrument (Amersham Pharmacia, USA). First, the collected cell culture was placed in a 96-well plate uniformly coated with primary collagenase antibody, and the antigen-antibody reaction was performed in a thermostat for 3 hours.
  • the chromophore-conjugated secondary collagen antibody was placed in a 96-well plate and reacted again for 15 minutes. After 15 minutes, the coloring stimulant was added, causing color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the reaction (color development). The color of the reaction solution was yellow and the degree of yellow color was different according to the progress of the reaction.
  • the absorbance of the yellowish 96-well plate (96-well plate) was measured at 405 nm using an absorbance meter, and the degree of synthesis of collagenase was calculated by Equation 1 below.
  • the reaction absorbance of the collected cell culture medium of the group not treated with the composition was used as a control. That is, the expression level of collagenase in the non-treated group was set to 100, and the expression level of collagenase in the group treated with the test substance was calculated, and the results are shown in Table 9 below.
  • Test substance Collagenase expression level (%) Untreated group 100 Tocopherol 63 Tea tree new varieties (Jangwon No. 3) extract (Example 1) 51 Yabugida Extract (Comparative Example 1) 69 Kanaya Midori Extract (Comparative Example 2) 74 Yutagami-dori Extract (Comparative Example 3) 76
  • Example 3 is more to the expression of collagenase than the general tea tree introduced varieties Yabugida, Kanayami-dori and Yutagami-dori extracts of Comparative Examples 1 to 3 It was confirmed that the effect of inhibiting collagen breakdown in the skin by effectively inhibiting the skin elasticity enhancing effect and wrinkle reduction effect is excellent.
  • the skin anti-inflammatory effect of each extract prepared in Example 1 and Comparative Examples 1 to 3 was evaluated as a production inhibitory effect of prostaglandins.
  • the anti-inflammatory effect was measured in macrophages using each of the extracts.
  • aspirin was added to macrophages taken from the abdominal cavity of mice to a final concentration of 500 M, thereby irreversibly inhibiting cyclooxygenase (COX) activity remaining in the cells.
  • COX cyclooxygenase
  • the suspension was added to each well of a 96-well cell culture tube and incubated for 2 hours in an incubator at 37 ° C. with 5% CO 2 to attach macrophages to the container surface.
  • the attached macrophages were then washed three times with PBS and used for the anti-inflammatory effect test.
  • Example 1 and Comparative Example 1 100 ⁇ l of each extract prepared in ⁇ 3 was used to quantify free prostaglandins using enzyme-linked immunosorbent assay (ELISA). At this time, the prostaglandin production inhibitory activity (%) of each extract prepared in Example 1 and Comparative Examples 1 to 3 is shown in Table 10 below.
  • Test substance Prostaglandin inhibitory ability (%) Untreated group (NT) 0 Control group (aspirin treated group) 58.6 Tea tree new varieties (Jangwon No. 3) extract (Example 1) 56.9 Yabugida Extract (Comparative Example 1) 37.5 Kanaya Midori Extract (Comparative Example 2) 27.4 Yutagami-dori Extract (Comparative Example 3) 33.8
  • the extract (Example 1) of a new type of tea tree (Changwon No. 3) was found to have a very high inhibitory effect on the production of prostaglandins as in the control group treated with aspirin, and the general tea tree of Comparative Examples 1 to 3 Compared with the introduced varieties Yabugida, Kanayamidori and Yutagamidori extracts, the prostaglandin production inhibitory effect was remarkably high.
  • the extract of tea tree new varieties (Changwon No. 3) according to the present invention and the composition comprising the same has an anti-inflammatory effect by inhibiting the expression of prostaglandin, a skin inflammation factor, and further improves skin acne and skin allergy by alleviating skin troubles.
  • the composition comprising the same has an anti-inflammatory effect by inhibiting the expression of prostaglandin, a skin inflammation factor, and further improves skin acne and skin allergy by alleviating skin troubles.
  • Example 1 Each extract prepared in Example 1 and Comparative Examples 1 to 3 was treated in each well according to the concentrations of Table 6, followed by reaction for 30 minutes, followed by PGSA (10 ⁇ g / ml), PGSA (50 ⁇ g / ml), and PGSA. (50 ⁇ g / ml) + LPS (1 ⁇ g / ml) were treated respectively.
  • PGSA peptidoglycan from S.
  • peptidoglycan is a peptidoglycan (peptidoglycan) extracted from Staphylococcus aureus, a major component of the cell wall of Gram-positive bacteria and bacterial membrane components are known to cause inflammation, In particular, in staphylococci, about 90% of patients with atopic dermatitis have been reported to cause secondary infection. After incubation for 24 hours at 37 °C, 5% CO 2 incubator, the culture medium was taken and subjected to ELISA for interleukin-8, the results are shown in Table 11 below. ELISA used the experimental method of the manufacturer (BD science).
  • Test substance IL-8 secretion (pg / ml) Untreated group (NT) 935.12 10 ⁇ g / ml PGSA 4725.64 PGSA 10 ⁇ g / ml + New Tea Tree (Changwon No. 3) Extract (Example 1) 25ppm 1503.29 PGSA 10 ⁇ g / ml + New Tea Tree (Changwon No.
  • the extract (Example 1) of a new tea tree (Changwon No. 3) was found to have a very high effect of inhibiting the secretion of IL-8 increased by PGSA, an inflammation-inducing stimulus, Comparative Examples 1 to 3 It was found that significantly reduced and inhibited IL-8 secretion compared to the extracts of Yabugida, Kanayami-dori and Yutagami-dori, which are introduced from the tea strains.
  • the extract of tea tree new varieties (Changwon No. 3) according to the present invention and the composition comprising the same has an anti-inflammatory effect by inhibiting the secretion of the skin inflammation-induced stimulus IL-8, and further alleviate the skin trouble to skin acne and skin allergy It could be confirmed that can be improved.
  • Extract of tea tree (Changwon No. 3) leaf (hereinafter referred to as tea tree new breed (Changwon No. 3) extract), or 3 " -O- Me-EGCG isolated from said extract, cancer cell line lung cancer cell line (A549), kidney cancer Cell lines (ACHN), colon cancer cell lines (HCT15), prostate cancer cell lines (LNCaP) and breast cancer cell lines (MCF-7) were treated and then incubated for 36 hours in a 37 ° C, 5% CO 2 incubator. After cultivation, the extract of tea tree varieties (Changwon No. 3), or 3 " -O- Me-EGCG on the cell line was confirmed by MTT assay, but negative control treated with 0.1% DMSO. Relative cancer cell proliferation was measured as a reference.
  • - O handling -Me-EGCG in a concentration of 50 ⁇ g ⁇ mL -1, 100 ⁇ g ⁇ mL -1 and 200 ⁇ g ⁇ mL -1 In this case, the proliferation rate of prostate cancer cell lines was about 46%, 37%, and 20%, respectively, and the cancer cell proliferation inhibitory effect was high, and the breast cancer cell line (MCF-7) was also derived from the new tea tree (Changwon 3) extract under the same conditions.
  • MCF-7 breast cancer cell line
  • Lung cancer cell line tea new varieties (manor No. 3) to (A549) extracts from 3 "- in case of processing the O -Me-EGCG in a concentration of 50 ⁇ g ⁇ mL -1, 100 ⁇ g ⁇ mL -1 and 200 ⁇ g ⁇ mL -1 , Cancer cell proliferation was about 41%, 20% and 16%, respectively, lung cancer cell line (A549) showed higher cancer cell proliferation inhibitory effect than prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7).
  • Green tea (fermented tea), oolong tea (semi-fermented tea), black tea (fermented tea), or black tea (post-fermented tea) has different characteristics such as shape, color, aroma, color search, and taste.
  • Semi-fermented tea), black tea (fermented tea), or black tea (post-fermented tea) changes in palatability, color, taste, etc. according to the fermentation progress, and the contained ingredients also change.
  • extracts of the new tea tree varieties (Changwon No.
  • Example 3 3) of Example 2, Yabugida (Japanese varieties) extract of Comparative Example 4, and Comparative Examples For Okumidori (Japanese varieties) extract of 5, appearance evaluation (shape, color; perfect score of 40 points) and quality evaluation (fragrance, search, taste; perfect score of 60 points) were carried out to investigate palatability and functionality as tea. ) was performed.
  • the new varieties of tea tree (Changwon No. 3) had higher palatability in both semi-fermented tea, fermented tea and post-fermented tea than Yabugida and Okumi-dori. It appeared to have, and has excellent characteristics in the production of various kinds of tea, and it was evaluated that the utilization was very high.
  • Nutritional cream was prepared in a conventional manner according to the composition described in Table 15 (unit: wt%).
  • the pack was prepared by the conventional method according to the composition described in Table 17 (unit: wt%).
  • Ointment was prepared in a conventional manner according to the composition described in Table 18 (unit: wt%).
  • Extract of new tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, beeswax 4 mg and lecithin 9 mg were mixed and mixed according to a conventional method to fill soft capsules. A liquid was prepared. 400 mg per capsule was filled to prepare a soft capsule. In addition, a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
  • Extract of tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, galactooligosaccharide 200 mg, lactose 60 mg and maltose 140 mg were mixed and granulated using a fluidized bed dryer and then sugar ester (sugar ester) 6 mg was added. Tablets were prepared by compression of 504 mg of these compositions in a conventional manner.
  • Extract of a new tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, glucose 10 g, citric acid 0.6 g, and 25 g of liquid oligosaccharides were mixed and 300 ml of purified water was added to each bottle 200 ml. Filled very hard. After filling the bottle sterilized for 4 to 5 seconds at 130 °C to prepare a beverage.
  • Extract of tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, 250 g of anhydrous glucose, and 550 mg of starch were mixed and formed into granules using a fluidized bed granulator, and then filled into sachets. It was prepared by.
  • the tea leaf temperature was maintained at 90 ° C. for 30 seconds using a boiler-operated steamer. . After drying enough to have a water content of 6% or less, and milled to a particle size of 0.5 ⁇ 4mm using a grinding machine was prepared as 1.0g tea bag.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a composition containing an extract of Camellia sinensis, preferably an extract of a novel variety of Camellia sinensis (Jangwon number 3), and more particularly, to a composition containing, as an active ingredient, an extract of Camellia sinensis having a high content of epigallocatechin-3-O-(3-O-methyl) gallate (EGCG3"Me; 3"-O-Me-EGCG). A composition according to the present invention containing, as an active ingredient, an extract of Camellia sinensis having a high content of epigallocatechin-3-O-(3-O-methyl) gallate has an antioxidant effect due to the elimination and suppression of free radicals, has an anti-aging effect on the skin due to having an excellent ability to inhibit the formation of collagenase, has an anti-inflammatory effect due to inhibiting the expression and secretion of inflammatory factors, such as prostaglandin and IL-8 and the like, in skin cells, and has an excellent anticancer effect with respect to cancer cell lines derived from various tissues.

Description

차나무의 추출물을 함유하는 조성물Composition containing extract of tea tree
본 발명은 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 함유하는 조성물로서, 더욱 상세하게는 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물을 유효성분으로 함유하는 조성물에 관한 것이다. The present invention is a composition containing an extract of a tea tree, preferably an extract of a new type of tea tree (Jangwon No. 3), more specifically epigallocatechin-3- O- (3- O -methyl) gallate (epigallocatechin- The present invention relates to a composition containing an extract of Camellia sinensis , which contains a high content of 3-O- (3-O-methyl) gallate; EGCG3 ”Me; 3” -O- Me-EGCG) as an active ingredient.
인간의 피부는 나이가 들어감에 따라 여러 가지 내적, 외적 요인에 의해 변화를 겪는다. 즉, 내적으로는 신진대사를 조절하는 각종 호르몬의 분비가 감소하고, 면역 세포의 기능과 세포들의 활성이 저하되어 생체에 필요한 면역 단백질 및 생체 구성 단백질들의 생합성이 줄어들게 되며, 외적으로는 오존층 파괴로 인하여 태양 광선 중 지표에 도달하는 자외선의 함량이 증가하고 환경오염이 더욱 심화됨에 따라 자유 라디칼 및 활성 유해산소 등이 증가함으로써, 피부의 두께가 감소하고, 주름이 증가하며, 탄력이 감소될 뿐 아니라 피부 혈색도 칙칙해지고, 피부 트러블이 자주 발생하며, 기미와 주근깨 및 검버섯 또한 증가하는 등 여러 가지 변화를 일으키게 된다.Human skin is changed by a number of internal and external factors as it ages. That is, internally, the secretion of various hormones that regulate metabolism decreases, and the function of immune cells and the activity of cells decreases, thereby reducing the biosynthesis of immune proteins and constituent proteins necessary for living organisms. Due to the increase in the amount of ultraviolet rays that reach the surface of the sun's rays and intensifying environmental pollution, free radicals and active oxygen radicals increase, thereby reducing the thickness of the skin, increasing wrinkles, and reducing elasticity. The color of the skin becomes dull, skin problems frequently occur, and there are various changes such as blemishes, freckles, and black mushrooms.
노화가 진행될수록 피부를 구성하는 물질인 콜라겐, 엘라스틴, 히아루론산 및 당단백질의 함유량 및 배열이 변하거나 감소하는 증상들이 나타나게 되고, 자유 라디칼 및 활성 유해 산소에 의한 산화적 스트레스를 받게 된다. 또한, 노화가 진행되거나 자외선에 의해서, 피부를 구성하는 대부분의 세포에서는, 염증을 일으킨다고 알려져 있는 전염증성 사이토카인(proinflammatory cytokine)을 생성하는 효소인 사이클로옥시게나제-2(Cox-2, cyclooxygenase)의 생합성이 증가하고, 이들 염증성 인자에 의해 피부조직을 분해하는 효소인 매트릭스 메탈로프로테아제(MMP, matrix metalloproteinase)의 생합성이 증가하며, iNOS(inducible nitric oxide synthase)에 의한 NO(nitric oxide) 생성이 증가하는 것으로 알려져 있다. As aging progresses, symptoms such as changes and decreases in the content and arrangement of collagen, elastin, hyaluronic acid and glycoproteins, which are constituents of the skin, appear and are subject to oxidative stress caused by free radicals and active harmful oxygen. In addition, cyclooxygenase-2 (Cox-2, cyclooxygenase), an enzyme that produces proinflammatory cytokine, which is known to cause inflammation in most cells constituting the skin, due to aging or ultraviolet rays. ) Increases biosynthesis, increases the biosynthesis of matrix metalloproteinase (MMP), an enzyme that breaks down skin tissue by these inflammatory factors, and produces nitric oxide (NO) by inducible nitric oxide synthase (iNOS) This is known to increase.
즉, 자연적으로 진행되는 내인성 노화에 따른 세포활성의 감소 및 미세염증에 의해 기질물질의 생합성이 감소되고, 여러 가지 유해 환경에 의한 스트레스의 증가 및 태양 광선에 의한 활성 산소 종의 증가와 같은 외적 요인에 의해 분해 및 변성이 가속화되어 피부 기질이 파괴되고 얇아지면서 피부 노화의 제반 증상들이 나타나게 된다. 따라서, 이러한 노화의 현상들을 방지하고, 개선시킬 수 있는 활성성분에 대하여 많은 연구가 행해지고 있는 것이 현실이다. That is, the biosynthesis of the substrate material is reduced due to the decrease of cellular activity and micro-inflammatory due to the naturally occurring endogenous aging, the external factors such as the increase of stress caused by various harmful environments and the increase of free radical species by the sun's rays. Degradation and degeneration are accelerated by this, resulting in the destruction and thinning of the skin matrix, resulting in various symptoms of skin aging. Therefore, a lot of research is being conducted on the active ingredient that can prevent and improve the phenomenon of aging.
항산화제에 대한 연구는 1969년 McCord와 Fridovich가 수퍼옥사이드 라디칼(superoxide radical)을 소거하는 효소인 SOD(superoxide dismutase)를 발견한 것을 계기로 생체내의 활성산소의 발생, 생물독성 및 방어ㆍ소거기구 등에 관하여 관심을 갖게 되면서 본격적으로 진행되었다. In 1969, McCord and Fridovich discovered superoxide dismutase (SOD), an enzyme that eliminates superoxide radicals. Interested in regards to progress in earnest.
수퍼옥사이드와 같은 프리라디칼은 외부 스트레스, 자외선, 흡연, 약물, 활성산소 등에 의해 신체 내 생성되며 세포구성 성분들인 지질, 단백질, 당, 핵산(예컨대, DNA) 등에 대하여 비선택적, 비가역적인 파괴작용을 함으로써 노화는 물론 암을 비롯하여 뇌졸중, 파킨슨병 등의 뇌질환과 심장질환, 허혈, 동맥경화, 피부질환, 소화기질환, 염증, 류마티스, 자기면역질환 등의 각종 질병을 일으키는 것으로 알려져 있다. 이렇게 프리라디칼은 세포에 대한 산화적 파괴로 인한 각종 기능장애를 야기함으로써 노화와 질병의 원인이 되기도 한다.Free radicals, such as superoxide, are produced in the body by external stress, ultraviolet rays, smoking, drugs, free radicals, etc., and have non-selective and irreversible destruction against cellular components such as lipids, proteins, sugars, and nucleic acids (eg, DNA). By doing so, it is known to cause various diseases such as cancer, stroke, Parkinson's disease, heart disease, ischemia, arteriosclerosis, skin disease, digestive disease, inflammation, rheumatism, autoimmune disease, as well as aging. In this way, free radicals cause various functional disorders due to oxidative destruction of cells, thereby causing aging and disease.
최근 각종 질병 및 노화 등에 활성산소 및 수퍼옥사이드가 직접적인 원인으로 작용한다는 사실이 밝혀지면서 항산화제 연구는 식품 첨가물로서의 항산화제 개발 연구로부터 노화억제 및 질병치료제로서의 항산화제를 찾는 연구로 전환되고 있는 실정이다.Recently, it has been found that active oxygen and superoxide act directly as a cause of various diseases and aging. Antioxidant research is shifting from research on developing antioxidants as food additives to finding antioxidants as anti-aging and disease treatment agents. .
차나무는 동백나무과(Family: Theaceae), 동백나무속(Genus: Camellia)에 속하는 상록수로, 학명은 카멜리아 시넨시스(Camellia sinensis)이다. 재배종인 차나무는 앗삼종(var. assamica) 및 중국종(var.sinesis)으로 나눌 수 있으며, 상기 앗삼종은 대엽의 특성을 가지며, 인도, 스리랑카 등 열대, 아열대 지역에 분포하며 내한성이 약하지만 홍차용으로 많이 이용되고 있으며, 중국종은 소엽의 특성을 가지면, 한국, 중국, 일본 등 온대 지역에 분포하며 내한성이 강하다. The tea tree is an evergreen belonging to the family Camellia (Family: Theaceae ), and the scientific name is Camellia sinensis . The cultivated tea tree can be divided into varieties ( var. Assamica ) and Chinese varieties ( var.sinesis ), which have broad leaf characteristics and are distributed in tropical and subtropical areas such as India and Sri Lanka. It is widely used as a dragon, and Chinese species have lobular characteristics, and are distributed in temperate regions such as Korea, China, and Japan, and have strong cold resistance.
한국 재래종 차나무는 주로 중국종으로 분류된다. 차나무는 아열대성 작물로 연평균 기온 14~16℃가 생육 최적 온도이다. 저온은 차나무 생육의 한계요인으로서 내한성이 강한 품종도 -15℃에서 1시간 경과할 경우 잎이 고사되며, 40℃를 넘을 경우에는 고온장해가 발생한다. 차나무의 생육에 필요한 강수량은 최소 1,300mm이지만, 최적의 차 재배를 위해서는 연 1,500mm 이상의 강수량을 필요로 한다.Korean native tea trees are mainly classified as Chinese species. The tea tree is a subtropical crop with an average annual temperature of 14 ~ 16 ℃. Low temperature is a limiting factor for the growth of tea trees, and even after a one-hour pass at -15 ℃, the leaves will die, and if it exceeds 40 ℃, a high temperature disorder occurs. The minimum amount of precipitation required to grow the tea tree is at least 1,300 mm, but for optimal tea cultivation requires more than 1,500 mm of precipitation per year.
한국의 경우 차나무는 신라 말기 828년 대렴이 중국에서 차 종자를 들여와 지리산 주변에 심었다고 보고되고 있으나 가락국 초기 허황옥의 인도 도입설도 있다. 자생지는 주로 평균기온 13℃의 재배 한계선 이남인 남부지방에 자생되고 있으며 전북, 전남, 경남, 제주 등지에서 재배되고 있다.In Korea, the tea tree is reported to have been planted around China in Jirisan during the late Silla 828. Native plants are grown in the southern part of Korea, which is below the cultivation limit of 13 ℃, and are grown in Jeonbuk, Jeonnam, Gyeongnam, and Jeju.
차는 다른 기호 음료에 비해 질소 화합물, 폴리페놀, 당, 유기산, 비타민 및 무기질 등을 많이 함유하고 있는 것이 특징이며, 아미노산은 차의 맛과 깊은 관계가 있고 데아닌과 같은 특정 아미노산은 품질에 크게 영향을 미치며 또한 이들 아미노산의 성분들이 제품의 가격과 상관이 있다고 알려져 있다. 차 잎의 성분 중 총 질소 함량은 전통적으로 아미노산과 더불어 차의 품질을 결정하는 중요 인자이다.Tea is characterized by a higher content of nitrogen compounds, polyphenols, sugars, organic acids, vitamins and minerals than other beverages.Amino acids are closely related to the taste of tea and certain amino acids such as deanine affect the quality. It is also known that the components of these amino acids correlate with the price of the product. The total nitrogen content of tea leaves is traditionally an important factor in determining the quality of tea along with amino acids.
차 잎의 총 질소 함량 중 약 20중량%는 카페인이며, 그 외의 질소 화합물로는 아미노산, 아미드, 단백질, 핵산 등이 있다. 차 단백질은 제조과정 중 탄닌과 결합하거나 가열에 의해 응고되어 거의 용출되지 않으나, 아미노산과 아미드는 수용성이므로 용출되어 차의 맛에 크게 관여한다.About 20% by weight of the total nitrogen content of tea leaves is caffeine, and other nitrogen compounds include amino acids, amides, proteins, nucleic acids, and the like. Tea protein is hardly eluted due to coagulation with tannin or coagulation by heating in the manufacturing process, but amino acids and amides are water soluble and are eluted to greatly influence the taste of tea.
또한, 차는 예로부터 기호 음료뿐만 아니라 다양한 약리 작용이 있어 많이 이용되어 왔다. 최근에는 차의 기능성에 주목하여 이에 관한 연구가 활발히 진행되고 있다. 차에는 특히 폴리페놀류가 많이 함유되어 있는데, 차의 폴리페놀류는 카테킨 화합물로 알려진 플라보노이드류가 대부분이다.In addition, tea has been used since ancient times as well as various pharmacological action. In recent years, research on this has been actively conducted, focusing on the functionality of the car. Tea is particularly rich in polyphenols, and most of the polyphenols in tea are flavonoids known as catechin compounds.
데아닌은 녹차의 총 유리 아미노산 중 약 40~60중량% 정도를 차지하는 비중이 높은 성분으로서 다른 작물들에서 거의 발견되지 않고 차나무의 잎에만 함유되어 있는 성분이다. 데아닌 성분은 차의 감칠맛에 많은 영향을 미치며 총 유리 아미노산, 총 질소와 함께 차의 품질과 상관관계를 보이고 관능 평가와 함께 품질 평가시 중요한 지표로 이용되고 있으며, 이는 차나무 신품종 개발에 있어 중요한 선발인자로 평가되고 있다.Deanine is a high component of about 40 to 60% by weight of the total free amino acids of green tea, which is rarely found in other crops and is contained only in the leaves of tea trees. Deanin has a great influence on the taste of tea, and it is correlated with the quality of tea along with total free amino acids and total nitrogen, and is used as an important indicator for quality evaluation along with sensory evaluation. It is evaluated as a factor.
한편, 차나무는 유전자형이 서로 다른 개체들 사이에 타가수분이 이루어지는 타식성 작물로서, 개체간 변이가 심하다. 따라서, 일반적으로 재배되는 재래종 차나무는 단일 품종이 아니라, 유성번식에 의해 오랫동안 내려온 잡종으로, 차나무 각각의 유전적 형질이 모두 달라, 수확시기, 생장 속도, 엽의 형태와 색깔, 성분, 내병성, 내한성 등의 여러 특성들이 다르다. 이러한 재래종은 품종육성을 위한 유전학적 가치는 높지만, 번식을 여러번 거쳐도 우수한 기능성을 나타내면서 균일한 품질을 유지할 수 있는 차나무 품종의 개발이 시급하다.On the other hand, the tea tree is a corrosive crop in which the pollination is made between individuals with different genotypes, and the variation between individuals is severe. Therefore, conventionally grown cultivated tea is not a single cultivar, but a hybrid that has been descended for a long time by sexual reproduction, and the genetic characteristics of each tea tree are all different. Harvesting time, growth rate, leaf shape and color, composition, disease resistance, and cold resistance And many other characteristics. These conventional species have high genetic value for breeding, but it is urgent to develop tea varieties that can maintain a uniform quality while showing excellent functionality even after multiple breeding.
일 예로, 재래종 차나무에 비해 카테킨 함량이 높고, 이로 인해 항산화 효과가 우수한 신규 차나무 품종("장원 1호"로 명명)의 육종방법(한국 공개특허공보 제10-2011-0020676호)과, 재래종 차나무에 비해 아미노산 및 데아닌 함량이 높은 신규 차나무 품종("장원 2호"로 명명)의 육종방법(한국 공개특허공보 제10-2012-0107751호)이 개발된 바 있다. 이들 육종방법은 모두, 재래종 차나무 중에서 목표하는 특성을 가지고 있는 차나무를 선발하여, 삽목에 의해 무성 번식시킴으로써 우수한 유전 형질을 변이 없이 반복 재현할 수 있다는 점에 특징이 있다.For example, the method of breeding the new tea tree varieties (named "Changwon No. 1") and the conventional tea tree, which has a higher catechin content than the conventional tea tree, and thus has an excellent antioxidant effect. Compared to the breeding method of the new tea tree varieties (named "Changwon No. 2") having a high amino acid and deanin content (Korean Patent Publication No. 10-2012-0107751) has been developed. All of these breeding methods are characterized by selecting tea trees having the desired characteristics among conventional tea trees, and abundantly breeding by cutting to reproduce excellent genetic traits without mutation.
이와 같이, 특정 성분을 다량 함유하는 신규 차나무 품종의 육종방법은 다소 알려져 있으나, 차나무는 다른 영년생 식물과 마찬가지로 육종기간이 오래 걸린다는 문제점 외에 타식성이여서 유전적으로 매우 잡박하기 때문에 차나무 품종개량이 어렵고, 이들 차나무로부터 얻어지는 찻잎 추출물의 효능에 대해서는 구체적으로 밝혀진 바가 없다.As such, the breeding method of new tea tree varieties containing a large amount of specific ingredients is somewhat known, but tea tree varieties are difficult to improve because they are genetically very sparse because they have a long breeding period like other young plants. However, the efficacy of the tea leaf extract obtained from these tea trees has not been specifically identified.
이에, 본 발명자들은 차나무 신품종의 육종방법 및 재배방법을 통해 생산된 차나무 신품종(장원 3호)의 찻잎으로부터 얻어지는 추출물의 성분 및 그 효능을 분석하고 이를 약학, 화장료, 식품 등에 적용하기 위해 예의 노력한 결과, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물은 특히 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하며, 항산화, 항염, 항노화 및 항암 효과가 우수함을 발견하고, 본 발명을 완성하게 되었다.Therefore, the present inventors analyzed the components of the extract obtained from the tea leaves of the new tea tree varieties (Changwon No. 3) produced through the breeding method and the cultivation method of the new tea tree and its efficacy and applied to pharmaceuticals, cosmetics, food, etc. , a tea extract, preferably a new variety of tea (manor third) extract of 3-epi catechins in particular go O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl ) gallate; EGCG3 ”Me; 3” -O- Me-EGCG), and found to be excellent in antioxidant, anti-inflammatory, anti-aging and anti-cancer effects, and completed the present invention.
본 발명의 목적은, 본 발명에 따른 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 유효성분으로 함유하는 조성물을 제공하는 데 있다.An object of the present invention, the epi catechins to go in accordance with the present invention -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" It is to provide a composition containing an extract of a tea tree containing a high content of O -Me-EGCG, preferably an extract of a new tea tree (Changwon No. 3) as an active ingredient.
본 발명의 다른 목적은, 본 발명에 따른 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 유효성분으로 함유하고, 항산화, 항염증, 항노화 및 항암 용도를 갖는 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물을 제공하는 데 있다.Another object of the present invention, the extract of the tea tree containing a high content of epigallocatechin-3- O- (3- O -methyl) gallate according to the present invention, preferably of a new type of tea tree (Changwon No. 3) The present invention provides a pharmaceutical composition, a cosmetic composition or a nutraceutical composition containing the extract as an active ingredient and having antioxidant, anti-inflammatory, anti-aging and anticancer uses.
상기 목적을 달성하기 위하여, In order to achieve the above object,
본 발명은 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 유효성분으로 함유하는 조성물을 제공한다.The present invention is a composition containing an extract of tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new type of tea tree (Jangwon No. 3) as an active ingredient. To provide.
본 발명은 또한, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 유효성분으로 함유하는 항산화용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물을 제공한다.The present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient. To provide an antioxidant pharmaceutical composition, cosmetic composition or health functional food composition.
본 발명은 또한, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 유효성분으로 함유하는 항염증용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물을 제공한다.The present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient. To provide an anti-inflammatory pharmaceutical composition, cosmetic composition or health functional food composition.
본 발명은 또한, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 유효성분으로 함유하는 항노화용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물을 제공한다.The present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient. To provide an anti-aging pharmaceutical composition, cosmetic composition or health functional food composition.
본 발명은 또한, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 유효성분으로 함유하는 항암용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물을 제공한다.The present invention also contains an extract of a tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in a high content, preferably an extract of a new tea tree species (Changwon No. 3) as an active ingredient. To provide an anticancer pharmaceutical composition, cosmetic composition or health functional food composition.
본 발명은 또한, 항산화용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항산화제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an antioxidant pharmaceutical composition or medicament. The use of the extract of (Changwon 3) as an antioxidant is provided.
본 발명은 또한, 항산화용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항산화제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the production of an antioxidant cosmetic composition, preferably a new kind of tea tree (Changwon 3 The use of the extract of the present invention) as an antioxidant.
본 발명은 또한, 항산화용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항산화제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an antioxidant functional food composition. The use of the extract of Jangwon 3) as an antioxidant.
본 발명은 또한, 항염증 또는 소염용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항염증제 또는 소염제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a pharmaceutical composition or medicament for anti-inflammatory or anti-inflammatory, preferably Provides the use of an extract of tea tree new varieties (Jangwon 3) as an anti-inflammatory or anti-inflammatory agent.
본 발명은 또한, 항염증 또는 소염용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항염증제 또는 소염제로서의 용도를 제공한다.The present invention is also an extract of a tea tree, preferably a new kind of tea tree, which comprises a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the preparation of an anti-inflammatory or anti-inflammatory cosmetic composition. The use of the extract of (Changwon 3) as an anti-inflammatory or anti-inflammatory agent is provided.
본 발명은 또한, 항염증 또는 소염용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항염증제 또는 소염제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate, in the preparation of an anti-inflammatory or anti-inflammatory health food composition. Provided is an anti-inflammatory or anti-inflammatory agent of an extract of a new tea tree species (Changwon No. 3).
본 발명은 또한, 항노화용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항노화제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anti-aging pharmaceutical composition or medicament. The use of the extract of (Changwon 3) as an anti-aging agent is provided.
본 발명은 또한, 항노화용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항노화제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the preparation of an anti-aging cosmetic composition, preferably a new kind of tea tree (Jangwon 3 The use of the extract of the present invention) as an anti-aging agent.
본 발명은 또한, 항노화용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항노화제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anti-aging dietary supplement composition, preferably a new kind of tea tree ( The use of the extract of Jangwon 3) as an anti-aging agent.
본 발명은 또한, 항암용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항암제로서의 용도를 제공한다.The present invention is also an extract of a tea tree, preferably a new type of tea tree, comprising a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a pharmaceutical composition or medicine for anticancer The use of the extract of (Changwon 3) as an anticancer agent is provided.
본 발명은 또한, 항암용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항암제로서의 용도를 제공한다.The present invention also provides an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of an anticancer cosmetic composition, preferably a new kind of tea tree (Changwon 3 An anticancer agent is provided as an anticancer agent.
본 발명은 또한, 항암용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 항암제로서의 용도를 제공한다.The present invention is also an extract of a tea tree containing a high content of epigallocatechin-3-O- (3-O-methyl) gallate in the manufacture of a dietary supplement composition for anticancer, preferably a new kind of tea tree ( The use of the extract of Jangwon 3) as an anticancer agent.
본 발명에 따른 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 고함량으로 포함하는 차나무의 추출물을 유효성분으로 함유하는 조성물은 자유 라디칼 소거 및 억제로 인한 항산화 효과와 콜라게나아제의 생성 억제능이 우수하여 피부 노화를 방지하는 효과, 피부 세포 내 프로스타글란딘 및 IL-8 등 염증 인자의 발현 및 분비를 억제하여 항염 효과가 있으며, 다양한 조직으로부터 유래한 암 세포주에 대한 항암 효과가 우수하다.The composition containing the extract of the tea tree containing epigallocatechin-3- O- (3- O -methyl) gallate in high content according to the present invention as an active ingredient has an antioxidant effect and cola due to free radical scavenging and inhibition. It has an excellent inhibitory ability to generate geneases to prevent skin aging, and it has anti-inflammatory effect by inhibiting the expression and secretion of inflammatory factors such as prostaglandin and IL-8 in skin cells, and anti-cancer effect against cancer cell lines derived from various tissues. great.
도 1은 수집한 녹차 나무 생식질(germplasm)의 엘리트라인 선별을 나타낸 것이다.Figure 1 shows the elite line selection of the collected green tea tree germplasm (germplasm).
도 2는 선별된 녹차 나무의 단일 삽수에 의한 번식법(single cutting propagation)을 나타낸 것이다.Figure 2 shows the single cutting propagation of a single tea tree of the selected green tea tree.
도 3은 차나무 신품종(장원 3호)을 나타낸 것이다.Figure 3 shows a new varieties of tea tree (Mountain 3).
도 4는 차나무 신품종(장원 3호) 추출물의 수퍼옥사이드 음이온(superoxide anion) 소거 활성을 나타낸 것이다.Figure 4 shows the superoxide anion scavenging activity of the new tea extract (Changwon No. 3).
도 5는 차나무 신품종(장원 3호) 추출물의 수산기 라디칼(hydroxyl radical) 소거 활성을 나타낸 것이다.Figure 5 shows the hydroxyl radical (hydroxyl radical) scavenging activity of a new tea (Jangwon No. 3) extract.
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술 분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 가진다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술 분야에서 잘 알려져 있고 통상적으로 사용되는 것이다.Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.
이하, 본 발명에 대하여 보다 구체적으로 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated more concretely.
본 발명의 일 실시예에서는, 선발된 차나무 신품종(New Cultivar of Camellia sinensis)인 차나무 신품종(장원 3호)(종자 수탁번호: KCTC(Korean Collection for Type Cultures) 12213BP (2012.5.14); 아래 [수탁번호] 참조)의 찻잎 추출물을 제조한 다음, 상기 추출물의 성분을 분석한 결과, 카테킨의 총함량은 차나무 신품종(장원 3호) 찻잎의 추출물에서 41.1중량%로 나타나, 일반 차나무 도입 품종인 야부기다 잎의 추출물(28.1중량%), 가나야미도리 잎의 추출물(26.7중량%), 유타가미도리 잎의 추출물(26.4중량%)보다 높게 나타났다. 또한, 차나무 신품종(장원 3호)의 추출물은 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 2.5중량%의 양으로 함유하여 일반 차나무 도입 품종보다 10배 이상 고함량으로 함유하는 것으로 확인되었다(실시예 1 및 시험예 1, 표 6 참조).In one embodiment of the present invention, the new tea varieties (New Cultivar of Camellia sinensis) is a new tea varieties (Changwon No. 3) (seed accession number: KCTC (Korean Collection for Type Cultures) 12213BP (2012.5.14); No.] of the tea leaf extract, after analyzing the components of the extract, the total content of the catechin is 41.1% by weight of the extract of the new tea (Changwon No. 3) tea leaves, Yabugi is a general tea tree introduced varieties Leaf extract (28.1% by weight), kanayamidori leaf extract (26.7% by weight), utagamidori leaf extract (26.4% by weight) was higher than the extract. In addition, new varieties of tea (manor third) extract of catechin to go epi -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) was contained in an amount of 2.5% by weight, and was found to contain 10 times or more higher than the general tea tree introduced varieties (see Example 1 and Test Example 1, Table 6).
한편, 다류(茶類) 제품으로서 제조한 차나무 신품종(장원 3호) 잎의 추출물 및 야부기다 잎의 추출물의 카테킨 및 카페인 성분을 비교 분석한 결과, 차나무 신품종(장원 3호) 잎의 추출물은 야부기다 추출물보다 카테킨의 총함량이 높게 나타났다. 또한, 차나무 신품종(장원 3호) 잎의 추출물의 3”-O-Me-EGCG)의 함량은 녹차, 우롱차(반발효차) 및 홍차(발효차)에서 각각 4.7mg·g-1, 3.6mg·g-1, 1.94mg·g-1으로 나타났다(실시예 2 및 시험예 1, 표 7 참조).On the other hand, as a result of comparing and analyzing the catechin and caffeine components of the extract of the new tea tree (Changwon No. 3) and the extract of Yabugida leaf prepared as a tea product, the extract of the new tea tree (Changwon No. 3) leaf was Yabu The total content of catechin was higher than the extract. In addition, the content of 3 ” -O- Me-EGCG) in the extracts of the leaves of the new tea tree (Changwon No. 3) was 4.7 mg · g -1 , 3.6 in green tea, oolong tea (semi-fermented tea) and black tea (fermented tea), respectively. mg.g -1 and 1.94 mg.g -1 .
본 발명의 다른 실시예에서는, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물의 항산화 효과를 확인하였다. 그 결과, 표 8에 나타낸 바와 같이, (i) DPPH(1,1-디페닐-2-피크릴하이드라질; 1,1-diphenyl-2-picryl hydrazyl) 시험에서, 차나무 신품종(장원 3호)의 추출물(실시예 1)은 양성 대조군으로 사용한 항산화제인 아스코르브산(비타민 C)과 비교하여 유사한 항산화 효과를 나타냈으며, 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 및 유타가미도리 추출물과 비교했을 때 월등히 높은 항산화 효능을 나타내었고, (ii) 수퍼옥사이드 음이온 소거 활성 시험에서, 차나무 신품종(장원 3호) 추출물은 양성 대조군인 아스코르브산보다 높은 수퍼옥사이드 음이온 소거활성을 나타내었으며, (iii) 수산기 라디칼 소거 활성 시험에서, 차나무 신품종(장원 3호) 추출물은 야부기다 추출물보다 수산기 라디칼 소거활성이 더 높게 나타났다(시험예 2 참조).In another embodiment of the present invention, the antioxidant effect of the extract of tea tree new varieties (Jangwon No. 3) according to the present invention was confirmed. As a result, as shown in Table 8, (i) new tea tree varieties (Changwon 3) in the DPPH (1,1-diphenyl-2-picrylhydrazyl; 1,1-diphenyl-2-picryl hydrazyl) test Extract (Example 1) showed a similar antioxidant effect compared to the ascorbic acid (vitamin C), an antioxidant used as a positive control, and extracts Yabugida, Kanayamidori and Yutagami-dori extracts of general tea trees of Comparative Examples 1 to 3 Compared with, it showed significantly higher antioxidant efficacy, and (ii) In the superoxide anion scavenging activity test, the new tea extract (Changwon No. 3) showed higher superoxide anion scavenging activity than the positive control ascorbic acid, (iii In the hydroxyl radical scavenging activity test, the new extract of tea tree (Changwon No. 3) showed higher hydroxyl radical scavenging activity than Yabugida extract (see Test Example 2).
본 발명의 또 다른 실시예에서는, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물의 항노화 효과를 콜라게나아제의 생성 억제능을 통해 확인하였다. 그 결과, 표 9에 나타낸 바와 같이, 콜라게나아제의 발현 정도가 낮을수록 콜라게나아제의 발현 억제능이 높고, 피부내의 콜라겐의 분해가 적게 일어나 피부 탄력 감소가 저해되며, 생성되는 주름의 양은 적어졌다. 즉, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물(실시예 1)은 시험관내(in vitro)에서 콜라게나아제의 발현을 효과적으로 억제하였으며, 양성 대조군으로 사용한 토코페롤보다도 콜라게나아제의 발현 억제능이 우수함을 확인할 수 있었다. 특히, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물(실시예 1)은 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 및 유타가미도리 추출물에 비하여 콜라게나아제의 발현을 더욱 효과적으로 억제함으로써 피부내의 콜라겐 분해를 억제하여 피부 탄력 증진 효과 및 주름 감소 효과가 우수함을 확인하였다(시험예 3 참조).In another embodiment of the present invention, the anti-aging effect of the extract of the new tea varieties (Changwon No. 3) according to the present invention was confirmed through the ability to inhibit the production of collagenase. As a result, as shown in Table 9, the lower the expression level of collagenase, the higher the expression inhibiting ability of collagenase, less degradation of collagen in the skin, inhibiting the decrease in skin elasticity, and the amount of wrinkles produced decreased. . That is, the extract of the new tea tree (Changwon No. 3) according to the present invention (Example 1) effectively inhibited the expression of collagenase in vitro , and inhibited the expression of collagenase than tocopherol used as a positive control. This excellence could be confirmed. In particular, the extract of Tea tree new varieties (Changwon No. 3) according to the present invention (Example 1) is more to the expression of collagenase than the general tea tree introduced varieties Yabugida, Kanayami-dori and Yutagami-dori extracts of Comparative Examples 1 to 3 It was confirmed that the effect of inhibiting collagen breakdown in the skin by effectively inhibiting the skin elasticity enhancing effect and wrinkle reduction effect is excellent (see Test Example 3).
본 발명의 또 다른 실시예에서는, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물의 항염 효과를 프로스타글란딘의 생성 억제 효과 및 인터루킨-8(Interleukin-8, IL-8) 생성 억제 효과를 통해 확인하였다. 그 결과, 표 10에 나타낸 바와 같이, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물(실시예 1)은 아스피린을 처리한 대조군과 같이 프로스타글란딘의 생성 억제 효과가 매우 높음을 알 수 있었으며, 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 또는 유타가미도리 추출물과 비교했을 때 프로스타글란딘 생성 억제 효과가 현저히 높음을 알 수 있었다. 또한, 표 11에 나타낸 바와 같이, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물(실시예 1)은 염증 유발 자극원인 PGSA에 의해 증가한 IL-8의 분비 억제 효과가 매우 높음을 알 수 있었으며, 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 또는 유타가미도리 추출물보다 IL-8의 분비를 현저히 감소 및 억제시킴을 알 수 있었다(시험예 4 참조).In another embodiment of the present invention, the anti-inflammatory effect of the extract of the new tea tree (Changwon No. 3) according to the present invention is confirmed through the inhibitory effect of the production of prostaglandins and the inhibitory effect of the production of Interleukin-8 (IL-8) It was. As a result, as shown in Table 10, the extract (Example 1) of the new tea tree (Changwon No. 3) according to the present invention was found to have a very high inhibitory effect of the production of prostaglandins, as in the control group treated with aspirin, compared to It was found that the effect of inhibiting prostaglandin production was significantly higher than that of Yabugida, Kanayami-dori, or Yutagami-dori extracts. In addition, as shown in Table 11, it was found that the extract (Example 1) of the new tea tree varieties (Changwon No. 3) according to the present invention has a very high inhibitory effect on the secretion of IL-8 increased by PGSA, an inflammation-inducing stimulant. It was found that the secretion of IL-8 was significantly reduced and suppressed compared to the general tea tree-introduced varieties Yabugida, Kanayami-dori or Yutagami-dori extracts of Comparative Examples 1 to 3 (see Test Example 4).
본 발명의 또 다른 실시예에서는, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물의 항암 효과를 암세포 증식 억제 효과를 통해 확인하였다. 그 결과, 표 12에 나타낸 바와 같이, (i) 차나무 신품종(장원 3호) 추출물을 100㎍·mL-1의 농도로 각각의 암세포주에 처리할 경우, 모든 암세포주에서 50% 이하의 암세포 증식율(생존율)을 나타내었고; 차나무 신품종(장원 3호) 추출물을 200㎍·mL-1의 농도로 각각의 암세포주에 처리할 경우, 폐암 세포주(A549), 전립선암 세포주(LNCaP) 및 유방암 세포주(MCF-7)에서 각각 12%, 24% 및 16%의 암세포 증식율을 나타내어, 차나무 신품종(장원 3호) 추출물은 암세포 증식 억제 효과가 있음을 확인하였다. (ii) 또한, 차나무 신품종(장원 3호) 추출물로부터 분리한 3"-O-Me-EGCG를 각각의 암세포주에 처리한 결과, 모든 암세포주에 대하여 농도 의존적으로 암세포 증식을 억제하였고, 특히 전립선암 세포주(LNCaP)에 3"-O-Me-EGCG를 50㎍·mL-1, 100㎍·mL-1 및 200㎍·mL-1의 농도로 처리할 경우, 암세포 증식율이 각각 46%, 37.7% 및 20%로 나타나 차나무 신품종(장원 3호) 추출물보다 높은 암세포 증식 억제 효과를 나타내었고, 유방암 세포주(MCF-7)도 동등한 조건에서 3"-O-Me-EGCG를 처리할 경우 높은 암세포 증식 억제 효과를 나타내었으며, 폐암 세포주(A549)에 3"-O-Me-EGCG를 50㎍·mL-1, 100㎍·mL-1 및 200㎍·mL-1의 농도로 처리할 경우, 암세포 증식율이 각각 41.0%, 20.0% 및 16.0%로 나타나, 폐암 세포주(A549)는 전립선암 세포주(LNCaP) 및 유방암 세포주(MCF-7)보다 높은 암세포 증식 억제 효능을 나타내었다(시험예 5 참조).In another embodiment of the present invention, the anticancer effect of the extract of the new tea tree varieties (Changwon No. 3) according to the present invention was confirmed through the cancer cell proliferation inhibitory effect. As a result, as shown in Table 12, when (i) a new tea tree (Changwon No. 3) extract was treated to each cancer cell line at a concentration of 100 µg · mL −1 , the cancer cell proliferation rate was 50% or less in all cancer cell lines. (Survival rate); When a new tea tree (Changwon No. 3) extract was treated to each cancer cell line at a concentration of 200 µg · mL −1 , 12 cells of lung cancer cell line (A549), prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7) Cancer cell proliferation rate of%, 24% and 16%, it was confirmed that the new extract of tea tree (Changwon No. 3) has a cancer cell proliferation inhibitory effect. (ii) In addition, treatment of each cancer cell line with 3 " -O- Me-EGCG isolated from the new tea tree (Changwon No. 3) extract inhibited cancer cell proliferation in a concentration-dependent manner for all cancer cell lines, in particular, the prostate gland. a cancer cell line (LNCaP) 3 "- O 50㎍ the -Me-EGCG · mL -1, 100㎍ · mL -1 and 200㎍ · in case of processing at a concentration of -1 mL, cancer jeungsikyul 46%, respectively 37.7 % And 20% showed higher cancer cell proliferation inhibitory effect than the new tea tree (Changwon No. 3) extract, and breast cancer cell line (MCF-7) also showed high cancer cell proliferation when treated with 3 " -O- Me-EGCG under the same conditions. Lung cancer cell line (A549) showed cancer cell proliferation rate when 3 ” -O- Me-EGCG was treated at concentrations of 50 μg mL- 1 , 100 μg mL- 1 and 200 μg mL- 1 . 41.0%, 20.0%, and 16.0%, respectively, and lung cancer cell line (A549) inhibited cancer cell proliferation higher than prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7). It exhibited the features (see Test Example 5).
본 발명의 또 다른 실시예에서는, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물을 함유하는 다류의 관능 평가를 수행하였다. 그 결과, 표 13에 나타낸 바와 같이, 관능 평가에서 가공방법과는 무관하게 차나무 신품종(장원 3호)은 야부기다와 오꾸미도리보다 반발효차, 발효차, 후발효차 모두에서 높은 기호성을 가지는 것으로 평가되었다(시험예 6 참조).In another embodiment of the present invention, the sensory evaluation of the polysaccharide containing the extract of a new type of tea tree (Changwon No. 3) according to the present invention was performed. As a result, as shown in Table 13, regardless of the processing method in the sensory evaluation, the new variety of tea tree (Changwon No. 3) had higher palatability in both semi-fermented tea, fermented tea, and post-fermented tea than Yabugida and Okumi-dori. Was evaluated (see Test Example 6).
따라서, 본 발명은 일 관점에서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물을 유효성분으로 함유하는 조성물에 관한 것이다.Therefore, the invention in one aspect, to go epi catechins -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - It relates to a composition containing as an active ingredient the extract of Camellia sinensis containing a high content of O- Me-EGCG).
상기 차나무의 추출물은 차나무 신품종(장원 3호)의 추출물인 것을 특징으로 할 수 있으나, 이에 한정되는 것은 아니다.The extract of the tea tree may be characterized in that the extract of the tea tree new varieties (Changwon No. 3), but is not limited thereto.
상기 조성물은 항산화, 항염증, 항노화 및 항암용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물일 수 있으나, 이에 한정되는 것은 아니다.The composition may be an antioxidant, anti-inflammatory, anti-aging and anticancer pharmaceutical composition, cosmetic composition or health functional food composition, but is not limited thereto.
상기 차나무의 추출물에 포함된 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%이다.The content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
본 발명은 다른 관점에서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)를 고함량으로 포함하는 차나무의 추출물을 유효성분으로 함유하는 항산화용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물로서,The invention from another point of view, as the epi catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O - As pharmaceutical composition, cosmetic composition or health functional food composition for antioxidant, containing as an active ingredient the extract of the tea tree ( Camellia sinensis ) containing a high content of Me-EGCG),
상기 차나무의 추출물에 포함된 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%인 것을 특징으로 하는, 조성물에 관한 것이다.The content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
본 발명은 또 다른 관점에서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)를 고함량으로 포함하는 차나무의 추출물을 유효성분으로 함유하는 항염증용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물로서,The invention in another aspect, the epi-catechins to go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O An anti-inflammatory pharmaceutical composition, cosmetic composition or health functional food composition containing an extract of tea tree containing Camellia sinensis with a high content of -Me-EGCG as an active ingredient,
상기 차나무의 추출물에 포함된 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%인 것을 특징으로 하는, 조성물에 관한 것이다.The content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
본 발명은 또 다른 관점에서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)를 고함량으로 포함하는 차나무의 추출물을 유효성분으로 함유하는 항노화용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물로서,The invention in another aspect, the epi-catechins to go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O As an anti-aging pharmaceutical composition, cosmetic composition or health functional food composition containing the extract of the tea tree ( Camellia sinensis ) containing a high content of -Me-EGCG as an active ingredient,
상기 차나무의 추출물에 포함된 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%인 것을 특징으로 하는, 조성물에 관한 것이다.The content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
본 발명은 또 다른 관점에서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)를 고함량으로 포함하는 차나무의 추출물을 유효성분으로 함유하는 항암용 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물로서,The invention in another aspect, the epi-catechins to go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me;3" - O As anti-cancer pharmaceutical composition, cosmetic composition or health functional food composition, containing as an active ingredient an extract of tea tree containing Camellia sinensis with a high content of -Me-EGCG),
상기 차나무의 추출물에 포함된 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%인 것을 특징으로 하는, 조성물에 관한 것이다.The content of epigallocatechin-3- O- (3- O -methyl) gallate contained in the extract of the tea tree is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight %, Most preferably 2.25 to 6.00% by weight.
본 발명에 따른 차나무 신품종(장원 3호)(종자 수탁번호: KCTC(Korean Collection for Type Cultures) 12213BP (2012.5.14))은 (주)장원으로부터 공급받은 것이다. 차나무 신품종(장원 3호)은 항산화, 항노화, 피부 미백, 항암, 항알레르기 효과가 뛰어나 각종 스트레스성 질환 예방 및 개선에 효과적인 기능성 성분인 카테킨을 다량 함유한 기능성 차나무의 품종 개발을 목적으로 하여 얻어진 품종으로, 2006년에 수집된 제주도 서귀포시 안덕면 재래종 차나무 유전자원을 대상으로 분리 육종의 방법을 실시한 후 생육 특성, 성분 함량 분석 등의 평가로 카테킨 함량이 높은 차나무 소수의 자원을 대상으로 선발하였다. 선발된 차나무 자원의 작물학적 특성이 좋지 않았기 때문에 품질, 수량성을 고려하여 우수 육성계통과 교배를 실시하였다. 교배 실생을 대상으로 육종 하우스 내에 파종을 하였으며 본 포장에 정식을 한 이후 2010년에 성분분석과 식물특성 평가를 통하여 2차 선발을 실시하였다. 작물학적 특성은 대한민국 국립종자원의 국제식물유전자원평가기준(International Union for the Protection of New Varieties of Plants, UPOV)에 의거하여 측정하였다(하기 제조예 참조).Tea tree new varieties (Jangwon No. 3) (seed accession number: KCTC (Korean Collection for Type Cultures) 12213BP (2012.5.14)) according to the present invention is supplied from Jangwon. A new type of tea tree (Changwon No. 3) is obtained for the purpose of developing varieties of functional tea trees containing a large amount of catechins, which are excellent in antioxidant, anti-aging, skin whitening, anti-cancer and anti-allergic effects. As a cultivar, we conducted a separate breeding method on tea tree genes of Andeok-myeon, Andeok-myeon, Seogwipo-si, collected in 2006, and selected a small number of tea trees with high catechins by evaluation of growth characteristics and component contents. As the crop characteristics of the selected tea tree resources were not good, the mating and breeding system was conducted in consideration of quality and quantity. The seedlings were sown in breeding houses for mating livestock, and after the formalization of this pavement, the second selection was carried out in 2010 through component analysis and plant characteristics evaluation. Crop characteristics were measured according to the International Union for the Protection of New Varieties of Plants (UPOV) of the Korean National Species (see Preparation Example below).
본 발명에 있어서, 상기 차나무의 추출물은 차나무의 꽃, 잎, 열매, 줄기 및 뿌리로 구성된 군에서 선택되는 적어도 어느 1종의 추출물일 수 있으나, 이에 한정되는 것은 아니하고, 바람직하게는 차나무 잎의 추출물이다.In the present invention, the extract of the tea tree may be at least one extract selected from the group consisting of flowers, leaves, fruits, stems and roots of the tea tree, but is not limited thereto, preferably the extract of the tea tree leaves to be.
본 발명에 따른 차나무는, 특히, 그 잎에 카테킨 함량이 높은 특성이 있는데, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물에 포함된 카테킨 중 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%이다.The tea tree according to the present invention, in particular, has a high catechin content in its leaves, epigallocatechin-3- O − among the catechins contained in the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3). The content of (3- O -methyl) gallate is at least 1.25% by weight, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight, most preferably 2.25 to 6.00% by weight.
상기 차나무의 추출물은 차나무의 꽃, 잎, 열매, 줄기 또는 뿌리의 수확 시기(수확 계절), 또는 채엽 시기(채엽 계절)에 따라 차나무의 꽃, 잎, 열매, 줄기 또는 뿌리에 함유된 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량은 차이가 있을 수 있다. 예컨대, 차나무 신품종(장원 3호)의 채엽 시기가 5월인 경우 2.50중량%, 8월인 경우 4.16중량%, 또는 11월인 경우 5.36중량%의 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 함유하는 차나무 잎 추출물을 수득할 수 있다.The extract of the tea tree is epigallo contained in the tea tree's flowers, leaves, berries, stems or roots depending on the harvest time (harvest season), or the harvesting time (harvest season) of the flower, leaf, fruit, stem or root of the tea tree. The content of catechin-3- O- (3- O -methyl) gallate may vary. For example, 2.50% by weight of the new cultivated tea tree (Changwon No. 3) in May, 4.16% in August, or 5.36% in November by epigallocatechin-3- O- (3- O -methyl ) Tea leaf extract containing gallate can be obtained.
본 발명에 있어서, 상기 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate)는 O-메틸화된 형태를 가지는 EGCG으로서, 3”-O-Me-EGCG 또는 EGCG3”Me으로 명명된다.In the present invention, as the epi catechins go -3- O - (3- O - methyl) acrylate go (epigallocatechin-3- O - (3- O -methyl) gallate) are O - as EGCG with a methylated form , 3 ” -O- Me-EGCG or EGCG3” Me.
본 발명에 따른 차나무는, 특히, 그 잎에 카테킨 함량이 높은 특성이 있는데, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물은 갈로카테킨(gallocatechin, GC), 에피갈로카테킨(epigallocatechin, EGC), 카테킨(catechin, C), 에피카테킨(epicatechin, EC), 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG), 갈로카테킨 갈레이트(gallocatechin gallate, GCG), 에피카테킨 갈레이트(epicatechin gallate, ECG) 및 카테킨 갈레이트(catechin gallate, CG)의 총 8종의 카테킨을 20.55~82.2중량%, 바람직하게는 30.8~61.65중량%, 더욱 바람직하게는 37~51.38중량%로 함유한다.The tea tree according to the present invention, in particular, has a high catechin content in its leaves, the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3) is gallocatechin (gallocatechin (GC), epigallocatechin ( epigallocatechin (EGC), catechin (C), epicatechin (EC), epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), epicatechin gallate (Epicatechin gallate) Eight catechins of ECG) and catechin gallate (CG) are contained in an amount of 20.55 to 82.2 wt%, preferably 30.8 to 61.65 wt%, more preferably 37 to 51.38 wt%.
본 발명에 있어서, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물은 조성물 총 중량에 대하여 0.01~20중량% 함유되는 것을 특징으로 할 수 있다. 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물이 0.01중량% 미만으로 함유되는 경우에는 항산화 효과, 항염 효과, 항노화 효과, 및 항암 효과를 기대할 수 없으며, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물의 함량이 20중량%를 초과하게 되면, 세포 독성으로 인한 피부 자극이 우려될 수 있다.In the present invention, the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3) may be characterized by containing 0.01 to 20% by weight relative to the total weight of the composition. When the extract of the tea tree, preferably the extract of the new type of tea tree (Changwon No. 3) is contained less than 0.01% by weight, anti-oxidant effect, anti-inflammatory effect, anti-aging effect, and anti-cancer effect can not be expected, extract of tea tree, preferably When the content of the extract of tea tree new varieties (Changwon No. 3) exceeds 20% by weight, skin irritation due to cytotoxicity may be concerned.
본 발명에 따른 차나무 신품종(장원 3호)은, 재래종 차나무에서 하기 (1) 내지 (5)의 특성을 갖는 차나무를 선발하는 단계; 상기 선발된 차나무를 첫 번째 차를 수확하지 않은 줄기의 밑부분이 경화되기 시작하는 때 채취하는 단계; 및 1절 1엽과 2절 2엽으로 삽수하고 삽목에 의해 무성번식법으로 번식하는 차나무 신품종을 얻는 단계;를 포함하는 차나무 신품종의 육종방법에 의해 얻어진 것임을 특징으로 한다.Tea tree new varieties (Jangwon No. 3) according to the present invention, the step of selecting a tea tree having the characteristics of the following (1) to (5) in the conventional tea tree; Harvesting the selected tea tree when the base of the stem which has not harvested the first tea begins to harden; It is obtained by the breeding method of a new type of tea tree, including the step of inserting into 1 section and 2 sections 2 leaves 1 and obtaining a new tea tree breeding by the asexual propagation method by cutting.
상기 선발되는 차나무는 하기 (1) 내지 (5)의 특성을 갖는 것을 특징으로 한다:The selected tea tree is characterized by having the following characteristics (1) to (5):
(1) 차나무의 추출물(예컨대, 찻잎 추출물)에 포함된 카테킨 중 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%;1 of the tea extract (e.g., the extract of the tea leaves) to epi go of the catechins contained in the catechin -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate EGCG3 ”Me; 3” -O- Me-EGCG) is 1.25% by weight or more, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight, most preferably 2.25 to 6.00% by weight ;
(2) 엽폭은 37~47mm, 바람직하게는 39~46mm, 더욱 바람직하게는 43~45mm, 가장 바람직하게는 44.1mm이고, 엽장은 85~95mm, 바람직하게는 87~95mm, 더욱 바람직하게는 94~95mm, 가장 바람직하게는 94.2mm이며, 엽면적은 2200~3200mm2 또는 4000~4500mm2, 바람직하게는 2500~2800mm2 또는 4100~4300mm2, 더욱 바람직하게는 4150~4200mm2, 가장 바람직하게는 4154.2mm2; (2) The leaf width is 37-47 mm, preferably 39-46 mm, more preferably 43-45 mm, most preferably 44.1 mm, and the leaf length is 85-95 mm, preferably 87-95 mm, more preferably 94 ~ 95mm, most preferably be 94.2mm, leaf area is 2200 ~ 3200mm 2 or 4000 ~ 4500mm 2, preferably 2500 ~ 2800mm 2 or 4100 ~ 4300mm 2, more preferably 4150 ~ 4200mm 2, and most preferably from 4154.2 mm 2 ;
(3) 엽형은 장타원형이고, 모용은 중간이며, 엽색은 녹색;(3) the lobe is long oval, the mother's hair is medium, and the lobe is green;
(4) 신아장은 145.0~165.0mm, 바람직하게는 150.0~165.0mm, 더욱 바람직하게는 162.0~164.0mm, 가장 바람직하게는 163.5mm이고, 백아중은 123.0~143.0g/100bud, 바람직하게는 128.0~139.0g/100bud, 더욱 바람직하게는 136.0~139.0g/100bud, 가장 바람직하게는 138.3g/100bud; 및(4) The new chickpea is 145.0-165.0 mm, preferably 150.0-165.0 mm, more preferably 162.0-164.0 mm, most preferably 163.5 mm, and among white eggs 123.0-143.0 g / 100bud, preferably 128.0- 139.0 g / 100bud, more preferably 136.0-139.0 g / 100bud, most preferably 138.3 g / 100bud; And
(5) 가지의 수자는 직립성임;을 특징으로 하는, 육종방법을 제공한다.(5) the number of eggplant is upright; provides a breeding method, characterized in that.
본 발명에 있어서, 상기 선발되는 차나무는 하기 (6) 내지 (17)의 특성을 추가적으로 갖는 차나무일 수 있다.In the present invention, the selected tea tree may be a tea tree additionally having the following properties (6) to (17).
(6) 엽록소 함량(soil & plant analyzer development, SPAD)은 58~62;(6) chlorophyll content (soil & plant analyzer development, SPAD) is 58-62;
(7) 총 아미노산(total amino acid, TFAA) 함량은 3.50중량% 이상;(7) the total amino acid (TFAA) content is at least 3.50 wt%;
(8) 데아닌 함량은 2.20중량% 이상;(8) the deanine content is at least 2.20% by weight;
(9) 총 질소 함량은 6.00중량% 이상;(9) the total nitrogen content is at least 6.00% by weight;
(10) 카페인 함량은 23.5mg/g 이하;(10) the caffeine content is 23.5 mg / g or less;
(11) 가지의 수세는 중이며, 가지 굵기 및 가지 밀도는 중간;(11) The water washing of the eggplant is medium, and the eggplant thickness and eggplant density are medium;
(12) 맹아 시기는 3월 하순임;(12) The germination period is late March;
(13) 개화 시작 시기는 9월이고, 만개 시작 시기는 10월이며, 만개 종료 시기는 10월이고, 개화 종료 시기는 11월임;(13) flowering start time is September, full bloom start time is October, full bloom end time is October, flowering end time is November;
(14) 5월, 6~8월 및 10월 3~4회 수확 가능;(14) three to four harvests in May, June-August and October;
(15) 조만성은 중생이고, 내한성은 강이고, 내병성은 중임;(15) premature is rebirth, cold is strong, and disease is severe;
(16) 차나무의 추출물은 6.35~25.4중량%, 바람직하게는 9.53~19.05중량%, 더욱 바람직하게는 11.4~15.9중량% 에피갈로카테킨(epigallocatechin, EGC), 9.4~37.6중량%, 바람직하게는 14.1~28.2중량%, 더욱 바람직하게는 16.9~23.5중량% 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG) 및 2.65~10.6중량%, 바람직하게는 3.98~7.95중량%, 더욱 바람직하게는 4.77~6.63중량% 에피카테킨 갈레이트(epicatechin gallate, ECG)를 포함함; 및(16) The extract of the tea tree is 6.35 to 25.4% by weight, preferably 9.53 to 19.05% by weight, more preferably 11.4 to 15.9% by weight epigallocatechin (EGC), 9.4 to 37.6% by weight, preferably 14.1-28.2 wt%, more preferably 16.9-23.5 wt% epigallocatechin gallate (EGCG) and 2.65-10.6 wt%, preferably 3.98-7.95 wt%, more preferably 4.77-66.63 Weight percent epicatechin gallate (ECG); And
(17) 차나무의 추출물에 포함된 갈로카테킨(gallocatechin, GC), 에피갈로카테킨(epigallocatechin, EGC), 카테킨(catechin, C), 에피카테킨(epicatechin, EC), 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG), 갈로카테킨 갈레이트(gallocatechin gallate, GCG), 에피카테킨 갈레이트(epicatechin gallate, ECG) 및 카테킨 갈레이트(catechin gallate, CG)의 카테킨의 총함량은 20.55~82.2중량%, 바람직하게는 30.8~61.65중량%, 더욱 바람직하게는 37~51.38중량%.(17) gallocatechin (Gloc), epigallocatechin (EGC), catechin (C), epicatechin (EC), epigallocatechin gallate (epigallocatechin gallate) contained in extracts of tea tree , EGCG), gallocatechin gallate (GCG), epicatechin gallate (ECG), and catechin gallate (catechin gallate (CG), the total content of the catechin 20.55 ~ 82.2% by weight, preferably 30.8 61.65 weight%, More preferably, 37-51.38 weight%.
본 발명에 있어서, 상기 육종방법은 삽수 후 최하단 잎에서 2~3cm 정도 남겨 자른 가지의 밑부분을 비스듬하게 절단하여 1~2시간 동안 물에 침지시키는 단계를 추가로 포함하는 것을 특징으로 할 수 있다.In the present invention, the breeding method may further comprise the step of immersing in water for 1 to 2 hours by cutting the lower part of the cut branch obliquely left 2 ~ 3 cm from the lowermost leaf after the insertion. .
본 발명에서는 재래종 차나무의 일반적인 재배 조건을 적용하였으며, 예를 들어, 하기와 같이 실시할 수 있다. 삽목 직후에 해가림을 실시하며 선투과율 30~45% 내외가 되도록 한다. 삽수는 발근할 때까지는 절화(切花)와 같이 아랫쪽 잘린 절구(切口)로부터 흡수되어 생존해가기 때문에 보통은 아침·저녁으로 충분히 관수한다. 삽목 후 약 1개월 경과하여 발근하는데 삽수를 약간 절제한다. 발근 후는 최대용수량의 50~60%가 적당하다. 시비는 8월 이후부터 하며 추비(9월)부터 시작해도 좋다. 묘상에서의 제초, 병해충 방제는 정성들여 실시해야 하며, 충분하게 발근, 생육 후에 해가림을 제거한다.In the present invention, the general cultivation conditions of the conventional tea plant is applied, for example, it can be carried out as follows. Sunscreening should be done immediately after cutting and the transmittance should be around 30 ~ 45%. Until the roots are inserted, they are usually absorbed from the lower cut mortar, such as cut flowers, and survive. Approximately 1 month after cutting, root cuttings are excised slightly. After rooting, 50 to 60% of the maximum water is appropriate. Fertilization starts after August and may start from September. Weeding and pest control in seedlings should be carried out with care and sufficient debris after rooting and growth.
아울러, 차나무에 포함된 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)의 함량을 증가시키기 위하여, 하기 (1) 내지 (5)의 조건하에서 차나무를 재배하는 것을 특징으로 하는, 차나무(Camellia sinensis) 신품종의 재배방법을 이용하여 차나무를 재배하였다:In addition, in the epi-catechins contained in the tea to go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - O -Me In order to increase the content of -EGCG), the tea tree was grown using the cultivation method of the new Camellia sinensis species, characterized by growing the tea tree under the conditions of (1) to (5):
(1) 30~45%의 선투과율; (1) 30% to 45% transmittance;
(2) 삽수의 발근을 위하여 하루 2회 관수;(2) watering twice a day for rooting of the incision;
(3) 삽목 후 1개월 경과하여 발근하는데 살수 절제;(3) sprinkle resection for rooting 1 month after cutting;
(4) 발근 후 최대용수량은 50~60%; 및(4) the maximum amount of water after rooting is 50-60%; And
(5) 시비는 8월 또는 9월 이후부터 함.(5) Fertilization starts from August or September.
상기 재배되는 차나무는 특별히 한정되지 아니하나, 하기 특성 (1) 내지 (16)을 갖는 본 발명에 따른 차나무 신품종인 것이 바람직하다:The cultivated tea tree is not particularly limited, but is preferably a new tea tree species according to the present invention having the following characteristics (1) to (16):
(1) 차나무 신품종의 추출물(예컨대, 찻잎 추출물)에 포함된 카테킨 중 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)의 함량은 1.25중량% 이상, 바람직하게는 1.25~8.00중량%, 더욱 바람직하게는 1.88~7.00중량%, 가장 바람직하게는 2.25~6.00중량%;(1) extract of the tea plant new varieties (e.g., the extract of the tea leaves) to epi catechins go of the catechins contained in the -3- O - (3- O - methyl) acrylate (epigallocatechin-3- O go - (3- O -methyl) gallate; EGCG3 ”Me; 3” -O- Me-EGCG) is at least 1.25% by weight, preferably 1.25 to 8.00% by weight, more preferably 1.88 to 7.00% by weight, most preferably 2.25 to 6.00% by weight %;
(2) 엽록소 함량(soil & plant analyzer development, SPAD)은 58~62;(2) chlorophyll content (soil & plant analyzer development, SPAD) is 58-62;
(3) 총 아미노산(total amino acid, TFAA) 함량은 3.50중량% 이상;(3) the total amino acid (TFAA) content is at least 3.50% by weight;
(4) 데아닌 함량은 2.20중량% 이상;(4) the deanine content is at least 2.20% by weight;
(5) 총 질소 함량은 6.00중량% 이상;(5) the total nitrogen content is at least 6.00% by weight;
(6) 카페인 함량은 23.5mg/g 이하;(6) the caffeine content is 23.5 mg / g or less;
(7) 엽폭은 37~47mm, 바람직하게는 39~46mm, 더욱 바람직하게는 43~45mm, 가장 바람직하게는 44.1mm이고, 엽장은 85~95mm, 바람직하게는 87~95mm, 더욱 바람직하게는 94~95mm, 가장 바람직하게는 94.2mm이며, 엽면적은 2200~3200mm2 또는 4000~4500mm2, 바람직하게는 2500~2800mm2 또는 4100~4300mm2, 더욱 바람직하게는 4150~4200mm2, 가장 바람직하게는 4154.2mm2; (7) The leaf width is 37 to 47 mm, preferably 39 to 46 mm, more preferably 43 to 45 mm, most preferably 44.1 mm, and the leaf length is 85 to 95 mm, preferably 87 to 95 mm, more preferably 94 ~ 95mm, most preferably be 94.2mm, leaf area is 2200 ~ 3200mm 2 or 4000 ~ 4500mm 2, preferably 2500 ~ 2800mm 2 or 4100 ~ 4300mm 2, more preferably 4150 ~ 4200mm 2, and most preferably from 4154.2 mm 2 ;
(8) 엽형은 장타원형이고, 모용은 중간이며, 엽색은 녹색;(8) the lobes are long oval, the hairs medium and the lobes are green;
(9) 신아장은 145.0~165.0mm, 바람직하게는 150.0~165.0mm, 더욱 바람직하게는 162.0~164.0mm, 가장 바람직하게는 163.5mm이고, 백아중은 123.0~143.0g/100bud, 바람직하게는 128.0~139.0g/100bud, 더욱 바람직하게는 136.0~139.0g/100bud, 가장 바람직하게는 138.3g/100bud;(9) The new chickpea is 145.0-165.0 mm, preferably 150.0-165.0 mm, more preferably 162.0-164.0 mm, most preferably 163.5 mm, and among white eggs 123.0-143.0 g / 100bud, preferably 128.0- 139.0 g / 100bud, more preferably 136.0-139.0 g / 100bud, most preferably 138.3 g / 100bud;
(10) 가지의 수자는 직립성이고, 가지의 수세는 중이며, 가지 굵기 및 가지 밀도는 중간;(10) the number of branches is upright, the washing of the branches is medium, the thickness of the branches and the density of the branches are medium;
(11) 맹아 시기는 3월 하순임;(11) The germination period is late March;
(12) 개화 시작 시기는 9월이고, 만개 시작 시기는 10월이며, 만개 종료 시기는 10월이고, 개화 종료 시기는 11월임;(12) flowering start time is September, full bloom start time is October, full bloom end time is October, flowering end time is November;
(13) 5월, 6~8월 및 10월 3~4회 수확 가능;(13) three to four harvests in May, June-August and October;
(14) 조만성은 중생이고, 내한성은 강이고, 내병성은 중임;(14) prematurity is rebirth, cold resistance is strong, and disease resistance is severe;
(15) 차나무 신품종의 추출물은 6.35~25.4중량%, 바람직하게는 9.53~19.05중량%, 더욱 바람직하게는 11.4~15.9중량% 에피갈로카테킨(epigallocatechin, EGC), 9.4~37.6중량%, 바람직하게는 14.1~28.2중량%, 더욱 바람직하게는 16.9~23.5중량% 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG) 및 2.65~10.6중량%, 바람직하게는 3.98~7.95중량%, 더욱 바람직하게는 4.77~6.63중량% 에피카테킨 갈레이트(epicatechin gallate, ECG)를 포함함; 및(15) The extract of the new varieties of tea tree is 6.35 to 25.4% by weight, preferably 9.53 to 19.05% by weight, more preferably 11.4 to 15.9% by weight epigallocatechin (EGC), 9.4 to 37.6% by weight, preferably 14.1-28.2% by weight, more preferably 16.9-23.5% by weight epigallocatechin gallate (EGCG) and 2.65-10.6% by weight, preferably 3.98-7.95% by weight, more preferably 4.77- 6.63 wt% epicatechin gallate (ECG); And
(16) 차나무 신품종의 추출물에 포함된 갈로카테킨(gallocatechin, GC), 에피갈로카테킨(epigallocatechin, EGC), 카테킨(catechin, C), 에피카테킨(epicatechin, EC), 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG), 갈로카테킨 갈레이트(gallocatechin gallate, GCG), 에피카테킨 갈레이트(epicatechin gallate, ECG) 및 카테킨 갈레이트(catechin gallate, CG)의 카테킨의 총함량은 20.55~82.2중량%, 바람직하게는 30.8~61.65중량%, 더욱 바람직하게는 37~51.38중량%.(16) Gallocatechin (Gloc), epigallocatechin (EGC), catechin (C), epicatechin (EC), epigallocatechin gallate (epigallocatechin) contained in extracts of new varieties of tea tree The total content of catechins of gallate, EGCG), gallocatechin gallate (GCG), epicatechin gallate (ECG) and catechin gallate (CG) is preferably 20.55 to 82.2% by weight, preferably 30.8-61.65 weight%, More preferably, 37-51.38 weight%.
본 발명에 있어서, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 함유하는 약학 조성물은 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질(담체, 부형제, 희석제 등)을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 경구 투여제 또는 비경구 투여제 형태로 제형화할 수 있다.In the present invention, the pharmaceutical composition containing the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3) is a pharmaceutical, such as preservatives, stabilizers, wetting or emulsifiers, salts and / or buffers for the control of osmotic pressure Adjuvants and other therapeutically valuable substances (carriers, excipients, diluents, etc.) may further be contained and may be formulated in various oral or parenteral dosage forms in accordance with conventional methods.
용어 "담체(carrier)"는 세포 또는 조직 내로의 화합물의 부가를 용이하게 하는 화합물로 정의된다. 예를 들어, 디메틸술폭사이드(DMSO)는 생물체의 세포 또는 조직 내로의 많은 유기 화합물들의 투입을 용이하게 하는 통상 사용되는 담체이다.The term "carrier" is defined as a compound that facilitates the addition of a compound into a cell or tissue. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the incorporation of many organic compounds into cells or tissues of an organism.
용어 "부형제(excipient)"는 정제나 환약 등의 제제 과정에서 주약(主藥)의 양이 적은 경우에 약을 먹기 쉽게 하거나 어떤 빛깔과 형태를 갖추게 하려고 더 넣는 물질로, 락토오스나 녹말을 주로 사용한다.The term "excipient" is a substance that is added to make it easier to take medicine or to have a certain color and form when the amount of the main medicine is small in the process of preparation of tablets or pills, such as lactose or starch. do.
용어 "희석제(diluent)"는 대상 화합물의 생물학적 활성 형태를 안정화시킬 뿐만 아니라, 화합물을 용해시키게 되는 물에서 희석되는 화합물로 정의된다. 버퍼 용액에 용해되어 있는 염은 당해 분야에서 희석제로 사용된다. 통상 사용되는 버퍼 용액은 포스페이트 버퍼 식염수이며, 이는 인간 용액의 염 상태를 모방하고 있기 때문이다. 버퍼 염은 낮은 농도에서 용액의 pH를 제어할 수 있기 때문에, 버퍼 희석제가 화합물의 생물학적 활성을 변형하는 일은 드물다.The term "diluent" is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 함유하는 조성물은 인간 환자에게 그 자체로서, 또는 결합 요법에서와 같이 다른 활성 성분들과 함께 또는 적당한 담체나 부형제와 함께 혼합된 의약 조성물로서, 투여될 수 있다.A composition containing an extract of a tea tree, preferably an extract of a new tea tree (Changwon No. 3), can be used as a medicament in human patients, either as such or in combination with other active ingredients or with a suitable carrier or excipient, as in combination therapy. As a composition, it may be administered.
상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
또한, 상기 경구 투여제는 산제, 과립제, 정제, 캡슐제, 시럽 등이 있고, 상기 비경구 투여제는 예를 들어, 주사제, 점적제, 연고, 로션, 겔, 크 림, 스프레이, 현탁제, 유제, 좌제(坐劑), 패취 등의 제형일 수 있으나, 이에 한정되는 것은 아니다.In addition, the oral dosage form may include powders, granules, tablets, capsules, syrups, etc. The parenteral dosage forms may include, for example, injections, drops, ointments, lotions, gels, creams, sprays, suspensions, Formulations such as emulsions, suppositories, and patches may be used, but are not limited thereto.
본 발명의 일 실시예에 따른 상기 약학 조성물은 비경구, 직장, 국소, 경피 등으로 투여될 수 있다. 본 발명의 일실시예에 따른 약학 조성물은 예를 들어 두피에 국소 투여될 수 있다.The pharmaceutical composition according to an embodiment of the present invention may be administered parenterally, rectally, topically, or transdermally. Pharmaceutical compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
또한, 상기 활성성분의 약제학적으로 허용 가능한 용량, 즉 투여량은 치료 받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있다. 투여량은, 예컨대, 하루에 체중 1㎏당 0.01~5000㎎, 바람직하게는 0.1~2000㎎, 더욱 바람직하게는 0.5~500㎎, 가장 바람직하게는 1~100㎎의 양으로 투여되도록 1 내지 수회에 나누어 투여할 수 있으나, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.In addition, the pharmaceutically acceptable dose, ie dosage, of the active ingredient depends on the age, sex, and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Will be different. Dosage determination based on these factors is within the level of skill in the art. The dosage is, for example, 1 to several times so as to be administered in an amount of 0.01 to 5000 mg, preferably 0.1 to 2000 mg, more preferably 0.5 to 500 mg, and most preferably 1 to 100 mg per kg of body weight per day. It can be administered in divided, but the dosage is not intended to limit the scope of the invention in any way.
본 발명에서 사용에 적합한 약학 조성물에는, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 포함하는 활성 성분들이 그것의 의도된 목적을 달성하기에 유효한 양으로 함유되어 있는 조성물이 포함된다. 더욱 구체적으로, 치료적 유효량은 치료될 객체의 생존을 연장하거나, 질환의 증상을 방지, 경감 또는 완화시키는데 유효한 화합물의 양을 의미한다. 치료적 유효량의 결정은, 특히, 여기에 제공된 상세한 개시 내용 측면에서, 당업자의 능력 범위 내에 있다.Pharmaceutical compositions suitable for use in the present invention include compositions in which the active ingredients, including extracts of tea tree, preferably extracts of the new tea tree species (Changwon No. 3), are contained in an amount effective to achieve their intended purpose. do. More specifically, a therapeutically effective amount means an amount of a compound effective to prolong the survival of the subject to be treated or to prevent, alleviate or alleviate the symptoms of a disease. Determination of a therapeutically effective amount is within the capabilities of those skilled in the art, in particular in terms of the detailed disclosure provided herein.
본 발명의 방법들에서 사용되는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물, 및 이를 유효성분으로 함유하는 조성물(화합물들)에 대한 치료적 유효량은 세포 배양 분석으로부터 초기에 측정될 수 있다. 예를 들어, 선량(dose)은 세포 배양에서 결정된 IC50(half maximal inhibitory concentration) 또는 EC50(half maximal effective concentration)를 포함하는 순환 농도 범위를 얻기 위하여 동물 모델에서 계산될 수 있다. 그러한 정보는 인간에서의 유용한 선량을 더욱 정확히 결정하는데 사용될 수 있다.A therapeutically effective amount for an extract of tea tree, preferably an extract of a new tea tree (Changwon No. 3), and a composition (compounds) containing the same as an active ingredient used in the methods of the present invention is determined initially from cell culture assays. Can be. For example, dose can be calculated in an animal model to obtain a range of circulating concentrations that includes an IC 50 (half maximal inhibitory concentration) or EC 50 (half maximal effective concentration) determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
여기에 기재되어 있는 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물, 또는 이를 유효성분으로 함유하는 조성물(화합물들)의 독성과 치료 효율성은, 예를 들어, LD50(군집의 50%에 대한 치사량), ED50(군집의 50%에 대해 치료 효과를 갖는 선량), IC50(군집의 50%에 대해 치료 억제 효과를 갖는 선량)을 결정하기 위하여, 세포 배양 또는 실험동물에서의 표분 제약 과정들에 의해 산정될 수 있다. 독성과 치료 효과 간의 선량 비가 치료 지수이고 이것은 LD50과 ED50(또는, IC50) 간의 비율로서 표현될 수 있다. 높은 치료 지수를 보이는 화합물들이 바람직하다. 이들 세포 배양 분석에서 얻어진 데이터는 인간에 사용하는 선량의 범위를 산정하는데 사용될 수 있다. 그러한 화합물들의 투여량(dosage) 또는 도포량은 바람직하게는 독성이 없거나 거의 없는 상태에서 ED50(또는, IC50)을 포함하는 순환 농도의 범위 내에 있다.Toxicity and therapeutic efficiency of the extracts of the tea tree described herein, preferably the extract of the new tea tree (Changwon No. 3), or compositions (compounds) containing the same as active ingredients, are described, for example, in LD 50 ( To determine lethal dose for 50%), ED 50 (dose with therapeutic effect for 50% of the population), IC 50 (dose with therapeutic inhibitory effect for 50% of the population), in cell culture or laboratory animals. It can be estimated by the table of constraint constraints of. The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 50 (or IC 50 ). Compounds showing high therapeutic indices are preferred. The data obtained from these cell culture assays can be used to estimate the range of doses used in humans. The dosage or dosage of such compounds is preferably in the range of circulating concentrations including ED 50 (or IC 50 ) in the absence or little toxicity.
본 발명에 있어서, 상기 약학 조성물의 제형은 연고, 로션, 겔, 크림, 스프레이, 현탁제, 유제, 및 패치로 이루어진 군에서 선택되는 어느 하나인 것이 바람직하다. 본 발명에 따른 조성물을 약학 조성물에 적용할 경우에는, 상기 조성물을 유효 성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 제제화 할 수 있다.　본 발명의 유효 성분을 상법에 따라서 실시하면 용이하게 제제화할 수 있으며, 계면활성제, 부형제, 착색제, 향신료, 안정화제, 방부제, 보존제, 수화제, 유화 촉진제, 현탁제, 삼투압 조절을 위한 염 및/또는 완충제, 기타 상용하는 보조제를 적당히 사용할 수 있다.In the present invention, the formulation of the pharmaceutical composition is preferably any one selected from the group consisting of ointments, lotions, gels, creams, sprays, suspensions, emulsions, and patches. When the composition according to the present invention is applied to a pharmaceutical composition, the composition may be formulated in a solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier using the composition as an active ingredient. If the active ingredient of the present invention is carried out according to the conventional method, it can be easily formulated, and it can be easily formulated with surfactants, excipients, colorants, spices, stabilizers, preservatives, preservatives, wetting agents, emulsifiers, suspending agents, salts for controlling osmotic pressure and / or Buffers and other commercial auxiliaries can be used as appropriate.
본 발명에 있어서, 상기 약학 조성물은 암 또는 종양 치료에 효능이 있는 약학 조성물일 수 있다.In the present invention, the pharmaceutical composition may be a pharmaceutical composition that is effective in treating cancer or a tumor.
용어 "암" 또는 "종양"은 전형적으로 조절되지 않은 세포 성장/증식을 특징으로 하는 포유동물의 생리학적 상태를 지칭하거나 기재한다. 암의 예는 암종, 림프종(예를 들어, 호지킨 및 비-호지킨 림프종), 모세포종, 육종 및 백혈병을 포함하나, 이에 한정되지는 않는다. 이러한 암의 보다 특정한 예는 편평세포암, 소세포 폐암, 비소세포 폐암, 폐의 선암종, 폐의 편평세포 암종, 복막암, 간세포성암, 위장암, 췌장암, 신경교종, 자궁경부암, 난소암, 간암, 방광암, 간세포암, 유방암, 결장암, 결장직장암, 자궁내막 또는 자궁 암종, 타액선 암종, 신장암, 간암, 전립선암, 외음부암, 갑상선암, 간 암종, 백혈병 및 다른 림프구증식성 장애, 및 다양한 유형의 두경부암을 포함한다. 본 발명에서 상기 암은 바람직하게는 전립선암, 폐암 또한 유방암이다.The term “cancer” or “tumor” typically refers to or describes the physiological state of a mammal characterized by unregulated cell growth / proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma (eg, Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More specific examples of such cancers include squamous cell cancer, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, Bladder cancer, hepatocellular cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, liver carcinoma, leukemia and other lymphocytic disorders, and various types of two Contains cervical cancer. In the present invention, the cancer is preferably prostate cancer, lung cancer or breast cancer.
본 발명에 있어서, 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 함유하는 화장료 조성물은 피부 외용제 조성물로서, 유연화장수, 수렴화장수, 영양화장수, 로션, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스, 및 팩으로 이루어진 군에서 선택되는 어느 하나로 제형화되는 것을 특징으로 할 수 있다. In the present invention, the cosmetic composition containing the extract of the tea tree, preferably the extract of the new tea tree (Changwon No. 3) is a skin external composition, supple cosmetics, astringent cosmetics, nourishing cosmetics, lotions, eye creams, nutrition creams, massage It may be characterized in that it is formulated into any one selected from the group consisting of cream, cleansing cream, cleansing foam, cleansing water, powder, essence, and pack.
또한, 본 발명에 의한 조성물은 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 상기 보조제는 화장품학 또는 피부과학 분야에서 일반적으로 사용되는 양으로 도입된다. 또한, 본 발명의 조성물은 피부 개선 효과를 증가시키기 위하여 피부 흡수 촉진 물질을 함유할 수 있다.In addition, the composition according to the present invention can be used for fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non- With ionic emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredients commonly used in cosmetics. It may contain adjuvants commonly used in the same cosmetic or dermatology field. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts. In addition, the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
아울러, 화장료 조성물에 유용한 담체로는 예를 들어, 물, 아세톤, 에탄올, 에틸렌 글리콜, 프로필렌 글리콜, 부탄-1,3-디올, 이소프로필 미리스테이트, 이소프로필 팔미테이트 또는 광유가 포함된다. 상기 담체는 용액제, 콜로이드성 분산제, 유제 (수중유 또는 유중수), 현탁제, 크림제, 로숀제, 겔제, 폼제, 무스제, 스프레이제 등일 수 있다. 상기 담체 및(또는) 배합물의 의도된 용도에 따라 선택될 수 있는 다른 성분들도 추가로 포함될 수 있다. 추가 가능한 성분으로는 (FD＆C 블루 #1과 같은) 수용성 착색제; (D＆C 그린 #6과 같은) 유용성 착색제; (유솔렉스(Eusolex) 232와 같은) 수용성 태양 차단제; (옥틸 메톡시신나메이트와 같은) 유용성 태양 차단제; (산화 아연과 같은) 미립자 태양 차단제; (BHT와 같은) 산화방지제; (이나트륨 EDTA와 같은) 킬레이팅제; (카르보머(carbomer)와 같은) 유화 안정화제; (메틸 파라벤과 같은) 방부제; (피넨과 같은) 향료; (소르비톨과 같은) 향미료; (글리세린과 같은) 휴멕탄트; (PVP/에이코센 공중합체와 같은) 방수제; (히드록시프로필 메틸셀룰로오스와 같은) 수용성 막형성제; (수소화 C-9 수지와 같은) 유용성 막형성제; (폴리콰터늄(polyquaternium) 10과 같은) 카티온산 중합체; (크산탄 검과 같은) 음이온성 중합체, (토코페롤과 같은) 비타민 등이 포함될 수도 있으나, 이에 한정되는 것은 아니다.In addition, carriers useful in cosmetic compositions include, for example, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate or mineral oil. The carrier may be a solution, a colloidal dispersant, an emulsion (oil-in-water or water-in-oil), a suspension, a cream, a lotion, a gel, a foam, a mousse, a spray, and the like. Other ingredients may also be included that may be selected depending on the intended use of the carrier and / or combination. Additional ingredients include water-soluble colorants (such as FD & C Blue # 1); Oil-soluble colorants (such as D & C Green # 6); Water-soluble sunscreens (such as Eusolex 232); Oil-soluble sunscreens (such as octyl methoxycinnamate); Particulate sunscreens (such as zinc oxide); Antioxidants (such as BHT); Chelating agents (such as disodium EDTA); Emulsion stabilizers (such as carbomers); Preservatives (such as methyl parabens); Flavoring (such as pinene); Flavorings (such as sorbitol); Humectant (such as glycerin); Waterproofing agents (such as PVP / eicosene copolymers); Water-soluble film forming agents (such as hydroxypropyl methylcellulose); Oil-soluble film-forming agents (such as hydrogenated C-9 resins); Cationic acid polymers (such as polyquaternium 10); Anionic polymers (such as xanthan gum), vitamins (such as tocopherols), and the like may be included, but are not limited thereto.
본 발명에서 '기능식품' 또는 '기능성 식품'이란, 일반 식품에 본 발명에 따른 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 첨가함으로써 일반 식품의 기능성을 향상시킨 식품을 의미한다.'Functional food' or 'functional food' in the present invention, means a food that improves the functionality of the general food by adding the extract of the tea tree according to the present invention, preferably the extract of the new tea tree (Changwon No. 3) to the general food do.
기능성은 물성 및 생리기능성으로 대별될 수 있는데, 본 발명의 추출물을 일반식품에 첨가할 경우, 일반 식품의 물성 및 생리기능성이 향상될 것이고, 본 발명은 이러한 향상된 기능의 식품을 포괄적으로 '기능식품(건강기능식품)' 또는 '기능성 식품(건강기능성 식품)'이라 정의한다.Functionality can be roughly divided into physical properties and physiological functions. When the extract of the present invention is added to general foods, the physical properties and physiological functions of general foods will be improved, and the present invention provides a food product of such an improved function as a comprehensive 'functional food. (Health functional food) "or" functional food (health functional food) ".
본 발명에서 '건강기능식품'이라 함은 건강기능식품에 관한 법률 제10219호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In the present invention, "health functional food" refers to a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Health Functional Food Act No. 10213, and nutrients for the structure and function of the human body. It is meant to be consumed for the purpose of regulating or obtaining a useful effect for health use such as physiological action.
본 발명에 따른 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 함유하는 건강기능식품은, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 또한, 본 발명의 조성물 자체가 다른 식품에 대한 첨가제의 형태로 사용될 수 있다.The health functional food containing the extract of the tea tree according to the present invention, preferably the extract of the new tea tree (Changwon No. 3), will give a synergistic effect to the main effect within the scope of not impairing the main effect of the present invention. And other ingredients that may be present. For example, it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties. In addition, supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included. The components may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, and the amount of the additives may be selected within a range that does not impair the object and effect of the present invention. In addition, the compositions of the present invention can be used in the form of additives for other foods.
본 발명에 따른 차나무의 추출물, 바람직하게는 차나무 신품종(장원 3호)의 추출물을 함유하는 건강기능식품의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 과립제, 드링크제, 음료, 용액, 유화물, 점성형 혼합물, 타블렛, 분말, 액제, 다류(茶類) 등의 다양한 형태로 제형화될 수 있으며, 바람직하게는 기능성 다류 조성물이다. 또한, 상기 건강기능식품 투여시 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다.The formulation of the functional food containing the extract of the tea tree, preferably the extract of tea tree (Changwon No. 3) according to the present invention is not particularly limited, for example, tablets, granules, drinks, beverages, solutions, emulsions, It may be formulated in various forms, such as viscous mixtures, tablets, powders, liquids, teas, and the like, and is preferably a functional tea composition. In addition, the health functional food administration may be administered by a variety of methods, such as simple drinking, injection, spray or squeeze method.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
[[ 제조예Production Example ] 차나무 품종을 개량하기 위한 육종방법Breeding Methods for Improving Tea Tree Varieties
본 명세서에 개시된 차나무(Camellia sinensis (L).) 신품종인 장원 3호는, 재래종, 야생종 차나무 유전자원을 대상으로 교잡육종의 방법을 실시하여 차나무의 화학적 성분 평가(하기 표 2 참조) 및 생육 특성 검정(하기 표 3 참조) 등의 분석을 통한 평가로 선발된 차나무 모본을 대상으로 첫물차(5월 초) 생육 시기가 지난 가지를 삽수로 사용하여 무성적 증식 과정을 통해 육성하여 차나무 모수와 동일하게 우수한 특성(하기 표 4 참조)이 안정적으로 유지되는 신품종으로서, 대한민국 제주도 서귀포시 안덕면 서광서리 1241번지에 위치한 설록차 연구소에서 개발한 것이다. Jangwon No. 3, a new species of Camellia sinensis (L) , disclosed herein, performs hybridization and breeding methods on conventional and wild tea genomes (see Table 2 below) and their growth characteristics. As a result of the analysis of the tea tree model selected by the analysis (see Table 3 below), the first tea tea (early May) was grown through the growth process by using a branch that was past the first growing season (early May) as the tea tree parameter. It is a new product that maintains excellent characteristics (see Table 4 below). It was developed by Sulloc Tea Research Institute located at 1241, Seogwangseo-ri, Andeok-myeon, Seogwipo-si, Jeju-do, Korea.
상기 분석 결과에 기초하여 최종 선발된 차나무 신품종을 "장원 3호"라 명명하였으며, 신품종인 장원 3호는 한국생명공학연구원에 종자기탁을 완료하였다(종자 수탁번호: KCTC(Korean Collection for Type Cultures) 12213BP (2012.5.14)).Based on the analysis results, the final selection of the new tea tree was named "Changwon No. 3", and the new varieties, Changwon No. 3, completed the seed deposit with the Korea Research Institute of Bioscience and Biotechnology (seed accession number: KCTC (Korean Collection for Type Cultures) 12213BP (2012.5.14)).
본 실시예에서 작부 방식 및 재배 관리는 대한민국 농촌진흥청 표준영농교번에 준하여 수행되었다.In this embodiment, the cropping method and cultivation management were performed according to the Rural Development Administration Standard Agricultural Exchange Number.
상기 교잡육종방법을 간략히 설명하면, 상기 교잡육종은 일차적으로 국내 재래종 차나무 유전자원들 중에서 특이 기능성분인 3"-O-Me-EGCG가 고함량으로 함유되어 있는 유전자원들을 선발한 후, 상기 유전자원을 모본으로 교배를 하여 실생 후대를 얻은 후 육성하되 3"-O-Me-EGCG이 고함량으로 함유된 엘리트라인을 육성하였다. Briefly describing the hybrid breeding method, the hybrid breeding is first selected from the gene source containing a high content of 3 " -O- Me-EGCG, a specific functional ingredient among domestic native tea tree gene sources, the gene After mating the originals to obtain lively progeny, they were grown, but elites containing high content of 3 " -O- Me-EGCG were grown.
상기 엘리트라인 중에서, 하기 각 특성들을 기준으로 기본적인 생육 특성이 우수한 차나무를 최종적으로 품종화하였다. 하기 각 특성은 대한민국 국립종자원의 국제식물유전자원평가기준(UPOV)에 의거하여 측정되는 것이 바람직하다.Of the elite line, based on the characteristics of each of the following to finally cultivate tea tree excellent in basic growth characteristics. Each of the following characteristics is preferably measured according to the UPOV of the National Species of Korea.
(i) 맹아시기 및 엽 특성(엽형, 모용, 엽색, 엽폭, 엽장, 엽면적, 엽록소 함량 등); (i) sprouting time and leaf properties (leaf shape, parenting, leaf color, leaf width, leaf length, leaf area, chlorophyll content, etc.);
(ii) 신아 특성: 신아장 및 백아중; (ii) neonatal characteristics: neonatal and white infants;
(iii) 가지 특성: 수자, 수세, 가지 굵기 및 가지 밀도; (iii) eggplant characteristics: soot, water washing, eggplant thickness and eggplant density;
(iv) 개화 특성: 개화 시작 시기, 만개 시작 시기, 만개 종료 시기 및 개화 종료 시기; 및(iv) flowering characteristics: flowering start time, full bloom start time, full bloom end time and flowering end time; And
(v) 기타 특성: 조만성, 내한성, 내병성 및 수확기(v) Other characteristics: fertility, cold resistance, disease resistance and harvest time
상기 생육 특성 검정은, 더욱 상세하게는, 첫물차 기간 중(4월 24일부터 5월 5일) 신아를 대상으로 출개도 70% 시기에, 가로, 세로 20cm의 격자를 차나무 위에 높고 격자 내의 1심 3엽 부위까지 새싹을 모두 채취하여 조만성, 엽장, 엽폭, 신아장, 신아중 등의 생육 지표 평균값을 대한민국 국립종자원의 국제식물유전자원평가기준에 의하여 측정하였다. 조만성은 전체 새싹 중 발아한 새싹의 비율이 70%가 되는 맹아기를 조사하여 비교하였다. 신아장은 새싹 기부에서부터 제일 상위엽까지의 잎줄기 길이를 측정하였다. 신아중은 새싹 100개의 무게인 백아중으로 평가하였다. 엽장, 엽폭, 엽면적의 조사 부위는 채취된 신아의 상부로부터 3번째 잎을 대상으로 하였으며, 엽면적은 엽면적 측정기(LI-3100 Area Meter, LI-COR. Inc., Japan)를 이용하여 측정하였다.The growth characteristics test, more specifically, in the first tea period (April 24 to May 5) at the time of opening 70% of the infants, a grid of 20 cm horizontal and vertical on the tea tree and 1 in the lattice All shoots were harvested up to 3 cores of the core, and the mean values of the growth indicators, including fertility, leaf length, leaf width, renal intestine and renal middle weight, were measured according to the International Plant Genetic Standards of Korea's National Species. Fertility was compared by examining the germination of the germination which is 70% of the total sprouts. Kidneys measured the stem length from the base of the shoot to the uppermost lobe. The infant weight was evaluated as the weight of 100 buds. Leaf area, leaf width, and leaf area were irradiated to the third leaf from the collected kidney, and leaf area was measured using a leaf area meter (LI-3100 Area Meter, LI-COR. Inc., Japan).
하기 표 1은 차나무 신품종의 선별 기준인 작물학적 특성을 나타낸 것이다.Table 1 below shows the cropping characteristics, which are the selection criteria for new varieties of tea tree.
Figure PCTKR2018005605-appb-T000001
Figure PCTKR2018005605-appb-T000001
하기 표 2는 차나무 신품종의 선별 기준인 화학적 성분 평가를 위한 화학성분 특성을 나타낸 것이다.Table 2 below shows the chemical component characteristics for the evaluation of chemical components, which is a selection criteria of new tea varieties.
성분 함량 특성Component Content Characteristics 함량 범위Content range
3”-O-Me-EGCG(mg/g)3 ” -O- Me-EGCG (mg / g) 4.00 이상4.00 or more
아미노산(TFAA) 총함량(중량%)Total amount of amino acid (TFAA) (% by weight) 3.50 이상3.50 or more
데아닌 함량(중량%)Deanine content (% by weight) 2.20 이상2.20 or more
질소 함량(중량%)Nitrogen content (% by weight) 6.00 이상6.00 or more
카페인 함량(mg/g)Caffeine Content (mg / g) 23.5 이하23.5 or less
카테킨 총함량(mg/g)Total catechin (mg / g) 100.0 이하100.0 or less
본 명세서에 기재된 "SPAD" 값은 엽록소 측정기(chlorophyll meter, SPAD-502, Minolta, Japan)를 이용하여 잎의 녹색 정도를 측정하여 잎의 엽록소 함량이나 질소함량을 예측하는 비파괴 방법에 의해 측정된 값을 의미한다. "SPAD(Soil & Plant analyzer development)"는 일본 농림수산성에서 토양과 식물체 분석기술 개발사업(Soil & Plant analyzer development, SPAD)에 의해 개발된 계측기이다. 이 계측기의 원리는 엽록소에 민감한 파장대인 650nm와 둔감한 파장대인 940nm 대역의 빛을 발광다이오드(light emitting diodes)를 이용하여 발생시키고, 이 빛을 2*3mm 창으로 통과하게 한 후 두께가 1.2mm이내의 식물체 잎을 통과한 빛 강도를 실리콘 광다이오드로 측정하고 두 파장대 값의 차이를 이용하여 엽록소 함량을 -9.9부터 99.9 사이의 값으로 나타내 준다. The "SPAD" value described herein is a value measured by a non-destructive method of predicting chlorophyll content or nitrogen content of a leaf by measuring the greenness of the leaf using a chlorophyll meter (SPAD-502, Minolta, Japan). Means. "SPAD (Soil & Plant analyzer development)" is a measuring instrument developed by the Soil & Plant Analyzer Development Project (SPAD) in the Ministry of Agriculture, Forestry and Fisheries. The principle of this instrument is to generate light in the chlorophyll-sensitive wavelength band of 650nm and insensitive wavelength band of 940nm using light emitting diodes, and then pass the light through a 2 * 3mm window and measure 1.2mm in thickness. The intensity of light passing through the leaves of plants within is measured with a silicon photodiode and the chlorophyll content is expressed as a value between -9.9 and 99.9 using the difference between the two wavelength bands.
또한, 근적외분광분석기(Near-Infrared Reflectance Spectroscopy, NIRs) 및 고성능 액체 크로마토그래피(High Performance Liquid Chromatography, HPLC)를 이용하여 데아닌, 총 아미노산(Total Amino Acid, TFAA), 총질소, 카페인, 카테킨 성분 분석을 실시하였다. 분석용 샘플은 첫물차(5월 초) 기간 중 1심 5엽기 출개도 70%인 시기를 기준으로 신초 상위 제1엽~제3엽까지 100g을 채취하여, 증열기(TERADA)에서 40초간 통과시켜 찌고 80℃ 건조기에서 건조시킨 후 분쇄기로 분말로 가공하여 60메쉬 체로 사별하여 얻은 분말을 이용하였다.In addition, Deanine, Total Amino Acid (TFAA), Total Nitrogen, Caffeine, Catechin using Near-Infrared Reflectance Spectroscopy (NIRs) and High Performance Liquid Chromatography (HPLC) Component analysis was performed. Analytical samples are collected 100g from the first to third leaves of the shoots and passed for 40 seconds in the TERADA based on the 70% of the first five-leaf openings during the first tea season (early May). Steamed and dried in an 80 ° C. dryer, and then processed into a powder by a grinder to use a powder obtained by separation into a 60 mesh sieve.
근적외분광분석은 NIR Analyzer (NIRs-XDS, Foss)를 사용하여 시료별 근적외 흡광 스펙트럼(400-2500nm)을 측정하고 개별 함량을 산출하였다.In the near infrared spectroscopy analysis, the NIR analyzer (NIRs-XDS, Foss) was used to measure the near-infrared absorption spectra (400-2500nm) for each sample, and the individual contents were calculated.
하기 표 3은 차나무 신품종의 선별 기준인 생육 특성을 나타낸 것이다.Table 3 below shows the growth characteristics that are the selection criteria of new varieties of tea tree.
Figure PCTKR2018005605-appb-T000002
Figure PCTKR2018005605-appb-T000002
상기와 같은 선별 기준을 통해서 교잡육종에 의해 얻어진 차나무 신품종인 "장원 3호"는 하기 표 4의 특성을 갖는다.Tea tree new varieties "Changwon No. 3" obtained by hybrid breeding through the selection criteria as described above has the characteristics shown in Table 4.
Figure PCTKR2018005605-appb-T000003
Figure PCTKR2018005605-appb-T000003
[[ 실시예Example 1] 차나무 신품종의 추출물의 제조 1] Preparation of New Tea Extract
상술한 육종방법에 의해 선발된 차나무 신품종인 장원 3호를 첫물차(5월 초) 기간 중 1심 5엽기 출개도 70%인 시기를 기준으로 신초 상위 제1엽~제3엽까지 채취하여 증열기에서 40초간 통과시켜 찌고 80℃ 건조기에서 건조시킨 후 분쇄기로 분말 가공하여 60메쉬 체로 사별하고 분말화하였다. 이렇게 제조된 차나무 신품종(장원 3호) 분쇄시료 100g에 1L의 70%(v/v) 에탄올 수용액(absolute ethanol 70%(v/v) + distilled water 30%(v/v))을 첨가하여 환류 추출하고 여과한 후 40~45℃에서 감압 농축하여 최종적으로 차나무 신품종(장원 3호) 잎의 건조된 추출물(실시예 1) 19.2g을 확보하였다.Jangwon No. 3, a new type of tea tree selected by the above breeding method, was collected from the first to third leaves of the new shoots based on the 70% of the first five-leaf openings during the first water vehicle (early May). Steam was passed for 40 seconds in the hot air, dried in an 80 ℃ dryer, powdered by a grinder, and then separated into a 60 mesh sieve and powdered. 100 g of a new cultivated tea tree (Changwon No. 3) was refluxed by adding 1 L of 70% (v / v) aqueous solution of ethanol (v / v) + 30% (v / v) of distilled water). Extraction, filtration and concentration under reduced pressure at 40 ~ 45 ℃ finally secured 19.2g of the dried extract (Example 1) of the tea varieties (Changwon No. 3) leaves.
[[ 비교예Comparative example 1]  One] 야부기다(일반 차나무 품종)의Of Yabugida (general tea variety) 추출물의 제조 Preparation of Extract
실시예 1에서 차나무 신품종(장원 3호) 대신에 일반 차나무 도입 품종인 야부기다를 사용한 것을 제외하고, 실시예 1과 동일한 방법으로 제조하여 최종적으로 야부기다 잎의 건조된 추출물 17.5g을 확보하였다.Except for using a new tea tree varieties Yabugida in Example 1 instead of Yabugida varieties introduced in Example 1, was prepared in the same manner as in Example 1 to finally secure 17.5g of the dried extract of Yabugida leaves.
[[ 비교예Comparative example 2]  2] 가나야미도리(일반 차나무 품종)의Of Kanayami-dori 추출물의 제조 Preparation of Extract
실시예 1에서 차나무 신품종(장원 3호) 대신에 일반 차나무 도입 품종인 가나야미도리를 사용한 것을 제외하고, 실시예 1과 동일한 방법으로 제조하여 최종적으로 가나야미도리 잎의 건조된 추출물 17.1g을 확보하였다.Except for using a new tea varieties Kanayamidori instead of a new tea tree (Changwon No. 3) in Example 1 was prepared in the same manner as in Example 1 to finally secure 17.1g of the dried extract of Kanayamidori leaves.
[[ 비교예Comparative example 3]  3] 유타가미도리(일반 차나무 품종)의Of yutagami-dori 추출물의 제조 Preparation of Extract
실시예 1에서 차나무 신품종(장원 3호) 대신에 일반 차나무 도입 품종인 유타가미도리를 사용한 것을 제외하고, 실시예 1과 동일한 방법으로 제조하여 최종적으로 유타가미도리 잎의 건조된 추출물 18.3g을 확보하였다.Except for using a new tea tree (Changwon No. 3) in Example 1, except that the general tea tree introduced varieties Yutagami-dori, prepared in the same manner as in Example 1 finally secured 18.3g of the dried extract of the leaves of Yutagami-dori It was.
[[ 실시예Example 2] 차나무 신품종의 추출물의 제조 2] Preparation of Extracts of New Tea Varieties
다류(茶類)용For tea 추출물의 제조 Preparation of Extract
차나무 신품종인 장원 3호의 차나무 잎을 재배 시기별로 채취한 다음, 종래 가공방법에 따라 다양한 다류 제품을 제조하였다. 간략하게 설명하면, 차나무 신품종인 장원 3호의 차나무 잎을 증기로 찌거나 볶는 과정을 통하여 산화효소를 불활성화시켜 발효과정을 방지하는 녹차(불발효차)를 제조하고, 녹차의 발효 진행도(진행상태)에 따라 우롱차(반발효차), 홍차(발효차), 또는 미생물 발효에 의한 후발효차를 제조하였다(하기 제형예 10 참조).Tea leaves of Jangwon No. 3, a new type of tea tree, were harvested at each cultivation time, and various tea products were prepared according to conventional processing methods. Briefly, green tea (unfermented tea) to prevent fermentation by inactivating oxidase by steaming or roasting the tea leaves of Jangwon No. 3, a new kind of tea tree, by steaming or roasting them, and the fermentation progress of green tea (progress) Oolong tea (semi-fermented tea), black tea (fermented tea), or post-fermented tea by microbial fermentation was prepared (see Formulation Example 10).
[[ 비교예Comparative example 4]  4] 야부기다(일반 차나무 품종)의Of Yabugida (general tea variety) 추출물의 제조 Preparation of Extract
다류(茶類)용For tea 추출물의 제조 Preparation of Extract
실시예 2에서 차나무 신품종(장원 3호) 대신에 일반 차나무 도입 품종인 야부기다를 사용한 것을 제외하고, 실시예 2와 동일한 방법으로 불발효차, 우롱차(반발효차), 홍차(발효차) 및 후발효차를 제조하였다(하기 제형예 10 참조).Except for fermented tea, oolong tea (semi-fermented tea), and black tea (fermented tea) in the same manner as in Example 2, except that Yabugida, a general tea tree introduced variety, was used in place of the new tea tree varieties (Changwon No. 3). And post-fermented tea was prepared (see Formulation Example 10 below).
[[ 비교예Comparative example 5]  5] 오꾸미도리(일반 차나무 품종)의Of Okumi-dori 추출물의 제조 Preparation of Extract
다류(茶類)용For tea 추출물의 제조 Preparation of Extract
실시예 2에서 차나무 신품종(장원 3호) 대신에 일반 차나무 도입 품종인 오꾸미도리를 사용한 것을 제외하고, 실시예 2와 동일한 방법으로 불발효차, 우롱차(반발효차), 홍차(발효차) 및 후발효차를 제조하였다(하기 제형예 10 참조).Except for fermented tea, oolong tea (semi-fermented tea), and black tea (fermented tea) in the same manner as in Example 2, except that Okumidori, a general tea tree introduced variety, was used in place of the new tea tree varieties (Changwon No. 3). ) And post-fermented tea were prepared (see Formulation Example 10 below).
[[ 시험예Test Example 1] 추출물 성분 비교 분석 1] Comparative analysis of extract ingredients
실시예 1에서 제조한 차나무 신품종(장원 3호) 잎의 추출물과 비교예 1에서 제조한 야부기다 잎의 추출물, 비교예 2에서 제조한 가나야미도리 잎의 추출물, 비교예 3에서 제조한 유타가미도리 잎의 추출물 각각의 카테킨 및 카페인 성분을 분석하였다.Extract of the new tea varieties (Changwon No. 3) leaf prepared in Example 1, the extract of Yabugida leaf prepared in Comparative Example 1, the extract of the Kanayami-dori leaf prepared in Comparative Example 2, the yutagami-dori prepared in Comparative Example 3 The catechin and caffeine components of the extracts of the leaves were analyzed.
먼저, 카테킨 및 카페인 성분 분석을 위해, 상기 추출물 각각을 50% 메탄올에 녹여 10,000ppm 용액으로 만든 후, 고성능 액체 크로마토크래피(High-Performance Liquid Chromatography, HPLC)(Waters사)를 이용하여 성분 분석 (Waters사, 2996 PDA 검출기)을 진행하였다. 고정상은 Kanto Chemical의 Mightysil RP-18 GP 250*4.6 (5μm) 칼럼을 이용하였고, 이동상은 하기 표 5와 같은 조성비를 사용하였다. 필요한 경우, 카테킨 및 카페인 성분 분석은 근적외분광분석에 의해 수행될 수 있다.First, for catechin and caffeine component analysis, each of the extracts were dissolved in 50% methanol to make a 10,000 ppm solution, followed by component analysis using High-Performance Liquid Chromatography (HPLC) (Waters). Waters, 2996 PDA detector). The stationary phase was Mightysil RP-18 GP 250 * 4.6 (5μm) column of Kanto Chemical, and the mobile phase was used in the composition ratio shown in Table 5. If necessary, catechin and caffeine component analysis can be performed by near infrared spectroscopy.
시간 (분)Time (min) A: 물A: water B: 아세토나이트릴B: acetonitrile
00 9090 1010
1010 9090 1010
3030 8585 1515
4242 8080 2020
4444 55 9595
4545 55 9595
4949 9090 1010
5050 9090 1010
그 결과, 하기 표 6에 나타낸 바와 같이, 카테킨의 총함량은 차나무 신품종(장원 3호) 잎의 추출물에서 41.1중량%로 나타나, 일반 차나무 도입 품종인 야부기다 잎의 추출물(28.1중량%), 가나야미도리 잎의 추출물(26.7중량%), 유타가미도리 잎의 추출물(26.4중량%)보다 높게 나타났다. As a result, as shown in Table 6, the total content of catechin was 41.1% by weight in the extract of the new type of tea tree (Changwon No. 3) leaves, extract of Yabugida leaf (28.1% by weight), Ghana, the general tea tree introduced varieties It was higher than the extract of Yami-dori leaves (26.7 wt%) and the extract of Yutagami-dori leaves (26.4 wt%).
특히 차나무 신품종(장원 3호) 잎의 추출물은 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 2.5중량%의 양으로 함유하는 것이 확인되었는데, 이는 일반 차나무 도입 품종보다 10배 이상 고함량으로 함유되어 있는 것이다.In particular, tea tree new varieties (manor third) of the leaf extract is a catechin epi go -3- O - (3- O - methyl) gallate (epigallocatechin-3-O- (3 -O-methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) was found to be present in an amount of 2.5% by weight, which is more than 10 times higher than that of general tea plants.
이러한 카테킨의 총함량 및 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트의 함량 차이로 인하여 차나무 신품종(장원 3호)으로부터 유래되는 추출물은 일반 차나무 품종 추출물에 비해 항산화, 항노화 및 항염 효과가 더욱 우수할 것임을 예측할 수 있다.Due to the difference in the total content of catechins and the content of epigallocatechin-3- O- (3- O -methyl) gallate, the extracts derived from the new tea tree (Changwon No. 3) are more antioxidant and It can be expected that the aging and anti-inflammatory effects will be better.
Figure PCTKR2018005605-appb-T000004
Figure PCTKR2018005605-appb-T000004
한편, 실시예 2에서 제조한 차나무 신품종(장원 3호) 잎의 추출물, 비교예 4에서 제조한 야부기다 잎의 추출물의 카테킨 및 카페인 성분을 분석하였다. On the other hand, the catechin and caffeine components of the extract of the new tea leaves (Changwon No. 3) leaves prepared in Example 2, the extract of Yabugida leaves prepared in Comparative Example 4 were analyzed.
그 결과, 하기 표 7에 나타낸 바와 같이, 실시예 2의 차나무 신품종(장원 3호) 잎의 추출물은 비교에 4의 야부기다 추출물보다 카테킨의 총함량이 높게 나타났다. 이때, 상기 카테킨의 총함량은 갈산(gallic acid, GA), 갈로카테킨(gallocatechin, GC), 에피갈로카테킨(epigallocatechin, EGC), 카테킨(catechin, C), 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG), 에피카테킨(epicatechin, EC), 갈로카테킨 갈레이트(gallocatechin gallate, GCG), 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG) 및 에피카테킨 갈레이트(epicatechin gallate, ECG)의 총함량을 의미한다.As a result, as shown in Table 7 below, the extract of the new tea tree (Changwon No. 3) leaf of Example 2 showed a higher total content of catechin than Yabugida extract of 4. At this time, the total content of the catechin is gallic acid (GA), gallocatechin (gallocatechin, GC), epigallocatechin (epigallocatechin, EGC), catechin (catechin, C), epigallocatechin gallate (epigallocatechin gallate) , EGCG), epicatechin (epicatechin, EC), Gallo catechin gallate (gallocatechin gallate, GCG), to epi-catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" -O- Me-EGCG) and epicatechin gallate (ECG).
또한, 실시예 2의 차나무 신품종(장원 3호) 잎의 추출물의 3”-O-Me-EGCG)의 함량은 녹차, 우롱차(반발효차) 및 홍차(발효차)에서 각각 4.7mg·g-1, 3.6mg·g-1, 1.94mg·g-1으로 나타났다. 즉, 차나무 신품종(장원 3호)의 잎에 함유된 3”-O-Me-EGCG은 기타 카테킨 화합물과 같이 가공 시 산화반응에 의해 카테킨 중합체인 데오플라빈, 데오루비딘 등의 성분으로 변화되어 다류에 포함된 3”-O-Me-EGCG의 함량이 감소되는 것을 확인하였다.In addition, the content of 3 ” -O- Me-EGCG) of the extracts of the tea varieties (Changwon No. 3) leaves of Example 2 was 4.7 mg · g in green tea, oolong tea (semi-fermented tea) and black tea (fermented tea), respectively. 1, it is shown with 3.6mg · g -1, 1.94mg · g -1. That is, 3 ” -O- Me-EGCG contained in the leaves of the new tea tree (Changwon No. 3) is transformed into components such as deoflavin and deorubidine, which are catechin polymers by oxidation during processing like other catechin compounds. It was confirmed that the content of 3 ” -O- Me-EGCG contained in the tea stream was reduced.
Figure PCTKR2018005605-appb-T000005
Figure PCTKR2018005605-appb-T000005
[[ 시험예Test Example 2] 항산화 효과 시험 2] Antioxidant Effect Test
(1) (One) DPPHDPPH 시험 exam
실시예 1 및 비교예 1~3에서 제조한 각 추출물들의 항산화 효과를 알아보기 위하여 유리 라디칼인 DPPH(1,1-디페닐-2-피크릴하이드라질; 1,1-diphenyl-2-picryl hydrazyl)의 환원에 의해(항산화제는 산화됨) 발생되는 흡광도의 변화를 통해 DPPH 산화 억제 효능을 비교 측정함으로써 항산화능을 평가하는 방법을 수행하였다. 즉, 실시예 1 및 비교예 1~3에서 제조한 각각의 추출물에 대해 DPPH의 산화가 억제되어 흡광도가 대조군에 비해 감소되는 정도를 측정하여, 대조군의 흡광도에 비해서 50％ 이하의 흡광도를 나타내는 농도를 유효 항산화 농도로 평가하였다.In order to examine the antioxidant effects of the extracts prepared in Example 1 and Comparative Examples 1 to 3, the free radical DPPH (1,1-diphenyl-2-picrylhydrazyl; 1,1-diphenyl-2-picryl hydrazyl A method of evaluating antioxidant capacity was performed by comparing DPPH oxidation inhibition effect through a change in absorbance generated by reduction of (antioxidant oxidized). That is, the concentration of the extracts of Examples 1 and Comparative Examples 1 to 3 was inhibited by the oxidation of DPPH and the degree of absorbance decreased compared to the control group, and the absorbance was 50% or less than that of the control group. Was evaluated as the effective antioxidant concentration.
먼저, 100μM DPPH 용액(용매로 에탄올 사용) 190㎕와 실시예 1, 비교예 1~3에서 제조한 추출물, 양성 대조군을 각각 10㎕씩 넣어 반응액을 만들고 37℃에서 30분간 반응시킨 후 540nm에서 흡광도를 측정하였다. 상기 양성 대조군으로는 널리 사용하고 있는 항산화제인 아스코르브산(ascorbic acid, AsA, Vitamin C)를 사용하였다. 각 물질의 DPPH 분석 결과는 하기 표 8에 나타내었으며, IC50은 첨가한 시료에 의해 흡광도가 50％ 감소했을 때의 시료 농도를 의미한다.First, 190 μl of 100 μM DPPH solution (using ethanol as a solvent), 10 μl of the extract prepared in Example 1, Comparative Examples 1 to 3, and a positive control, respectively, were prepared to make a reaction solution, and reacted at 37 ° C. for 30 minutes, and then at 540 nm. Absorbance was measured. As a positive control, ascorbic acid (Ascorbic acid, AsA, Vitamin C), a widely used antioxidant, was used. DPPH analysis results of each substance are shown in Table 8 below, and IC 50 means the sample concentration when the absorbance was reduced by 50% by the added sample.
시험물질Test substance IC50 (ppm)IC 50 (ppm)
AsA(Vitamin C)AsA (Vitamin C) 7.17.1
차나무 신품종(장원 3호) 추출물 (실시예 1)Tea tree new varieties (Jangwon No. 3) extract (Example 1) 10.210.2
야부기다 추출물 (비교예 1)Yabugida Extract (Comparative Example 1) 35.135.1
가나야미도리 추출물 (비교예 2)Kanaya Midori Extract (Comparative Example 2) 31.531.5
유타가미도리 추출물 (비교예 3)Yutagami-dori Extract (Comparative Example 3) 37.737.7
표 8에 나타낸 바와 같이, 차나무 신품종(장원 3호)의 추출물(실시예 1)은 양성 대조군으로 사용한 항산화제인 아스코르브산과 비교하여 유사한 항산화 효과를 나타냈으며, 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 및 유타가미도리 추출물과 비교했을 때 월등히 높은 항산화 효능을 나타냈다.As shown in Table 8, the extract (Example 1) of a new type of tea tree (Changwon No. 3) showed a similar antioxidant effect as compared to the ascorbic acid, an antioxidant used as a positive control. Compared to Gan, Kanaya Midori and Yutagamidori extracts, it showed significantly higher antioxidant efficacy.
(2) 수퍼옥사이드 음이온 소거 활성 시험(2) superoxide anion scavenging activity test
차나무 신품종(장원 3호) 추출물(실시예 1) 및 야부기다 추출물(비교예 1)의 수퍼옥사이드 음이온(superoxide anion) 소거 활성을 확인하기 위해서, 10μM 및 20μM의 농도에서 차나무 신품종(장원 3호) 추출물, 야부기다 추출물 및 양성 대조군인 아스코르브산(ascorbic acid, AsA, Vitamin C)의 수퍼옥사이드 음이온 소거 활성을 ESR spectrophotometer로 측정하여 비교하였다. In order to confirm the superoxide anion scavenging activity of the new extract of Tea tree (Changwon 3) and the Yabugida extract (Comparative Example 1), the new tea tree (Changwon 3) at concentrations of 10 μM and 20 μM Superoxide anion scavenging activity of the extract, Yabugida extract and ascorbic acid (Ascorbic acid, AsA, Vitamin C) as a positive control was measured by ESR spectrophotometer.
그 결과, 도 4에 나타낸 바와 같이, 10μM(또는 20μM)의 농도에서 차나무 신품종(장원 3호) 추출물 또는 야부기다 추출물의 수퍼옥사이드 음이온 소거 활성은 양성 대조군인 아스코르브산보다 높게 나타나는 것을 확인하였다. 즉, 차나무 신품종(장원 3호) 추출물은 10μM의 농도에서 54.8%, 20μM의 농도에서 76.3%의 소거활성을 나타내었고, 야부기다 추출물은 10μM의 농도에서 47.4%, 20μM의 농도에서 64.9%의 소거활성을 나타내었으며, AsA는 20μM의 농도에서 21.2%의 소거활성을 나타내었다. As a result, as shown in FIG. It was confirmed that superoxide anion scavenging activity was higher than that of ascorbic acid as a positive control. In other words, the extract of tea tree (Changwon No. 3) showed 54.8% scavenging activity at 10μM concentration and 76.3% scavenging activity at 20μM concentration, and Yabugida extract was 47.4% at 10μM concentration and 64.9% scavenging at 20μM concentration. AsA showed 21.2% scavenging activity at a concentration of 20 μM.
이러한 결과를 통하여 항산화제의 처리 없이 발생된 DMPO-OOH signal을 강력히 소거할 수 있고, mol 수로 계산하여 보면 DMPO가 수퍼옥사이드 음이온과 반응하는 비율보다 차나무 신품종(장원 3호) 추출물(또는, 3"-O-Me-EGCG)이 수퍼옥사이드 음이온과 반응하는 비율이 약 10,000배 이상 높았다.Through this result, the DMPO-OOH signal generated without the treatment of antioxidants can be strongly erased, and when calculated by the number of mol, the extract of new tea tree (Changwon No. 3) than the rate of DMPO reacting with superoxide anion (or 3 " O- Me-EGCG) reacted with superoxide anion about 10,000 times higher.
차나무 신품종(장원 3호) 추출물의 수퍼옥사이드 음이온 소거 활성은 AsA보다 높은 활성을 나타내었는데 이는 차나무 신품종(장원 3호) 추출물에 함유된 주요 기능성 성분인 EGCG(epigallocatechin gallate) 및 3"-O-Me-EGCG가 공통적으로 가지고 있는 갈레이트 작용기(gallate group)와 B 링(B ring)에 가지고 있는 ortho-trihydroxy에 기인하는 것으로 판단된다. The superoxide anion scavenging activity of the extract of new tea tree (Changwon 3) was higher than that of AsA, which is the major functional ingredient of EGCG (epigallocatechin gallate) and 3 " -O -Me This may be due to ortho-trihydroxy in the gallate group and the B ring.
아울러, 차나무 신품종(장원 3호) 추출물이 야부기다 추출물보다 더 높은 수퍼옥사이드 음이온 소거 활성을 나타내는 것은 차나무 잎에 공통으로 함유되어 있는 EGCG 성분뿐만 아니라 카테킨 성분인 3"-O-Me-EGCG에 의한 상승효과에 의한 것으로 판단된다.In addition, the new extract of tea tree (Changwon No. 3) showed higher superoxide anion scavenging activity than Yabugida extract, not only by the catechin component but also by the catechin component 3 " -O- Me-EGCG. We believe this is due to a synergistic effect.
(3) 수산기 라디칼 소거 활성 시험(3) hydroxyl radical scavenging activity test
차나무 신품종(장원 3호) 추출물(실시예 1) 및 야부기다 추출물(비교예 1)의 수산기 라디칼(hydroxyl radical) 소거 활성을 확인하기 위해서, 10μM, 25μM 및 50μM의 농도에서 차나무 신품종(장원 3호) 추출물, 야부기다 추출물 및 양성 대조군인 아스코르브산(ascorbic acid, AsA)의 수산기 라디칼 소거 활성을 ESR 분광 광도계(Electron Spin Resonance Spectrophotometer)로 측정하여 비교하였다. In order to confirm the hydroxyl radical scavenging activity of the new extract of Tea tree (Changwon No. 3) and the Yabugida extract (Comparative Example 1), the new tea tree (Changwon No. 3) at concentrations of 10 μM, 25 μM and 50 μM The hydroxyl radical scavenging activity of) extract, Yabugida extract and ascorbic acid (ASA), a positive control, were measured by ESR spectrophotometer (Electron Spin Resonance Spectrophotometer).
그 결과, 도 5에 나타낸 바와 같이, 차나무 신품종(장원 3호) 추출물은 야부기다 추출물보다 10μM 또는 25μM의 농도에서 소거활성이 더 높게 났다. 반면, 50μM 이상의 농도에서는 상기 2 추출물 간의 소거활성은 크게 다르지 않았으나, 차나무 신품종(장원 3호) 추출물은 AsA보다 약 5배 이상 높은 수준의 수산기 라디칼 소거 활성을 나타내었다.As a result, as shown in Figure 5, the new extract of tea tree (Changwon No. 3) was higher in scavenging activity at a concentration of 10μM or 25μM than Yabugida extract. On the other hand, at a concentration of 50 μM or more, the scavenging activity between the two extracts was not significantly different, but the new extract of tea tree (Changwon No. 3) showed about 5 times higher hydroxyl radical scavenging activity than AsA.
따라서, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물과, 이를 포함하는 조성물은 우수한 항산화 효과를 제공할 수 있음을 확인할 수 있었다.Therefore, it was confirmed that the extract of tea tree new varieties (Jangwon No. 3) according to the present invention, and the composition comprising the same can provide an excellent antioxidant effect.
[시험예 3] 콜라게나아제의 생성 억제능 측정Test Example 3 Measurement of Inhibition of Production of Collagenase
실시예 1 및 비교예 1~3에서 제조한 각 추출물들의 콜라게나아제 생성 억제능을 토코페롤(Tocopherol)과 비교하여 측정하였다. 토코페롤은 대표적인 항산화 물질로서 피부의 표피 세포를 재생시켜 피부의 노화를 방지하는 기능이 있는 것으로 알려진 물질이다. The collagenase production inhibitory ability of each extract prepared in Example 1 and Comparative Examples 1 to 3 was measured by comparing with Tocopherol. Tocopherol is a representative antioxidant that is known to have a function of preventing skin aging by regenerating epidermal cells of the skin.
시험은 2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어 있는 96-웰 평판배양기(96-well microtiter plate)에 인간의 섬유아세포를 5,000세포/well이 되도록 넣고, 90% 정도 자랄 때까지 배양하였다. 그 후 무혈청 DMEM 배지에서 24시간 배양한 다음, 무혈청 DMEM 배지에 녹여진 제조예 1 및 비교예 1~3 각각의 추출물들을 50ppm 농도, 토코페롤을 1x10-4몰 농도로 24시간 동안 처리한 후 세포배양액을 채취하였다.The test was performed by placing human fibroblasts at 5,000 cells / well in a 96-well microtiter plate containing Dulbecco's Modified Eagle's Media (DMEM) medium containing 2.5% fetal calf serum. Incubate until growth. After culturing in serum-free DMEM medium for 24 hours, the extracts of Preparation Example 1 and Comparative Examples 1 to 3 dissolved in serum-free DMEM medium were treated at 50 ppm concentration and tocopherol at 1x10 -4 molar concentration for 24 hours. Cell culture was collected.
채취한 세포배양액을 상업적으로 이용가능한 콜라게나아제 측정기구(아머샴파마샤 사, 미국)를 이용하여 콜라게나아제 생성 정도를 측정하였다. 먼저, 1차 콜라게나아제 항체가 균일하게 도포된 96-웰 평판(96-well plate)에 채취된 세포 배양액을 넣고 3시간 동안 항원-항체 반응을 항온조에서 실시하였다.The collected cell culture solution was measured for the degree of collagenase production using a commercially available collagenase measuring instrument (Amersham Pharmacia, USA). First, the collected cell culture was placed in a 96-well plate uniformly coated with primary collagenase antibody, and the antigen-antibody reaction was performed in a thermostat for 3 hours.
3시간 후 발색단이 결합된 2차 콜라겐 항체를 96-웰 평판(96-well plate)에 넣고 다시 15분간 반응시켰다. 15분 후 발색유발물질을 넣어 실온에서 15분간 발색을 유발시키고, 다시 1M 황산을 넣어 반응(발색)을 중지시키면 반응액의 색깔은 노란색을 띄며 반응 진행의 정도에 따라 노란색의 정도가 다르게 나타났다.After 3 hours, the chromophore-conjugated secondary collagen antibody was placed in a 96-well plate and reacted again for 15 minutes. After 15 minutes, the coloring stimulant was added, causing color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the reaction (color development). The color of the reaction solution was yellow and the degree of yellow color was different according to the progress of the reaction.
노란색을 띠는 96-웰 평판(96-well plate)의 흡광도를 흡광계를 이용하여 405nm에서 측정하였고, 하기 수학식 1에 의해 콜라게나아제의 합성 정도를 계산하였다. 이때 조성물을 처리하지 않은 군의 채취된 세포배양액의 반응 흡광도를 대조군으로 하였다. 즉, 비 처리군에서의 콜라게나아제의 발현 정도를 100으로 하고, 이에 대비하여 시험물질을 처리한 군에서의 콜라게나아제의 발현 정도를 구하였으며, 그 결과는 하기 표 9에 나타내었다.The absorbance of the yellowish 96-well plate (96-well plate) was measured at 405 nm using an absorbance meter, and the degree of synthesis of collagenase was calculated by Equation 1 below. At this time, the reaction absorbance of the collected cell culture medium of the group not treated with the composition was used as a control. That is, the expression level of collagenase in the non-treated group was set to 100, and the expression level of collagenase in the group treated with the test substance was calculated, and the results are shown in Table 9 below.
Figure PCTKR2018005605-appb-M000001
Figure PCTKR2018005605-appb-M000001
시험물질Test substance 콜라게나아제 발현 정도(%)Collagenase expression level (%)
비처리군 Untreated group 100100
토코페롤Tocopherol 6363
차나무 신품종(장원 3호) 추출물 (실시예 1)Tea tree new varieties (Jangwon No. 3) extract (Example 1) 5151
야부기다 추출물 (비교예 1)Yabugida Extract (Comparative Example 1) 6969
가나야미도리 추출물 (비교예 2)Kanaya Midori Extract (Comparative Example 2) 7474
유타가미도리 추출물 (비교예 3)Yutagami-dori Extract (Comparative Example 3) 7676
콜라게나아제의 발현 정도가 낮을수록 콜라게나아제의 발현 억제능이 높고 피부내의 콜라겐의 분해가 적게 일어나 피부 탄력 감소가 저해되며, 생성되는 주름의 양은 적어진다. 표 9에 나타낸 바와 같이, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물(실시예 1)은 시험관내(in vitro)에서 콜라게나아제의 발현을 효과적으로 억제하였으며, 양성 대조군으로 사용한 토코페롤보다도 콜라게나아제의 발현 억제능이 우수함을 확인할 수 있었다. 특히, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물(실시예 1)은 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 및 유타가미도리 추출물에 비하여 콜라게나아제의 발현을 더욱 효과적으로 억제함으로써 피부내의 콜라겐 분해를 억제하여 피부 탄력 증진 효과 및 주름 감소 효과가 우수함을 확인하였다. The lower the expression level of collagenase, the higher the expression inhibiting ability of collagenase, less breakdown of collagen in the skin, inhibiting the decrease in skin elasticity, and the amount of wrinkles produced is smaller. As shown in Table 9, the extract (Example 1) of a new type of tea tree (Changwon No. 3) according to the present invention effectively inhibited the expression of collagenase in vitro , and cola than tocopherol used as a positive control. It was confirmed that the genease inhibitory ability is excellent. In particular, the extract of Tea tree new varieties (Changwon No. 3) according to the present invention (Example 1) is more to the expression of collagenase than the general tea tree introduced varieties Yabugida, Kanayami-dori and Yutagami-dori extracts of Comparative Examples 1 to 3 It was confirmed that the effect of inhibiting collagen breakdown in the skin by effectively inhibiting the skin elasticity enhancing effect and wrinkle reduction effect is excellent.
따라서, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물과 이를 포함하는 조성물은 우수한 항노화 효과를 제공할 수 있음을 확인할 수 있었다.Therefore, it was confirmed that the extract of tea tree varieties (Jangwon No. 3) according to the present invention and the composition comprising the same can provide an excellent anti-aging effect.
[시험예 4] 항염 효과 시험Test Example 4 Anti-inflammatory Effect Test
1. 프로스타글란딘의 생성 억제 효과1. Inhibitory Effect of Prostaglandin Production
실시예 1 및 비교예 1~3에서 제조한 각각의 추출물의 피부 항염 효과를 프로스타글란딘의 생성 억제 효과로 평가하였다. 상기 각각의 추출물을 이용하여 대식세포를 대상으로 항염 효과를 측정하였다. 우선, 마우스의 복강에서 채취한 대식세포에 최종농도가 500M이 되도록 아스피린을 첨가해 세포에 잔존하는 시클로옥시제나제(cyclooxygenase, COX) 활성을 비가역적으로 억제하였다. 그런 다음 상기 현탁액을 96웰의 세포 배양관의 각 웰에 100μl를 넣어 5% CO2와 37℃ 조건의 배양기에서 2시간 동안 배양하여 대식 세포를 용기 표면에 부착시켰다. 이어, 부착된 대식 세포를 PBS로 3회 세척한 후 이를 항염증 효과 시험에 사용하였다. 상기 배양된 대식세포 5x104세포/ml에 LPS(Lipopolysaccharides)를 1%(w/v)로 함유하는 RPMI 배지를 첨가하여 12시간 동안 배양한 후 프로스타글란딘의 생성을 유발하고 실시예 1 및 비교예 1~3에서 제조한 각각의 추출물을 100μl 처리하여 유리된 프로스타글란딘을 효소면역 분석법(ELISA)을 이용하여 정량하였다. 이때, 실시예 1 및 비교예 1~3에서 제조한 각각의 추출물의 프로스타글란딘 생성 억제 활성능(%)을 하기 표 10에 나타내었다.The skin anti-inflammatory effect of each extract prepared in Example 1 and Comparative Examples 1 to 3 was evaluated as a production inhibitory effect of prostaglandins. The anti-inflammatory effect was measured in macrophages using each of the extracts. First, aspirin was added to macrophages taken from the abdominal cavity of mice to a final concentration of 500 M, thereby irreversibly inhibiting cyclooxygenase (COX) activity remaining in the cells. Then, the suspension was added to each well of a 96-well cell culture tube and incubated for 2 hours in an incubator at 37 ° C. with 5% CO 2 to attach macrophages to the container surface. The attached macrophages were then washed three times with PBS and used for the anti-inflammatory effect test. Incubated for 12 hours by adding RPMI medium containing 1% (w / v) of Lipopolysaccharides (LPS) to 5 × 10 4 cells / ml of the cultured macrophages to induce the production of prostaglandins, Example 1 and Comparative Example 1 100 μl of each extract prepared in ˜3 was used to quantify free prostaglandins using enzyme-linked immunosorbent assay (ELISA). At this time, the prostaglandin production inhibitory activity (%) of each extract prepared in Example 1 and Comparative Examples 1 to 3 is shown in Table 10 below.
시험물질Test substance 프로스타글란딘 억제능(%)Prostaglandin inhibitory ability (%)
무처리군 (NT)Untreated group (NT) 00
대조군 (아스피린 처리군)Control group (aspirin treated group) 58.658.6
차나무 신품종(장원 3호) 추출물 (실시예 1)Tea tree new varieties (Jangwon No. 3) extract (Example 1) 56.956.9
야부기다 추출물 (비교예 1)Yabugida Extract (Comparative Example 1) 37.537.5
가나야미도리 추출물 (비교예 2)Kanaya Midori Extract (Comparative Example 2) 27.427.4
유타가미도리 추출물 (비교예 3)Yutagami-dori Extract (Comparative Example 3) 33.833.8
표 10에 나타낸 바와 같이, 차나무 신품종(장원 3호)의 추출물(실시예 1)은 아스피린을 처리한 대조군과 같이 프로스타글란딘의 생성 억제 효과가 매우 높음을 알 수 있었으며, 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 및 유타가미도리 추출물과 비교했을 때 프로스타글란딘 생성 억제 효과가 현저히 높음을 알 수 있었다. As shown in Table 10, the extract (Example 1) of a new type of tea tree (Changwon No. 3) was found to have a very high inhibitory effect on the production of prostaglandins as in the control group treated with aspirin, and the general tea tree of Comparative Examples 1 to 3 Compared with the introduced varieties Yabugida, Kanayamidori and Yutagamidori extracts, the prostaglandin production inhibitory effect was remarkably high.
따라서, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물 및 이를 포함하는 조성물은 피부 염증 인자인 프로스타글란딘의 발현을 억제하여 항염 효과를 가지며, 나아가 피부 트러블을 완화하여 피부 여드름 및 피부 알레르기를 개선할 수 있음을 확인할 수 있었다.Therefore, the extract of tea tree new varieties (Changwon No. 3) according to the present invention and the composition comprising the same has an anti-inflammatory effect by inhibiting the expression of prostaglandin, a skin inflammation factor, and further improves skin acne and skin allergy by alleviating skin troubles. Could confirm.
2. IL-8 생성 억제 효과2. Inhibitory Effect of IL-8 Production
실시예 1 및 비교예 1~3에서 제조한 각 추출물들의 피부 항염 효과를 염증인자인 인터루킨-8(Interleukin-8, IL-8) 생성 억제 효과로 평가하였다. 먼저, 실험 하루 전 피부 각화상피세포(Normal human skin keratinocyte, NHEK, 입수처: Lonza)를 96웰(well) 플레이트에 5x104 세포/웰이 되도록 분주한 후 37℃, 5% CO2 인큐베이터(incubator)에서 24시간 동안 배양하였다. 24시간 후, PBS로 세포를 2회 씻어주고 무혈청 KBM(serum free keratinocyte basement media)으로 갈아주었다. 각각의 웰에 실시예 1 및 비교예 1~3에서 제조한 각각의 추출물을 표 6의 농도별로 처리하여 30분간 반응시킨 후, PGSA(10㎍/㎖), PGSA(50㎍/㎖), PGSA(50㎍/㎖)+LPS(1㎍/㎖)를 각각 처리하였다. 여기서, PGSA(peptidoglycan from S. aureus)는 포도상구균에서 추출한 펩티도글리칸(peptidoglycan)으로서, 그람 양성(+)균의 세포벽의 주요 구성 성분이고 박테리아의 세포막 성분들은 염증을 유발시키는 것으로 알려져 있으며, 특히 포도상구균의 경우 아토피 환자의 90% 정도가 이 균에 의한 2차 감염을 일으키는 것으로 보고되어 있다. 24시간 동안 37℃, 5% CO2 인큐베이터에서 배양한 후 배양액을 취하여 인터루킨-8에 대한 ELISA를 진행하였으며, 그 결과를 하기 표 11에 나타내었다. ELISA는 제조회사(BD science)의 실험방법을 이용하였다.Skin anti-inflammatory effect of each extract prepared in Example 1 and Comparative Examples 1 to 3 was evaluated by the inhibitory effect of the production of inflammatory factors Interleukin-8 (IL-8). First, one day prior to the experiment, normal human skin keratinocytes (NHEK, obtained from Lonza) were dispensed into 96 well plates at 5x10 4 cells / well, followed by 37 ° C and 5% CO 2 incubator. Incubated for 24 hours. After 24 hours, the cells were washed twice with PBS and changed to serum-free keratinocyte basement media (KBM). Each extract prepared in Example 1 and Comparative Examples 1 to 3 was treated in each well according to the concentrations of Table 6, followed by reaction for 30 minutes, followed by PGSA (10 µg / ml), PGSA (50 µg / ml), and PGSA. (50 μg / ml) + LPS (1 μg / ml) were treated respectively. Here, PGSA (peptidoglycan from S. aureus ) is a peptidoglycan (peptidoglycan) extracted from Staphylococcus aureus, a major component of the cell wall of Gram-positive bacteria and bacterial membrane components are known to cause inflammation, In particular, in staphylococci, about 90% of patients with atopic dermatitis have been reported to cause secondary infection. After incubation for 24 hours at 37 ℃, 5% CO 2 incubator, the culture medium was taken and subjected to ELISA for interleukin-8, the results are shown in Table 11 below. ELISA used the experimental method of the manufacturer (BD science).
시험물질Test substance IL-8 분비(pg/㎖)IL-8 secretion (pg / ml)
무처리군 (NT)Untreated group (NT) 935.12935.12
PGSA 10㎍/㎖10 μg / ml PGSA 4725.644725.64
PGSA 10㎍/㎖ + 차나무 신품종(장원 3호) 추출물(실시예 1) 25ppmPGSA 10µg / ml + New Tea Tree (Changwon No. 3) Extract (Example 1) 25ppm 1503.291503.29
PGSA 10㎍/㎖ + 차나무 신품종(장원 3호) 추출물(실시예 1) 50ppmPGSA 10µg / ml + New Tea Tree (Changwon No. 3) Extract (Example 1) 50ppm 1002.571002.57
PGSA 10㎍/㎖ + 야부기다 추출물(비교예 1) 25ppmPGSA 10µg / ml + Yabugida Extract (Comparative Example 1) 25ppm 2765.422765.42
PGSA 10㎍/㎖ + 야부기다 추출물(비교예 1) 50ppm10 g / ml PGSA + Yabugida extract (Comparative Example 1) 50 ppm 2185.222185.22
PGSA 10㎍/㎖ + 가나야미도리 추출물(비교예 2) 25ppmPGSA 10µg / ml + Kanayamidori Extract (Comparative Example 2) 25ppm 2864.772864.77
PGSA 10㎍/㎖ + 가나야미도리 추출물(비교예 2) 50ppm10ppm / ml PGSA + Kanayamidori Extract (Comparative Example 2) 50ppm 2186.592186.59
PGSA 10㎍/㎖ + 유타가미도리 추출물(비교예 3) 25ppm PGSA 10 µg / ml + Utagamidori Extract (Comparative Example 3) 25 ppm 2869.102869.10
PGSA 10㎍/㎖ + 유타가미도리 추출물(비교예 3) 50ppm10 g / ml PGSA + Uppami Midori Extract (Comparative Example 3) 50 ppm 2105.732105.73
표 11에 나타낸 바와 같이, 차나무 신품종(장원 3호)의 추출물(실시예 1)은 염증 유발 자극원인 PGSA에 의해 증가한 IL-8의 분비 억제 효과가 매우 높음을 알 수 있었으며, 비교예 1~3의 일반 차나무 도입 품종 야부기다, 가나야미도리 및 유타가미도리 추출물보다 IL-8의 분비를 현저히 감소 및 억제시킴을 알 수 있었다. As shown in Table 11, the extract (Example 1) of a new tea tree (Changwon No. 3) was found to have a very high effect of inhibiting the secretion of IL-8 increased by PGSA, an inflammation-inducing stimulus, Comparative Examples 1 to 3 It was found that significantly reduced and inhibited IL-8 secretion compared to the extracts of Yabugida, Kanayami-dori and Yutagami-dori, which are introduced from the tea strains.
따라서, 본 발명에 따른 차나무 신품종(장원 3호)의 추출물 및 이를 포함하는 조성물은 피부 염증 유발 자극원인 IL-8의 분비를 억제하여 항염 효과를 가지며, 나아가 피부 트러블을 완화하여 피부 여드름 및 피부 알레르기를 개선할 수 있음을 확인할 수 있었다.Therefore, the extract of tea tree new varieties (Changwon No. 3) according to the present invention and the composition comprising the same has an anti-inflammatory effect by inhibiting the secretion of the skin inflammation-induced stimulus IL-8, and further alleviate the skin trouble to skin acne and skin allergy It could be confirmed that can be improved.
[시험예 5] 암세포주의 증식 억제 시험Test Example 5 Proliferation Inhibition Test of Cancer Cell Line
차나무 신품종(장원 3호) 잎의 추출물(이하, 차나무 신품종(장원 3호) 추출물이라 함), 또는 상기 추출물로부터 분리한 3"-O-Me-EGCG를 암세포주인 폐암 세포주(A549), 신장암 세포주(ACHN), 결장암 세포주(HCT15), 전립선암 세포주(LNCaP) 및 유방암 세포주(MCF-7)에 처리한 다음, 37℃, 5% CO2 인큐베이터(incubator)에서 36시간 동안 배양하였다. 36시간 배양 후, 상기 세포주에 대한 차나무 신품종(장원 3호) 추출물, 또는 3"-O-Me-EGCG의 암세포 증식 억제 효과를 MTT 분석(MTT assay)으로 확인하되, 0.1% DMSO로 처리한 음성 대조군을 기준으로 상대적인 암세포 증식율을 측정하였다.Extract of tea tree (Changwon No. 3) leaf (hereinafter referred to as tea tree new breed (Changwon No. 3) extract), or 3 " -O- Me-EGCG isolated from said extract, cancer cell line lung cancer cell line (A549), kidney cancer Cell lines (ACHN), colon cancer cell lines (HCT15), prostate cancer cell lines (LNCaP) and breast cancer cell lines (MCF-7) were treated and then incubated for 36 hours in a 37 ° C, 5% CO 2 incubator. After cultivation, the extract of tea tree varieties (Changwon No. 3), or 3 " -O- Me-EGCG on the cell line was confirmed by MTT assay, but negative control treated with 0.1% DMSO. Relative cancer cell proliferation was measured as a reference.
그 결과, 하기 표 12에 나타낸 바와 같이,As a result, as shown in Table 12 below,
(i) 차나무 신품종(장원 3호) 추출물, 또는 3"-O-Me-EGCG를 100㎍·mL-1의 농도로 각각의 암세포주에 처리할 경우, 모든 암세포주에서 50% 이하의 암세포 증식율(생존율)을 나타내었고,(i) Up to 50% cancer cell proliferation rate in all cancer cell lines when a new tea tree extract (Changwon No. 3) extract or 3 " -O- Me-EGCG was treated to each cancer cell line at a concentration of 100 µg mL -1 (Survival rate),
차나무 신품종(장원 3호) 추출물을 200㎍·mL-1의 농도로 각각의 암세포주에 처리할 경우, 폐암 세포주(A549), 전립선암 세포주(LNCaP) 및 유방암 세포주(MCF-7)에서 각각 약 18%, 24% 및 16%의 암세포 증식율을 나타내어, 차나무 신품종(장원 3호) 추출물은 암세포 증식 억제 효과가 있음을 확인하였다.When a new tea tree (Changwon No. 3) extract was treated to each cancer cell line at a concentration of 200 µg · mL −1, the drug was treated in lung cancer cell line (A549), prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7), respectively. The cancer cell proliferation rate of 18%, 24% and 16% was confirmed, and it was confirmed that the extract of tea tree new variety (Changwon No. 3) had an inhibitory effect on cancer cell proliferation.
(ii) 또한, 차나무 신품종(장원 3호) 추출물, 또는 3"-O-Me-EGCG를 각각의 암세포주에 처리한 결과, 모든 암세포주에 대하여 농도 의존적으로 암세포 증식을 억제하였고,(ii) In addition, the treatment of each cancer cell line with a new tea tree extract (Changwon No. 3), or 3 " -O- Me-EGCG, inhibited cancer cell proliferation concentration-dependently for all cancer cell lines,
특히 전립선암 세포주(LNCaP)에 차나무 신품종(장원 3호) 추출물 유래 3"-O-Me-EGCG를 50㎍·mL-1, 100㎍·mL-1 및 200㎍·mL-1의 농도로 처리할 경우, 전립선암 세포주의 증식율이 각각 약 46%, 37% 및 20%로 높은 암세포 증식 억제 효과를 나타내었고, 유방암 세포주(MCF-7)도 동등한 조건에서 차나무 신품종(장원 3호) 추출물 유래 3"-O-Me-EGCG를 처리할 경우 높은 암세포 증식 억제 효과를 나타내었으며,Particularly prostate cancer cell line (LNCaP) in tea new varieties (manor No.3) derived extract 3 "- O handling -Me-EGCG in a concentration of 50㎍ · mL -1, 100㎍ · mL -1 and 200㎍ · mL -1 In this case, the proliferation rate of prostate cancer cell lines was about 46%, 37%, and 20%, respectively, and the cancer cell proliferation inhibitory effect was high, and the breast cancer cell line (MCF-7) was also derived from the new tea tree (Changwon 3) extract under the same conditions. " -O -Me-EGCG treatment showed a high inhibitory effect on cancer cell proliferation,
폐암 세포주(A549)에 차나무 신품종(장원 3호) 추출물 유래 3"-O-Me-EGCG를 50㎍·mL-1, 100㎍·mL-1 및 200㎍·mL-1의 농도로 처리할 경우, 암세포 증식율이 각각 약 41%, 20% 및 16%로 나타나, 폐암 세포주(A549)는 전립선암 세포주(LNCaP) 및 유방암 세포주(MCF-7)보다 높은 암세포 증식 억제 효능을 나타내었다. Lung cancer cell line tea new varieties (manor No. 3) to (A549) extracts from 3 "- in case of processing the O -Me-EGCG in a concentration of 50㎍ · mL -1, 100㎍ · mL -1 and 200㎍ · mL -1 , Cancer cell proliferation was about 41%, 20% and 16%, respectively, lung cancer cell line (A549) showed higher cancer cell proliferation inhibitory effect than prostate cancer cell line (LNCaP) and breast cancer cell line (MCF-7).
Figure PCTKR2018005605-appb-T000006
Figure PCTKR2018005605-appb-T000006
[[ 시험예Test Example 6]  6] 실시예Example 2 및  2 and 비교예Comparative example 4~5에서 제조된 추출물들의 관능 평가 Sensory Evaluation of Extracts Prepared in 4-5
녹차(불발효차), 우롱차(반발효차), 홍차(발효차), 또는 흑차(후발효차)는 형상, 색상, 향, 수색, 맛 등의 특성이 서로 상이한데, 특히 우롱차(반발효차), 홍차(발효차), 또는 흑차(후발효차)는 발효 진행도에 따라서 향, 수색, 맛 등의 기호성의 변화가 크게 발생하며 함유된 성분도 변화를 하게 되는데, 극차광을 통한 찻잎을 대상으로 발효도에 따른 가공방법에 의한 기호성과 기능성의 변화를 비교하고자, 상기 실시예 2의 차나무 신품종(장원 3호)의 추출물, 비교예 4의 야부기다(일본 품종) 추출물 및 비교예 5의 오꾸미도리(일본 품종) 추출물에 대하여, 다류(茶類)로서의 기호성 및 기능성을 알아보기 위해 외관 평가(형상, 색상; 40점 만점) 및 내질 평가(향기, 수색, 맛; 60점 만점)를 수행하였다. Green tea (fermented tea), oolong tea (semi-fermented tea), black tea (fermented tea), or black tea (post-fermented tea) has different characteristics such as shape, color, aroma, color search, and taste. Semi-fermented tea), black tea (fermented tea), or black tea (post-fermented tea) changes in palatability, color, taste, etc. according to the fermentation progress, and the contained ingredients also change. To compare the palatability and functionality of tea leaves by processing methods according to the degree of fermentation, extracts of the new tea tree varieties (Changwon No. 3) of Example 2, Yabugida (Japanese varieties) extract of Comparative Example 4, and Comparative Examples For Okumidori (Japanese varieties) extract of 5, appearance evaluation (shape, color; perfect score of 40 points) and quality evaluation (fragrance, search, taste; perfect score of 60 points) were carried out to investigate palatability and functionality as tea. ) Was performed.
그 결과, 하기 표 13에 나타낸 바와 같이, 관능 평가에서 가공방법과는 무관하게 차나무 신품종(장원 3호)은 야부기다와 오꾸미도리보다 반발효차, 발효차, 후발효차 모두에서 높은 기호성을 가지는 것으로 나타나, 각종 다류 제조에 뛰어난 특징을 가지고 있어 활용도가 매우 높을 것으로 평가되었다.As a result, as shown in Table 13, regardless of the processing method in the sensory evaluation, the new varieties of tea tree (Changwon No. 3) had higher palatability in both semi-fermented tea, fermented tea and post-fermented tea than Yabugida and Okumi-dori. It appeared to have, and has excellent characteristics in the production of various kinds of tea, and it was evaluated that the utilization was very high.
Figure PCTKR2018005605-appb-T000007
Figure PCTKR2018005605-appb-T000007
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
또한, 이하 본 발명의 차나무 신품종(장원 3호) 추출물을 함유하는 조성물을 포함하는 제형예를 보다 상세하게 설명하나, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다.In addition, it will be described in more detail the formulation example comprising a composition containing a new tea tree (Changwon No. 3) extract of the present invention in detail, it will be apparent that the scope of the present invention is not limited thereby.
[[ 제형예Formulation example 1] 영양화장수의 제조 1] Preparation of Nutrients
표 14에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다(단위: 중량%).Nutrients were prepared in a conventional manner according to the composition described in Table 14 (unit: wt%).
성분ingredient 함량content
정제수Purified water 잔량Remaining amount
글리세린glycerin 8.08.0
부틸렌글리콜Butylene glycol 4.04.0
히알루론산 추출물Hyaluronic acid extract 5.05.0
베타글루칸Beta Glucan 7.07.0
카보머Carbomer 0.10.1
차나무 신품종(장원 3호) 추출물(실시예 1)Tea tree new varieties (Jangwon 3) extract (Example 1) 1.01.0
카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 8.08.0
스쿠알란Squalane 5.05.0
세테아릴 글루코사이드Cetearyl Glucoside 1.51.5
소르비탄 스테아레이트Sorbitan stearate 0.40.4
세테아릴 알코올Cetearyl Alcohol 1.01.0
트리에탄올아민Triethanolamine 0.10.1
[[ 제형예Formulation example 2] 영양크림의 제조 2] Preparation of Nutritional Cream
표 15에 기재된 조성에 따라 통상적인 방법으로 영양크림을 제조하였다(단위: 중량%).Nutritional cream was prepared in a conventional manner according to the composition described in Table 15 (unit: wt%).
성분ingredient 함량content
정제수Purified water 잔량Remaining amount
글리세린glycerin 3.03.0
부틸렌글리콜Butylene glycol 3.03.0
유동파라핀Liquid paraffin 7.07.0
베타글루칸Beta Glucan 7.07.0
카보머Carbomer 0.10.1
차나무 신품종(장원 3호) 추출물(실시예 1)Tea tree new varieties (Jangwon 3) extract (Example 1) 5.05.0
카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 3.03.0
스쿠알란Squalane 5.05.0
세테아릴 글루코사이드Cetearyl Glucoside 1.51.5
소르비탄 스테아레이트Sorbitan stearate 0.40.4
폴리솔베이트 60Polysorbate 60 1.21.2
트리에탄올아민Triethanolamine 0.10.1
[[ 제형예Formulation example 3] 마사지 크림의 제조 3] Preparation of Massage Cream
표 16에 기재된 조성에 따라 통상적인 방법으로 마사지 크림을 제조하였다(단위: 중량%).Massage creams were prepared in a conventional manner according to the composition described in Table 16 (unit: wt%).
성분ingredient 함량content
정제수Purified water 잔량Remaining amount
글리세린glycerin 8.08.0
부틸렌글리콜Butylene glycol 4.04.0
유동파라핀Liquid paraffin 45.045.0
베타글루칸Beta Glucan 7.07.0
카보머Carbomer 0.10.1
차나무 신품종(장원 3호) 추출물(실시예 1)Tea tree new varieties (Jangwon 3) extract (Example 1) 2.02.0
카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 3.03.0
밀납Beeswax 4.04.0
세테아릴 글루코사이드Cetearyl Glucoside 1.51.5
세스퀴올레인산 소르비탄Sesquioleic acid sorbitan 0.90.9
바세린Vaseline 3.03.0
파라핀paraffin 1.51.5
[[ 제형예Formulation example 4] 팩의 제조 4] manufacture of packs
표 17에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다(단위: 중량%).The pack was prepared by the conventional method according to the composition described in Table 17 (unit: wt%).
성분ingredient 함량content
정제수Purified water 잔량Remaining amount
글리세린glycerin 4.04.0
폴리비닐알콜Polyvinyl alcohol 15.015.0
히알루론산 추출물Hyaluronic acid extract 5.05.0
베타글루칸Beta Glucan 7.07.0
알란토인Allantoin 0.10.1
차나무 신품종(장원 3호) 추출물(실시예 1)Tea tree new varieties (Jangwon 3) extract (Example 1) 0.50.5
노닐페닐에테르Nonylphenyl Ether 0.40.4
폴리솔베이트 60Polysorbate 60 1.21.2
에탄올ethanol 6.06.0
[[ 제형예Formulation example 5] 연고의 제조 5] Preparation of Ointment
표 18에 기재된 조성에 따라 통상적인 방법으로 연고를 제조하였다(단위: 중량%).Ointment was prepared in a conventional manner according to the composition described in Table 18 (unit: wt%).
성분ingredient 함량content
정제수Purified water 잔량Remaining amount
글리세린glycerin 8.08.0
부틸렌글리콜Butylene glycol 4.04.0
유동파라핀Liquid paraffin 15.015.0
베타글루칸Beta Glucan 7.07.0
카보머Carbomer 0.10.1
차나무 신품종(장원 3호) 추출물(실시예 1)Tea tree new varieties (Jangwon 3) extract (Example 1) 1.01.0
카프릴릭/카프릭 트리글리세라이드Caprylic / Capric Triglycerides 3.03.0
스쿠알란Squalane 1.01.0
세테아릴 글루코사이드Cetearyl Glucoside 1.51.5
소르비탄 스테아레이트Sorbitan stearate 0.40.4
세테아릴 알코올Cetearyl Alcohol 1.01.0
밀납Beeswax 4.04.0
[[ 제형예Formulation example 6] 연질 캡슐의 제조 6] Preparation of Soft Capsule
차나무 신품종(장원 3호)의 추출물(실시예 1) 80mg, 비타민 E 9mg, 비타민 C 9mg, 팜유 2mg, 식물성 경화유 8mg, 황납 4mg 및 레시틴 9mg을 혼합하고, 통상의 방법에 따라 혼합하여 연질캡슐 충진액을 제조하였다. 1 캡슐당 400㎎씩 충진하여 연질캡슐을 제조하였다. 그리고 상기와 별도로 젤라틴 66 중량부, 글리세린 24 중량부 및 솔비톨액 10 중량부의 비율로 연질캡슐시트를 제조하고 상기 충진액을 충진시켜 본 발명에 따른 조성물 400mg이 함유된 연질캡슐을 제조하였다.Extract of new tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, beeswax 4 mg and lecithin 9 mg were mixed and mixed according to a conventional method to fill soft capsules. A liquid was prepared. 400 mg per capsule was filled to prepare a soft capsule. In addition, a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
[[ 제형예Formulation example 7] 정제의 제조 7] Preparation of Tablet
차나무 신품종(장원 3호)의 추출물(실시예 1) 80mg, 비타민 E 9mg, 비타민 C 9mg, 갈락토올리고당 200㎎, 유당 60㎎ 및 맥아당 140㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester) 6㎎을 첨가하였다. 이들 조성물 504mg을 통상의 방법으로 타정하여 정제를 제조하였다.Extract of tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, galactooligosaccharide 200 mg, lactose 60 mg and maltose 140 mg were mixed and granulated using a fluidized bed dryer and then sugar ester (sugar ester) 6 mg was added. Tablets were prepared by compression of 504 mg of these compositions in a conventional manner.
[[ 제형예Formulation example 8] 드링크제의 제조 8] Preparation of Drink
차나무 신품종(장원 3호)의 추출물(실시예 1) 80mg, 비타민 E 9mg, 비타민 C 9mg, 포도당 10g, 구연산 0.6g, 및 액상 올리고당 25g을 혼합한 후 정제수 300㎖를 첨가하여 각 병에 200㎖씩 되게 충진하였다. 병에 충진한 후 130℃에서 4∼5 초간 살균하여 음료를 제조하였다.Extract of a new tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, glucose 10 g, citric acid 0.6 g, and 25 g of liquid oligosaccharides were mixed and 300 ml of purified water was added to each bottle 200 ml. Filled very hard. After filling the bottle sterilized for 4 to 5 seconds at 130 ℃ to prepare a beverage.
[[ 제형예Formulation example 9] 과립의 제조 9] Preparation of Granules
차나무 신품종(장원 3호)의 추출물(실시예 1) 80mg, 비타민 E 9mg, 비타민 C 9mg, 무수결정 포도당 250㎎ 및 전분 550㎎을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하여 제조하였다.Extract of tea tree (Changwon No. 3) (Example 1) 80 mg, vitamin E 9 mg, vitamin C 9 mg, 250 g of anhydrous glucose, and 550 mg of starch were mixed and formed into granules using a fluidized bed granulator, and then filled into sachets. It was prepared by.
[[ 제형예Formulation example 10] 다류 조성물의 제조 10] Preparation of Multiflow Composition
차나무 신품종(장원 3호)의 차 잎에서 폴리페놀 분해작용을 하는 폴리페놀 옥시데이즈(Polyphenol oxidase) 활성을 억제하기 위하여 보일러로 가동되는 증열기를 사용해 사용 차엽 온도를 90℃로 30초 정도 유지하였다. 이후 수분함량이 6% 이하가 되도록 충분히 건조한 후 마쇄기를 이용하여 입자크기가 0.5~4mm가 되도록 마쇄한 다음 이를 1.0g 티백으로 제조하였다.In order to suppress polyphenol oxidase activity, which is a polyphenol degrading effect, on tea leaves of the new tea tree (Changwon No. 3), the tea leaf temperature was maintained at 90 ° C. for 30 seconds using a boiler-operated steamer. . After drying enough to have a water content of 6% or less, and milled to a particle size of 0.5 ~ 4mm using a grinding machine was prepared as 1.0g tea bag.
[수탁번호][Accession number]
기탁기관명 : 한국생명공학연구원Depositary: Korea Research Institute of Bioscience and Biotechnology
수탁번호 : KCTC12213BPAccession number: KCTC12213BP
수탁일자 : 20120514Deposit Date: 20120514

Claims (36)

  1. 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물을 유효성분으로 함유하는 항산화용 조성물.Epi-catechins to go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - O -Me-EGCG) a high content of Antioxidant composition containing the extract of Camellia sinensis containing as an active ingredient.
  2. 제1항에 있어서, 상기 추출물은 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 1.25중량% 이상 포함하는 것을 특징으로 하는, 조성물.The composition of claim 1, wherein the extract comprises at least 1.25% by weight of epigallocatechin-3- O- (3- O -methyl) gallate.
  3. 제1항에 있어서, 상기 추출물은 6.35~25.4중량% 에피갈로카테킨(epigallocatechin, EGC), 9.4~37.6중량% 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG) 및 2.65~10.6중량% 에피카테킨 갈레이트(epicatechin gallate, ECG)를 더 포함하는 것을 특징으로 하는, 조성물.According to claim 1, wherein the extract is 6.35 ~ 25.4% by weight epigallocatechin (EGC), 9.4 ~ 37.6% by weight epigallocatechin gallate (EGCG) and 2.65 ~ 10.6% by weight epicatechin gallate (epicatechin gallate, ECG), characterized in that it further comprises.
  4. 제1항에 있어서, 상기 추출물은 차나무의 꽃, 잎, 열매, 줄기 및 뿌리로 구성된 군에서 선택되는 적어도 어느 1종의 추출물인 것을 특징으로 하는, 조성물.The composition of claim 1, wherein the extract is at least one extract selected from the group consisting of flowers, leaves, fruits, stems, and roots of tea trees.
  5. 제1항에 있어서, 상기 추출물은 조성물 총 중량에 대하여 0.01~20중량%의 양으로 함유되는 것을 특징으로 하는, 조성물.The composition of claim 1, wherein the extract is contained in an amount of 0.01 to 20% by weight based on the total weight of the composition.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서, 상기 조성물은 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물인 것을 특징으로 하는, 조성물.The composition according to any one of claims 1 to 5, wherein the composition is a pharmaceutical composition, a cosmetic composition or a nutraceutical composition.
  7. 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물을 유효성분으로 함유하는 항염증용 조성물.Epi-catechins to go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - O -Me-EGCG) a high content of Anti-inflammatory composition containing the extract of Camellia sinensis containing as an active ingredient.
  8. 제7항에 있어서, 상기 추출물은 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 1.25중량% 이상 포함하는 것을 특징으로 하는, 조성물.8. The composition of claim 7, wherein the extract comprises at least 1.25% by weight of epigallocatechin-3- O- (3- O -methyl) gallate.
  9. 제7항에 있어서, 상기 추출물은 6.35~25.4중량% 에피갈로카테킨(epigallocatechin, EGC), 9.4~37.6중량% 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG) 및 2.65~10.6중량% 에피카테킨 갈레이트(epicatechin gallate, ECG)를 더 포함하는 것을 특징으로 하는, 조성물.The method according to claim 7, wherein the extract is 6.35 to 25.4 wt% epigallocatechin (EGC), 9.4 to 37.6 wt% epigallocatechin gallate (EGCG) and 2.65 to 10.6 wt% epicatechin gallate (epicatechin gallate, ECG), characterized in that it further comprises.
  10. 제7항에 있어서, 상기 추출물은 차나무의 꽃, 잎, 열매, 줄기 및 뿌리로 구성된 군에서 선택되는 적어도 어느 1종의 추출물인 것을 특징으로 하는, 조성물.8. The composition of claim 7, wherein the extract is at least one extract selected from the group consisting of flowers, leaves, fruits, stems, and roots of tea trees.
  11. 제7항에 있어서, 상기 추출물은 조성물 총 중량에 대하여 0.01~20중량%의 양으로 함유되는 것을 특징으로 하는, 조성물.The composition of claim 7, wherein the extract is contained in an amount of 0.01 to 20% by weight based on the total weight of the composition.
  12. 제7항 내지 제11항 중 어느 한 항에 있어서, 상기 조성물은 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물인 것을 특징으로 하는, 조성물.The composition according to any one of claims 7 to 11, wherein the composition is a pharmaceutical composition, a cosmetic composition or a nutraceutical composition.
  13. 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물을 유효성분으로 함유하는 항노화용 조성물.Epi-catechins to go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - O -Me-EGCG) a high content of Anti-aging composition containing the extract of Camellia sinensis as an active ingredient.
  14. 제13항에 있어서, 상기 추출물은 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 1.25중량% 이상 포함하는 것을 특징으로 하는, 조성물.The composition of claim 13, wherein the extract comprises at least 1.25% by weight of epigallocatechin-3- O- (3- O -methyl) gallate.
  15. 제13항에 있어서, 상기 추출물은 6.35~25.4중량% 에피갈로카테킨(epigallocatechin, EGC), 9.4~37.6중량% 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG) 및 2.65~10.6중량% 에피카테킨 갈레이트(epicatechin gallate, ECG)를 더 포함하는 것을 특징으로 하는, 조성물.The method according to claim 13, wherein the extract is 6.35-25.4 wt% epigallocatechin (EGC), 9.4-37.6 wt% epigallocatechin gallate (EGCG) and 2.65-10.6 wt% epicatechin gallate (epicatechin gallate, ECG), characterized in that it further comprises.
  16. 제13항에 있어서, 상기 추출물은 차나무의 꽃, 잎, 열매, 줄기 및 뿌리로 구성된 군에서 선택되는 적어도 어느 1종의 추출물인 것을 특징으로 하는, 조성물.The composition of claim 13, wherein the extract is at least one extract selected from the group consisting of flowers, leaves, fruits, stems, and roots of tea trees.
  17. 제13항에 있어서, 상기 추출물은 조성물 총 중량에 대하여 0.01~20중량%의 양으로 함유되는 것을 특징으로 하는, 조성물.The composition of claim 13, wherein the extract is contained in an amount of 0.01 to 20% by weight based on the total weight of the composition.
  18. 제13항 내지 제17항 중 어느 한 항에 있어서, 상기 조성물은 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물인 것을 특징으로 하는, 조성물.The composition according to any one of claims 13 to 17, wherein the composition is a pharmaceutical composition, a cosmetic composition or a nutraceutical composition.
  19. 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물을 유효성분으로 함유하는 항암용 조성물.Epi-catechins to go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - O -Me-EGCG) a high content of An anticancer composition containing the extract of Camellia sinensis as an active ingredient.
  20. 제19항에 있어서, 상기 추출물은 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트를 1.25중량% 이상 포함하는 것을 특징으로 하는, 조성물.20. The composition of claim 19, wherein the extract comprises at least 1.25% by weight of epigallocatechin-3- O- (3- O -methyl) gallate.
  21. 제19항에 있어서, 상기 추출물은 6.35~25.4중량% 에피갈로카테킨(epigallocatechin, EGC), 9.4~37.6중량% 에피갈로카테킨 갈레이트(epigallocatechin gallate, EGCG) 및 2.65~10.6중량% 에피카테킨 갈레이트(epicatechin gallate, ECG)를 더 포함하는 것을 특징으로 하는, 조성물.The method of claim 19, wherein the extract is 6.35 to 25.4 weight percent epigallocatechin (EGC), 9.4 to 37.6 weight percent epigallocatechin gallate (EGCG) and 2.65 to 10.6 weight percent epicatechin gallate (epicatechin gallate, ECG), characterized in that it further comprises.
  22. 제19항에 있어서, 상기 추출물은 차나무의 꽃, 잎, 열매, 줄기 및 뿌리로 구성된 군에서 선택되는 적어도 어느 1종의 추출물인 것을 특징으로 하는, 조성물.The composition of claim 19, wherein the extract is at least one extract selected from the group consisting of flowers, leaves, fruits, stems, and roots of tea trees.
  23. 제19항에 있어서, 상기 추출물은 조성물 총 중량에 대하여 0.01~20중량%의 양으로 함유되는 것을 특징으로 하는, 조성물.The composition of claim 19, wherein the extract is contained in an amount of 0.01 to 20% by weight based on the total weight of the composition.
  24. 제19항 내지 제23항 중 어느 한 항에 있어서, 상기 조성물은 약학 조성물, 화장료 조성물 또는 건강기능식품 조성물인 것을 특징으로 하는, 조성물.The composition according to any one of claims 19 to 23, wherein the composition is a pharmaceutical composition, a cosmetic composition or a nutraceutical composition.
  25. 항산화용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항산화제로서의 용도.In the manufacture of a pharmaceutical composition or medicament for the antioxidant, catechin in epi go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; Use as an antioxidant of extract of Camellia sinensis which contains 3 ” -O- Me-EGCG) in high content.
  26. 항산화용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항산화제로서의 용도.In the production of antioxidant cosmetic composition, to go epi catechins -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - Use as an antioxidant of the extract of Camellia sinensis containing high content of O -Me-EGCG).
  27. 항산화용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항산화제로서의 용도.In the dietary antioxidant composition for the production of food, as the epi catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) as an antioxidant of the extract of Camellia sinensis containing high content.
  28. 항염증 또는 소염용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항염증제 또는 소염제로서의 용도.In the manufacture of a pharmaceutical composition or a medicament for anti-inflammatory or anti-inflammatory, a catechin epi go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 Use as an anti-inflammatory or anti-inflammatory agent of the extract of Camellia sinensis , which contains a high amount of ”Me; 3” -O- Me-EGCG).
  29. 항염증 또는 소염용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항염증제 또는 소염제로서의 용도.In the production of anti-inflammatory or anti-inflammatory cosmetic composition, in the epi catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; Use as an anti-inflammatory or anti-inflammatory agent of the extract of Camellia sinensis containing high content of 3 ” -O- Me-EGCG).
  30. 항염증 또는 소염용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항염증제 또는 소염제로서의 용도.In the production of anti-inflammatory or anti-inflammatory composition for dietary supplements, as a go-epi catechins -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) as an anti-inflammatory or anti-inflammatory agent of the extract of Camellia sinensis , which contains a high content.
  31. 항노화용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항노화제로서의 용도.In the production of the anti-nohwayong pharmaceutical composition or medicament, as the epi catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; Use as an anti-aging agent of extract of Camellia sinensis , which contains 3 ” -O- Me-EGCG) in high content.
  32. 항노화용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항노화제로서의 용도.In the manufacture of a cosmetic composition, wherein nohwayong, go to epi catechins -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - Use as an anti-aging agent of extract of Camellia sinensis containing high content of O- Me-EGCG).
  33. 항노화용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항노화제로서의 용도.In the production of the anti-nohwayong dietary supplement composition, in the epi catechins go -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) as an anti-aging agent for the extract of Camellia sinensis , which contains a high content.
  34. 항암용 약학적 조성물 또는 의약의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항암제로서의 용도.In the manufacture of a pharmaceutical composition or a medicament for anti-cancer, epi catechins in going -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; Use as an anticancer agent of the extract of Camellia sinensis , which contains 3 ” -O- Me-EGCG) in high content.
  35. 항암용 화장료 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항암제로서의 용도.In the manufacture of a cosmetic composition for anti-cancer, to go epi catechins -3- O - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me;3" - The use of the extract of Camellia sinensis which contains high content of O- Me-EGCG) as an anticancer agent.
  36. 항암용 건강기능식품 조성물의 제조에 있어서, 에피갈로카테킨-3-O-(3-O-메틸) 갈레이트(epigallocatechin-3-O-(3-O-methyl) gallate; EGCG3”Me; 3”-O-Me-EGCG)를 고함량으로 포함하는 차나무(Camellia sinensis)의 추출물의 항암제로서의 용도.In the production of anti-cancer health food composition, catechin -3- O to go epi - (3- O - methyl) gallate (epigallocatechin-3- O - (3- O -methyl) gallate; EGCG3 "Me; 3 ” -O- Me-EGCG) as an anticancer agent of the extract of Camellia sinensis containing high content.
PCT/KR2018/005605 2017-05-16 2018-05-16 Composition containing camellia sinensis extract WO2018212588A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880032982.9A CN111050783A (en) 2017-05-16 2018-05-16 Composition containing tea tree extract
MYPI2019006749A MY197901A (en) 2017-05-16 2018-05-16 Composition containing camellia sinensis extract

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0060641 2017-05-16
KR1020170060641A KR102428987B1 (en) 2017-05-16 2017-05-16 Composition Containing Extracts of Camellia sinensis

Publications (1)

Publication Number Publication Date
WO2018212588A1 true WO2018212588A1 (en) 2018-11-22

Family

ID=64274183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005605 WO2018212588A1 (en) 2017-05-16 2018-05-16 Composition containing camellia sinensis extract

Country Status (4)

Country Link
KR (1) KR102428987B1 (en)
CN (1) CN111050783A (en)
MY (1) MY197901A (en)
WO (1) WO2018212588A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3116438B1 (en) 2020-11-23 2022-10-14 Isp Investments Llc METHOD FOR OBTAINING AQUEOUS EXTRACTS FROM TEA LEAVES, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES
CN112545909B (en) * 2020-12-14 2022-06-21 湖南农业大学 Theaflavin composition and application thereof
FR3125425A1 (en) 2021-07-22 2023-01-27 Isp Investments Llc EXTRACT OF BLACK TEA LEAVES, COMPOSITIONS COMPRISING THEM AND COSMETIC USES THEREOF
KR102462676B1 (en) 2021-10-05 2022-11-03 권휘 Method for making tea by using shell of camellia sinensis fruit
KR20230136988A (en) 2022-03-21 2023-10-04 영남대학교 산학협력단 Composition comprising epigallocatechin gallate for inhibiting tetranectin activity
KR20230170163A (en) 2022-06-09 2023-12-19 대한민국(농촌진흥청장) New variety of tea plant and breeding method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015199169A1 (en) * 2014-06-27 2015-12-30 国立大学法人九州大学 Catechin function enhancement method
KR20160127860A (en) * 2015-04-27 2016-11-07 강원대학교산학협력단 Composition for anti-aging comprising methylated catechin as effective component
KR101722427B1 (en) * 2015-04-27 2017-04-04 강원대학교산학협력단 Composition for growth inhibition of cancer cell comprising methylated catechin as effective component

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2275463T3 (en) * 1999-08-16 2007-06-16 Dsm Ip Assets B.V. PROCESS FOR THE PRODUCTION OF EPIGALOCATEQUINE GALATE.
EP1157693A1 (en) * 2000-05-12 2001-11-28 National Agricultural Research Organisation (NARO) Use of epigallocatechin 3-o-(3-o-methyl) gallate and/or epigallocatechin 3-o-(4-o-methyl) gallate for the treatment of allergy and/or inflammation
JP4742752B2 (en) 2005-08-30 2011-08-10 独立行政法人農業・食品産業技術総合研究機構 Beverage production method
CN1951383A (en) * 2005-10-17 2007-04-25 美国安乃仁生命科技公司 Stabilized medical and cosmetic composition containing catechin
KR101213200B1 (en) * 2009-08-24 2012-12-18 주식회사 장원 New variety of tea-plant and breeding method thereof
KR20160069738A (en) * 2014-12-09 2016-06-17 (주)아모레퍼시픽 Composition comprising methylated catechin for activating ercc8 gene
KR20160069737A (en) * 2014-12-09 2016-06-17 (주)아모레퍼시픽 COMPOSITION COMPRISING METHYLATED CATECHIN FOR ACTIVATING Sirt-1 GENE
CN104820059B (en) * 2015-04-22 2016-07-06 湖南农业大学 A kind of " the method for Me Resources of Tea Plant that rapid screening contains EGCG3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015199169A1 (en) * 2014-06-27 2015-12-30 国立大学法人九州大学 Catechin function enhancement method
KR20160127860A (en) * 2015-04-27 2016-11-07 강원대학교산학협력단 Composition for anti-aging comprising methylated catechin as effective component
KR101722427B1 (en) * 2015-04-27 2017-04-04 강원대학교산학협력단 Composition for growth inhibition of cancer cell comprising methylated catechin as effective component

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAEDA-YAMAMOTO, MARI: "Changes in epigallocatechin-3-0-(3-0-methyl) gallate and strictinin contents of tea (Camellia sinensis L.) cultivar ''Benifuki'' in various degrees of maturity and leaf order", FOOD SCIENCE AND TECHNOLOGY RESEARCH, vol. 10, no. 2, May 2004 (2004-05-01), pages 186 - 190, XP055612773 *
ZHANG, XIN ET AL: "Antioxidant and hepatoprotective effect of (-)-epigallo catechin 3-0-(3-0-methyl) gallate (EGCG3'' Me) from Chinese oolong tea", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 62, no. 41, 2014, pages 10046 - 10054, XP055612775 *

Also Published As

Publication number Publication date
KR102428987B1 (en) 2022-08-04
CN111050783A (en) 2020-04-21
KR20180125828A (en) 2018-11-26
MY197901A (en) 2023-07-24

Similar Documents

Publication Publication Date Title
WO2018212588A1 (en) Composition containing camellia sinensis extract
WO2021137677A1 (en) Composition containing plant extract
US20100015071A1 (en) Compositions for Improving Skin Conditions Comprising Alpha-Bisabolol as an Active Ingredient
KR102152750B1 (en) Composition containing rose extract
WO2012169664A1 (en) External dermal agent and functional food containing rose placenta tissue-cultured product or extract thereof
WO2017146414A1 (en) Composition for skin moisturization and skin wrinkle alleviation, containing α-terpineol as active ingredient
KR101664025B1 (en) Cosmetic composition containing natural herb extracts
KR100785505B1 (en) Oriental medicine material extract having antioxidation effect and whitening effect, manufacturing method of those extract and cosmetics comprising the oriental medicine material
WO2018080039A1 (en) Composition for preventing hair loss or improving hair growth, containing yellow-colored soybean leaf extract
WO2022085858A1 (en) Composition for whitening skin or ameliorating wrinkles comprising dendropanax morbiferus extract
WO2018097388A1 (en) Composition for skin whitening, wrinkle alleviation, antioxidation, and ultraviolet light blocking, containing jujube seed extract as active ingredient
Puertas-Mejía et al. Screening of UVA/UVB absorption and in vitro antioxidant capacity of Bejaria aestuans, Cavendishia pubescens and Cavendishia bracteata leaf extracts
KR20200138003A (en) Composition for preventing, improving or treating metabolic syndrome accompanying obesity and/or diabetes comprising a complex of Emblica officinalis extract and Hordeum vulgare extract(IB Complex) as an active ingredient
KR20180043567A (en) Functional cosmetic composition with nipa fruticans wurmb
KR101512811B1 (en) Cosmetic Composition Comprising Reynoutria japonica for. elata Extract for Skin Whitening
KR101889331B1 (en) A composition having anti-oxidation, anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient
KR102176618B1 (en) Composition comprising extract of zea mays linne
KR20220163542A (en) Composition for anti-oxidation, anti-inflammation, and anti-pollution containing an extraction of Backhousia citriodora and Sparassis crispa
KR100917281B1 (en) Agents for Skin Whitening Comprising Oxalis hedysaroides
KR101797843B1 (en) A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient
WO2023128630A1 (en) Cosmetic composition for skin improvement comprising extract of elaeocarpus sylvestris var. ellipticus (thunb.) hara
WO2017003190A1 (en) Whitening cosmetic composition comprising caragana sinica root extract
KR20190124351A (en) Composition comprising extract of Prasiola japonica for skin whitening
KR101434300B1 (en) Cosmetic Composition Comprising Vitis flexuosa Thunb, Penthorum chinense PURSH Extract for Skin Whitening
KR102419455B1 (en) Cosmetic composition containing sedum tosaense makino callus extract

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18802462

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18802462

Country of ref document: EP

Kind code of ref document: A1